# 2026年1月23日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 高循环肿瘤细胞与高危细胞遗传学：多发性骨髓瘤中的危险组合？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569625)
**期刊：** Blood
**PMID：** 41569625
**DOI：** 10.1182/blood.2025031606

### 第一部分 原文与翻译

**英文原标题：** High CTC, high-risk cytogenetics: a dangerous duo in MM?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文深入探讨了高水平循环肿瘤细胞（CTC）与高危细胞遗传学异常在多发性骨髓瘤（MM）预后评估中的协同作用。作者提出这两者的结合构成了一组极具侵袭性的“危险搭档”，显著增加了疾病复发风险并缩短了患者生存期。该评价强调了在临床实践中，整合功能性液体活检指标与基因组特征对于完善MM风险分层、识别超高危患者群体具有重要的指导价值。

---

## 2. USP25与衰老过程中的血小板高反应性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569622)
**期刊：** Blood
**PMID：** 41569622
**DOI：** 10.1182/blood.2025031416

### 第一部分 原文与翻译

**英文原标题：** USP25 and platelet hyperreactivity in aging.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献聚焦于去泛素化酶USP25在老龄化进程中对血小板功能的调控作用。研究旨在揭示USP25如何通过影响血小板的高反应性，进而介导老年群体中高发的血栓性风险。尽管目前详细摘要不可见，但该课题对于理解衰老相关血液系统病理生理机制具有重要的科学价值和临床指导意义。

---

## 3. 凝血因子VIII基因疗法的“帕多瓦时刻”

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569621)
**期刊：** Blood
**PMID：** 41569621
**DOI：** 10.1182/blood.2025032121

### 第一部分 原文与翻译

**英文原标题：** A Padua moment for factor VIII gene therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

这篇文章通过引用“帕多瓦时刻”这一具有里程碑意义的术语，高度肯定了凝血因子VIII基因疗法取得的重大突破。文章旨在探讨类似于功能增强型Factor IX-Padua变体的发现，如何为血友病A的基因修复带来革命性的性能提升。这一进展可能意味着在更低的免疫原性载体剂量下即可实现更高效的凝血因子表达，从而有效解决目前临床应用中表达水平不稳和剂量限制性毒性的难题。该文不仅总结了技术前沿，也为未来临床试验的设计与优化提供了关键视角。

---

## 4. 癌症治疗中辅助免疫疗法的成本效益：一项系统评价

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569596)
**期刊：** JAMA oncology
**PMID：** 41569596
**DOI：** 10.1001/jamaoncol.2025.6080

### 第一部分 原文与翻译

**英文原标题：** Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments: A Systematic Review.

> **英文摘要：**
> IMPORTANCE: Adjuvant immunotherapy is increasingly integrated into cancer care to reduce recurrence and improve survival. However, its high cost raises critical concerns regarding affordability and economic value across diverse health system contexts. OBJECTIVE: To synthesize published economic evaluations of adjuvant immunotherapy and assess cost-effectiveness outcomes, quality-adjusted life-year (QALY)/life-year (LY) gains, and methodologic approaches. EVIDENCE REVIEW: A systematic search was conducted of PubMed, Scopus, Embase, and Web of Science for full economic evaluations published between January 1, 2015, and January 31, 2025. Eligible studies included cost-effectiveness or cost-utility analyses of adjuvant immunotherapy across any cancer type. Data were extracted on cancer type, treatment strategy (single vs combination therapy), treatment line, model structure, health utility instruments, funding sources, and cost-effectiveness outcomes. Methodologic quality was appraised using the Criteria for Health Economic Quality Evaluation 2023. Due to heterogeneity of health systems, findings were narratively synthesized. FINDINGS: The analysis included 69 studies covering a range of cancer types, most frequently non-small cell lung cancer and melanoma. Of these, 46 (67%) evaluated first-line therapy with single-agent checkpoint inhibitors. Higher QALY/LY gains were consistently reported among the adjuvant immunotherapy group (63 [91%]), particularly for non-small cell lung cancer, industry-funded studies, and combination regimens. More than half of the evaluations (40 [58%]) concluded that adjuvant immunotherapy was cost-effective, although results varied by cancer type, model assumptions, drug pricing, funding organizations, and country-specific thresholds. Markov modeling was the dominant analytic approach (46 [67%]) and EuroQol 5 Dimensions was the most commonly used health utility instrument (56 [81%]). CONCLUSIONS AND RELEVANCE: This systematic review found that adjuvant immunotherapy was frequently associated with meaningful QALY/LY improvements and was often considered cost-effective in high-risk or first-line settings. However, economic value remains context-specific, shaped by treatment strategy, drug costs, and modeling assumptions. These findings support the selective, value-based adoption of adjuvant immunotherapy and underscore the need for transparent, standardized economic evaluations to guide reimbursement and policy decisions.

> **中文摘要：**
> 重要性：辅助免疫疗法正日益整合到癌症护理中，以减少复发并提高生存率。然而，其高昂的成本引发了对不同医疗系统背景下负担能力和经济价值的关键担忧。
> 
> 目的：综合已发表的辅助免疫疗法经济学评价，评估成本效益结果、质量调整生命年（QALY）/生命年（LY）增益以及方法学途径。
> 
> 证据审查：对 PubMed、Scopus、Embase 和 Web of Science 进行了系统检索，纳入 2015 年 1 月 1 日至 2025 年 1 月 31 日期间发表的完整经济学评价。符合条件的研究包括针对任何癌症类型的辅助免疫疗法的成本效益或成本效用分析。提取了有关癌症类型、治疗策略（单药 vs 联合治疗）、治疗线、模型结构、健康效用工具、资金来源和成本效益结果的数据。使用 2023 年卫生经济质量评估标准（CHEERS 2023）对方法学质量进行了评价。由于医疗系统的异质性，对研究结果进行了叙述性综合。
> 
> 结果：分析纳入了涵盖多种癌症类型的 69 项研究，其中最常见的是非小细胞肺癌和黑色素瘤。其中，46 项（67%）评估了单药免疫检查点抑制剂的一线治疗。辅助免疫疗法组一致报告了较高的 QALY/LY 增益（63 项 [91%]），尤其是在非小细胞肺癌、工业界资助的研究和联合方案中。超过一半的评估（40 项 [58%]）得出结论认为辅助免疫疗法具有成本效益，尽管结果因癌症类型、模型假设、药品价格、资助机构和国家特定阈值而异。马尔可夫模型是主要的分析方法（46 项 [67%]），EuroQol 5 维量表（EQ-5D）是最常用的健康效用工具（56 项 [81%]）。
> 
> 结论与相关性：这项系统评价发现，辅助免疫疗法通常与显著的 QALY/LY 改善相关，且在高风险或一线治疗背景下通常被认为具有成本效益。然而，经济价值仍取决于具体情境，受治疗策略、药物成本和模型假设的影响。这些发现支持选择性、基于价值的辅助免疫疗法采用，并强调需要透明、标准化的经济学评价来指导报销和政策决策。

### 第二部分 AI 大师评价

该系统评价详尽地分析了过去十年间辅助免疫疗法的经济学证据，揭示了其在提升患者生存质量与生命年方面的显著优势。研究指出，虽然超过半数的评价支持其成本效益，但结果受到药物定价、模型假设及资助来源的显著影响，具有明显的语境依赖性。此项综述的创新之处在于系统性地总结了辅助免疫治疗在不同癌种及医疗环境下的经济价值分布，为医保准入决策提供了重要的循证依据。局限性则主要在于纳入研究的方法学异质性较大，呼吁未来建立更透明、标准化的卫生经济学评估体系。

---

## 5. 50岁以下人群的主要癌症死因

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569583)
**期刊：** JAMA
**PMID：** 41569583
**DOI：** 10.1001/jama.2025.25467

### 第一部分 原文与翻译

**英文原标题：** Leading Cancer Deaths in People Younger Than 50 Years.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文发表于顶级医学期刊《JAMA》，核心聚焦于早发型癌症（50岁以下）这一日益严峻的公共卫生挑战。研究旨在通过详实的流行病学数据，明确该年龄组中最主要的癌症死因构成。尽管目前缺乏详细摘要，但其研究方向对于理解癌症发病年轻化趋势及制定针对性的早筛和预防政策具有极高的临床指导价值和政策参考意义。

---

## 6. 度普利尤单抗治疗皮肤免疫相关不良反应的发病率与死亡率结局分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569553)
**期刊：** JAMA oncology
**PMID：** 41569553
**DOI：** 10.1001/jamaoncol.2025.6092

### 第一部分 原文与翻译

**英文原标题：** Morbidity and Mortality Outcomes of Dupilumab for Cutaneous Immune-Related Adverse Events.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本项研究探讨了度普利尤单抗在管理免疫检查点抑制剂引起的皮肤免疫相关不良反应（irAEs）中的具体表现。研究核心关注于使用该生物制剂后患者的发病率与死亡率风险评估，旨在权衡其治疗获益与潜在风险。尽管摘要信息有限，但该课题切中了肿瘤免疫治疗中副作用管理的临床痛点，对优化皮肤毒性反应的精准干预具有重要的指导价值。

---

## 7. 让每一例癌症病例都发挥作用——来自山区的呼吁

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569550)
**期刊：** JAMA oncology
**PMID：** 41569550
**DOI：** 10.1001/jamaoncol.2025.5941

### 第一部分 原文与翻译

**英文原标题：** Make Every Cancer Case Count-A Call From the Mountains.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献是一篇发表于《JAMA Oncology》的呼吁性文章，强调了全面记录和分析每一例癌症病例的重要性，特别是针对偏远山区等资源匮乏地区的病例收集与登记。文章指出，建立完善的癌症监测系统对于实现医疗公平和优化公共卫生资源配置具有关键意义。通过来自“大山深处”的特定呼吁，作者旨在引发全球学界对欠发达地区癌症负担的关注，并推动肿瘤流行病学数据的完整性、代表性与包容性。

---

## 8. 帕博利珠单抗联合紫杉醇治疗 HER2 富集型或基底样亚型的 HR+/HER2- 乳腺癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569440)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41569440
**DOI：** 10.1158/1078-0432.CCR-25-2570

### 第一部分 原文与翻译

**英文原标题：** Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.

> **英文摘要：**
> PURPOSE: Hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined non-luminal subtypes, particularly the HER2-enriched (HER2-E) and Basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting. METHODS: SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2- mBC classified as HER2-Enriched or Basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-Enriched or Basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m² weekly). RESULTS: The primary endpoint, overall response rate (ORR), was 61.1% (95% CI: 35.7-82.7), and the clinical benefit rate (CBR) was 94.4% (95% CI: 72.7-99.9). Median progression-free survival (PFS) was 8.1 months (95% CI 5.9-10.4), and median overall survival (OS) was 26.0 months (95% CI 18-NR). Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, while luminal-related gene expression was associated with lower clinical benefit. CONCLUSIONS: These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined non-luminal subtypes of HR+/HER2- mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post-endocrine treatment decisions.

> **中文摘要：**
> 目的：激素受体阳性、HER2 阴性（HR+/HER2-）转移性乳腺癌（mBC）在生物学上与早期疾病不同，其基因定义的非管腔亚型（尤其是 HER2 富集型 [HER2-E] 和基底样亚型）的流行率更高。这些肿瘤具有高增殖性，对激素信号的依赖性较低，且与不良预后以及对内分泌治疗和 CDK4/6 抑制剂（CDK4/6i）的早期耐药相关。这种生物学转变突显了在 CDK4/6i 耐药背景下采用生物标志物驱动策略的必要性。方法：SOLTI-1716 TATEN 试验（NCT04251169）是一项 II 期单臂研究，旨在评估帕博利珠单抗联合紫杉醇在 CDK4/6i 进展后、经 PAM50 分类为 HER2 富集型或基底样亚型的 HR+/HER2- mBC 患者中的疗效。共有 126 名患者接受了 PAM50 基因检测筛选；其中 20 名具有 HER2 富集型或基底样亚型的患者入组并接受了帕博利珠单抗（每 3 周 200 mg）和紫杉醇（每周 80 mg/m²）治疗。结果：主要终点客观缓解率（ORR）为 61.1%（95% CI：35.7-82.7），临床获益率（CBR）为 94.4%（95% CI：72.7-99.9）。中位无进展生存期（PFS）为 8.1 个月（95% CI：5.9-10.4），中位总生存期（OS）为 26.0 个月（95% CI：18-未达到）。三名患者实现了持续 ≥24 个月的持久缓解。基因表达分析显示，增殖相关和免疫相关基因的高表达预示着更好的 ORR 和生存期，而管腔相关基因的表达与较低的临床获益相关。结论：这些结果表明，对于 CDK4/6i 耐药后基因定义的非管腔亚型 HR+/HER2- mBC 患者，化疗免疫疗法可能是一种有效的策略，并突显了分子分型在指导内分泌治疗后决策中的价值。

### 第二部分 AI 大师评价

这项 II 期 SOLTI-1716 TATEN 研究针对 CDK4/6 抑制剂耐药后的特殊 HR+/HER2- 乳腺癌群体，通过 PAM50 基因分型精准识别出非管腔亚型并给予帕博利珠单抗联合紫杉醇治疗。研究结果显著，ORR 达到 61.1%，中位 OS 达 26.0 个月，展示了化疗联合免疫治疗在这一高度侵袭性亚型中的巨大潜力。尽管样本量较小且为单臂设计，但其证明了分子亚型分析在指导晚期乳腺癌精准免疫治疗决策中的核心价值，挑战了传统临床分型的局限性。

---

## 9. 使用CD46靶向放射免疫治疗-抗体偶联药物协同治疗前列腺癌和多发性骨髓瘤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569419)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41569419
**DOI：** 10.1158/1078-0432.CCR-25-4110

### 第一部分 原文与翻译

**英文原标题：** Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates.

> **英文摘要：**
> PURPOSE: CD46 is highly expressed across multiple cancer types, including prostate cancer and multiple myeloma. We have developed CD46-targeting antibody drug conjugate and 225Ac-based alpha particle therapy agents that demonstrated a tumor-selective therapeutic effect. We hypothesized that a treatment strategy targeting CD46 using simultaneous antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) methods would have synergistic therapeutic efficacy with acceptable toxicity. EXPERIMENTAL DESIGN: Two CD46-targeted combination treatment strategies were evaluated: (1) co-administration of the ADC (YS5-MMAE) and Actinium-225-labeled antibody ([225Ac]Macropa-PEG4-YS5), and (2) a dual-payload radioconjugate ([225Ac]Macropa-PEG4-YS5-MMAE, R-ADC). The in vitro synergy was studied using cell viability, DNA damage, and apoptosis assays. In vivo studies were performed for biodistribution, toxicity, and therapeutic evaluation in subcutaneous, disseminated, and patient-derived xenograft models of prostate cancer and multiple myeloma. RESULTS: Combination therapy induced synergistic G2/M arrest, increased γ-H2AX foci, and enhanced cell death compared to monotherapies. R-ADC and co-administration strategies resulted in improved tumor control and survival benefit. CONCLUSIONS: By integrating orthogonal microtubule inhibition and high-linear-energy-transfer alpha irradiation on a single CD46 scaffold, potent, well-tolerated tumor control was achieved across diverse models. The dual-payload construct's compatibility with CD46 immuno-PET for real-time dosimetry further supports progression to early-phase clinical trials in prostate cancer and multiple myeloma.

> **中文摘要：**
> 目的：CD46在包括前列腺癌和多发性骨髓瘤在内的多种癌症类型中高表达。我们开发了靶向CD46的抗体偶联药物（ADC）和基于225Ac的α粒子治疗制剂，这些制剂显示出肿瘤选择性的治疗效果。我们假设，利用同时采用抗体偶联药物（ADC）和放射免疫治疗（RIT）方法的CD46靶向治疗策略，将在具有可接受毒性的前提下产生协同治疗功效。实验设计：评估了两种CD46靶向联合治疗策略：（1）ADC（YS5-MMAE）和锕-225标记抗体（[225Ac]Macropa-PEG4-YS5）的联合给药；（2）双载荷放射性偶联物（[225Ac]Macropa-PEG4-YS5-MMAE, R-ADC）。通过细胞活力、DNA损伤和细胞凋亡实验研究了体外协同作用。在前列腺癌和多发性骨髓瘤的皮下、播散和患者来源的异种移植（PDX）模型中，进行了生物分布、毒性和治疗评价的体内研究。结果：与单项疗法相比，联合疗法诱导了协同的G2/M期阻滞，增加了γ-H2AX病灶，并增强了细胞死亡。R-ADC和联合给药策略均改善了肿瘤控制并带来了生存获益。结论：通过在单一CD46支架上整合正交的微管抑制和高线能传递（LET）的α射线照射，在多种模型中实现了强效且耐受性良好的肿瘤控制。该双载荷构建体与CD46免疫PET实时剂量监测的兼容性，进一步支持了其进入前列腺癌和多发性骨髓瘤早期临床试验的进程。

### 第二部分 AI 大师评价

该研究创新性地提出了一种针对CD46靶点的“双重打击”策略，通过将α粒子放射免疫疗法（RIT）与抗体偶联药物（ADC）整合于同一支架或联合使用，实现了微管抑制与高LET辐射损伤的强大协同效应。实验在多种复杂的前列腺癌和多发性骨髓瘤模型中证实了卓越的肿瘤抑制效果和良好的安全性。其“诊疗一体化”潜力（配合PET成像进行实时剂量测定）为解决晚期实体瘤和血液恶性肿瘤的耐药性问题提供了坚实的转化医学依据。

---

## 10. 颅内间质性肿瘤，FET::CREB融合阳性：81例病例的综合分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569358)
**期刊：** Neuro-oncology
**PMID：** 41569358
**DOI：** 10.1093/neuonc/noag001

### 第一部分 原文与翻译

**英文原标题：** Intracranial mesenchymal tumor, FET::CREB fusion-positive: an integrative analysis of 81 cases.

> **英文摘要：**
> BACKGROUND: Intracranial mesenchymal tumors, FET::CREB fusion-positive (ICMT), show fusions involving FET RNA-binding protein family genes (EWSR1 or FUS) and CREB family of transcription factors (ATF1, CREB1 or CREM). The methylation signature(s), gene expression characteristics and clinical behavior of this important tumor type require further characterization. METHODS: We study the methylation profiles of 81 ICMT cases (61 newly profiled cases and 20 cases from publicly available sources). Clinicopathologic and genomic data were recorded for each case when available. RESULTS: ICMT showed a relatively distinct methylation signature compared to related tumors. Among the 65 cases where fusion types were documented, the identified fusions included EWSR1::ATF1 (25 cases), EWSR1::CREB1 (12 cases), EWSR1::CREM (21 cases), FUS::CREM (3 cases) and SMARCA2::CREM (4 cases). We confirmed the prior description of two distinct subgroups of ICMT (subclasses A and B). The majority of the cases belonged to subclass A (n = 69; 85%), which showed higher median age compared to subclass B patients (26 years vs. 15 years). Subclass B cases (n = 12; 15%) showed shorter progression-free survival (p < 0.01). Gene expression analysis of ICMT showed key overexpressed markers in ICMT, with significant CREM overexpression regardless of fusion type, when compared to either meningioma alone, or a larger group of CNS tumors. CONCLUSIONS: This work provides further characterization of ICMT as an important CNS mesenchymal neoplasm that is prone to tumor recurrence, showing 2 prognostically relevant methylation subclasses, and warranting diagnostic distinction from other epigenetically and histologically related tumors. ICMTs show substantial overexpression of the CREM gene, independent of fusion type.

> **中文摘要：**
> 背景：颅内间质性肿瘤，FET::CREB 融合阳性（ICMT），表现为涉及 FET RNA 结合蛋白家族基因（EWSR1 或 FUS）与 CREB 转录因子家族（ATF1、CREB1 或 CREM）的融合。这种重要肿瘤类型的甲基化特征、基因表达特征和临床行为需要进一步界定。方法：我们研究了 81 例 ICMT 病例（61 例新分析病例和 20 例来自公开来源的病例）的甲基化谱。在可行的情况下记录了每例病例的临床病理学和基因组数据。结果：与相关肿瘤相比，ICMT 显示出相对独特的甲基化特征。在记录了融合类型的 65 例病例中，鉴定的融合包括 EWSR1::ATF1（25 例）、EWSR1::CREB1（12 例）、EWSR1::CREM（21 例）、FUS::CREM（3 例）和 SMARCA2::CREM（4 例）。我们证实了先前描述的 ICMT 的两个不同亚组（亚型 A 和 B）。大多数病例属于亚型 A（n = 69；85%），其患者中位年龄高于亚型 B 患者（26 岁 vs 15 岁）。亚型 B 病例（n = 12；15%）表现出更短的无进展生存期（p < 0.01）。ICMT 的基因表达分析显示了 ICMT 中的关键过表达标志物，与单纯脑膜瘤或更大范围的中枢神经系统（CNS）肿瘤相比，无论融合类型如何，CREM 均显著过表达。结论：本项研究进一步明确了 ICMT 作为一种重要的、易于复发的中枢神经系统间质性肿瘤的特征，展示了 2 个具有预后相关性的甲基化亚型，并证明了将其与其他表观遗传学和组织学相关肿瘤进行诊断区分的必要性。ICMT 表现出显著的 CREM 基因过表达，且与融合类型无关。

### 第二部分 AI 大师评价

本研究通过对81例FET::CREB融合阳性颅内间质性肿瘤（ICMT）的大样本队列进行综合分析，系统阐明了这一罕见肿瘤的甲基化谱系特征。研究不仅验证了具有预后差异的两个分子亚组（亚型A和B），还发现CREM基因的普遍过表达是其关键的诊断性标志物。该工作为ICMT的精准病理诊断和预后评估提供了重要的分子依据，具有极高的临床应用价值。

---

## 11. 转录终止抵消了抑制 WEE1 后的 DNA 损伤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569153)
**期刊：** Nucleic acids research
**PMID：** 41569153
**DOI：** 10.1093/nar/gkaf1487

### 第一部分 原文与翻译

**英文原标题：** Transcription termination counteracts DNA damage after WEE1 inhibition.

> **英文摘要：**
> Transcription termination is a key regulatory step in transcription and a potential target for cancer therapy, but how it can be exploited for treatment is incompletely understood. Here we show that transcription termination plays a crucial role in mitigating DNA damage and cell death upon WEE1 inhibition by adavosertib. Depleting five different transcription termination factors (WDR82, PNUTS, XRN2, DDX5, or CPSF73) increased adavosertib-induced DNA damage in S-phase. Conversely, inhibiting active transcription with DRB or triptolide, or co-depleting CDC73, a component of the PAF1 transcription elongation complex, reduced such damage. Additionally, read-through transcription following WDR82 depletion was partially inhibited by co-depletion of CDC73, supporting that read-through transcription contributes to DNA damage in response to WEE1 inhibition. Moreover, combining adavosertib with the CPSF73 inhibitor JTE-607, an anticancer compound which promotes read-through transcription, increased DNA damage during S-phase. Elevated expression of CPSF73 is associated with aggressive disease in prostate cancer patients, and combining JTE-607 with adavosertib synergistically reduced prostate cancer cell survival. Our findings suggest that transcription termination helps prevent toxic conflicts between transcription and replication following increased replication initiation caused by WEE1 inhibition.

> **中文摘要：**
> 转录终止是转录过程中的一个关键调节步骤，也是癌症治疗的潜在靶点，但如何利用它进行治疗尚不完全清楚。在此，我们表明在通过 adavosertib 抑制 WEE1 时，转录终止在减轻 DNA 损伤和细胞死亡中发挥着至关重要作用。耗竭五种不同的转录终止因子（WDR82、PNUTS、XRN2、DDX5 或 CPSF73）会增加 adavosertib 诱导的 S 期 DNA 损伤。相反，使用 DRB 或雷公藤内酯醇抑制活性转录，或共同耗竭 PAF1 转录延伸复合物的成分 CDC73，可减少此类损伤。此外，WDR82 耗竭后的通读转录通过共同耗竭 CDC73 得到部分抑制，这支持了通读转录有助于响应 WEE1 抑制而产生 DNA 损伤的观点。此外，将 adavosertib 与促进通读转录的抗癌化合物 CPSF73 抑制剂 JTE-607 联合使用，会增加 S 期的 DNA 损伤。CPSF73 的高表达与前列腺癌患者的侵袭性疾病相关，且 JTE-607 与 adavosertib 联用可协同降低前列腺癌细胞的存活率。我们的发现表明，转录终止有助于防止在 WEE1 抑制导致复制起始增加后，转录与复制之间产生毒性冲突。

### 第二部分 AI 大师评价

本研究揭示了转录终止过程在维持基因组稳定性中的新机制，证实其能有效缓解 WEE1 抑制引起的转录与复制冲突。通过联合使用 WEE1 抑制剂 adavosertib 和转录终止因子 CPSF73 抑制剂 JTE-607，研究者在前列腺癌细胞中观察到了显著的协同杀伤效应。该发现不仅阐明了转录通读诱导 DNA 损伤的分子基础，还为临床治疗侵袭性前列腺癌提供了基于“合成致死”理念的潜在联合用药方案。其局限性可能在于需进一步在多种体内模型中验证该联合疗法的安全性和广谱适用性。

---

## 12. 靶向 CD27 增强疫苗诱导的免疫记忆

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41569091)
**期刊：** Cancer discovery
**PMID：** 41569091
**DOI：** 10.1158/2159-8290.CD-NW2026-0004

### 第一部分 原文与翻译

**英文原标题：** Targeting CD27 Boosts Vaccine-induced Immune Memory.

> **英文摘要：**
> A recent study shows that CD27 agonism can improve the efficacy and durability of vaccine-induced antitumor responses in HER2+ breast cancer. The outcomes may pave the way for approaches to improve the efficacy and durability of tumor antigen vaccines.

> **中文摘要：**
> 最近的一项研究表明，CD27 激动作用可以提高 HER2+ 乳腺癌中疫苗诱导的抗肿瘤反应的有效性和持久性。这些结果可能为提高肿瘤抗原疫苗有效性和持久性的方法铺平道路。

### 第二部分 AI 大师评价

该研究聚焦于通过 CD27 激动剂优化 HER2+ 乳腺癌疫苗的免疫应答，揭示了靶向共刺激分子在增强抗肿瘤免疫中的核心作用。研究重点解决了疫苗诱导反应中“持久性”不足的关键痛点，证实了 CD27 激动作用能显著提升免疫记忆。这些发现不仅为肿瘤抗原疫苗的改进提供了理论支撑，也为未来联合免疫治疗方案的设计提供了新的战略思路。尽管目前侧重于特定乳腺癌亚型，其机制对其他肿瘤疫苗的研发同样具有重要的参考价值。

---

## 13. 靶向肿瘤相关内皮细胞的工程化小细胞外囊泡有效重塑胶质瘤微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566763)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41566763
**DOI：** 10.1002/advs.202518490

### 第一部分 原文与翻译

**英文原标题：** Engineered Small Extracellular Vesicles Targeting Tumor-Associated Endothelial Cells to Effectively Remodel the Glioma Microenvironment.

> **英文摘要：**
> Owing to the existence of the blood-brain barrier (BBB), achieving high-efficacy, tumor-selective delivery of therapeutic agents continues to be a pivotal unmet need in the treatment of glioblastoma. Here, based on the finding that CD93 is exclusively up-regulated on glioma-associated vascular endothelial cells (VECs), small extracellular vesicles (sEVs) were modified with insulin-like growth factor-binding protein 7 (IGFBP7), a natural ligand of CD93, to create a delivery platform that can deliver therapeutic agents to glioma-associated VECs with high efficiency. At markedly reduced intravenous doses, IGFBP7-sEVs efficiently concentrated temozolomide (TMZ) within glioma and elicited pronounced tumor growth inhibition. More strikingly, systemic administration of stimulator of interferon genes (STING) agonist-loaded IGFBP7-sEVs outperformed direct intratumoral injection of free STING agonist: the glioma microenvironment (GME) was extensively remodeled and antigen-presenting capacity of myeloid cells was markedly enhanced. Moreover, endothelial-restricted STING activation attenuated the exhaustion of CD8 T cells. Consequently, the intensity of the tumor-specific immune response was markedly augmented. Our data suggest that IGFBP7-modified sEVs represent a novel platform that enables highly efficient, glioma VECs-targeted delivery of therapeutics into glioma, and are adaptable to a broad spectrum of agents, especially immunomodulators. It is a novel and effective strategy for treating gliomas.

> **中文摘要：**
> 由于血脑屏障（BBB）的存在，实现治疗药物的高效、肿瘤选择性递送仍然是胶质母细胞瘤治疗中一个关键的未满足需求。在此，基于CD93在胶质瘤相关血管内皮细胞（VECs）上特异性上调的发现，研究者利用CD93的天然配体——胰岛素样生长因子结合蛋白7（IGFBP7）对小细胞外囊泡（sEVs）进行修饰，构建了一个能够高效向胶质瘤相关VECs递送治疗药物的平台。在显著降低静脉注射剂量的情况下，IGFBP7-sEVs有效地使替莫唑胺（TMZ）富集在胶质瘤内，并诱导了显著的肿瘤生长抑制作用。更引人注目的是，系统性给予装载了干扰素基因刺激因子（STING）激动剂的IGFBP7-sEVs，其效果优于直接瘤内注射游离的STING激动剂：胶质瘤微环境（GME）得到了广泛重塑，骨髓细胞的抗原提呈能力显著增强。此外，局限于内皮细胞的STING激活减轻了CD8 T细胞的耗竭。因此，肿瘤特异性免疫反应的强度显著增加。我们的数据表明，IGFBP7修饰的sEVs代表了一种新型平台，能够实现治疗药物向胶质瘤的高效、胶质瘤VECs靶向递送，并适用于多种药物，特别是免疫调节剂。这是一种治疗胶质瘤的新颖且有效的策略。

### 第二部分 AI 大师评价

本研究针对胶质母细胞瘤治疗中血脑屏障阻碍药物递送的临床痛点，创新性地开发了以CD93为靶点的IGFBP7修饰化工程小细胞外囊泡（sEVs）。该递送平台不仅在降低给药剂量的前提下显著提升了化疗药物替莫唑胺的靶向富集效率，更通过系统性递送STING激动剂实现了内皮细胞限制性激活，成功重塑了胶质瘤微环境并逆转了T细胞耗竭。研究结果展示了该工程化囊泡在胶质瘤精准免疫治疗中的巨大应用潜力，为克服中枢神经系统递送障碍提供了极具价值的新策略。

---

## 14. 动态修饰DNA支架用于高分辨率癌症细胞亚型分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566757)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41566757
**DOI：** 10.1002/advs.202518307

### 第一部分 原文与翻译

**英文原标题：** Dynamic Decoration of DNA Scaffolds for High-Resolution Cancer Cell Subtyping.

> **英文摘要：**
> Precise imaging of cancer cells serves as the foundation for subtype analysis, significantly advancing the development of precision medicine. The unavoidable cellular internalization of fluorescent labels constrains the resolution and timeliness, presenting a significant obstacle. This study introduces a dynamic decorating strategy of DNA scaffolds that enables the execution of four distinct Boolean logic operations through self-assembly and self-disassembly. By integrating the in-built molecular circuit, the proposed assay achieved signal-amplified detection of low-abundance nucleic acid inputs. In the application of cell imaging, inputs were labeled with aptamers to operate membrane-confined self-assembly or self-disassembly of DNA scaffolds on the cell surface, enabling simultaneous identification of distinct subtypes of cancer cells with high fidelity. The intrinsic durability of DNA scaffolds successfully prevented cellular internalization for up to 300 min, boosting the long-duration imaging. Moreover, the assay was capable of profiling a broad spectrum of cancer cell abundances from as low as 0.1% to 10% in clinical blood samples, consistently achieving recognition efficiency exceeding 60%. These findings underscore the transformational potential of DNA scaffold-based imaging tools in biological research and precision medicine.

> **中文摘要：**
> 癌细胞的精确成像是亚型分析的基础，显著推动了精准医学的发展。荧光标记不可避免的细胞内化限制了成像的分辨率和时效性，构成了一个重大障碍。本研究引入了一种DNA支架的动态修饰策略，通过自组装和自拆卸实现四种不同的布尔逻辑运算。通过整合内置分子电路，该分析方法实现了对低丰度核酸输入的信号放大检测。在细胞成像应用中，输入端被适配体标记，以在细胞表面操作膜受限的DNA支架自组装或自拆卸，从而能够高保真地同时识别不同的癌细胞亚型。DNA支架固有的耐用性成功阻止了长达300分钟的细胞内化，增强了长时程成像能力。此外，该方法能够对临床血样中丰度低至0.1%到10%的广泛癌症细胞进行分析，识别效率始终保持在60%以上。这些发现强调了基于DNA支架的成像工具在生物研究和精准医学领域的变革潜力。

### 第二部分 AI 大师评价

该研究针对传统荧光成像中标签易内化导致的分辨率受限问题，开发了一种基于DNA支架动态修饰的成像平台，通过四种布尔逻辑运算实现了细胞表面的精确信号处理。该方法巧妙结合了内置分子电路与适配体识别，不仅显著延长了标签在细胞膜上的停留时间（达300分钟），还实现了对复杂临床样本中低丰度癌症细胞的高灵敏度亚型鉴定。研究展示了DNA纳米技术在提升成像分辨率与长效性方面的卓越性能，为精准医学中的癌症分型提供了高效、高保真的技术手段。

---

## 15. 基于机器学习增强的表面增强拉曼光谱法分析外泌体表面唾液酸，用于卵巢癌的诊断与治疗监测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566747)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41566747
**DOI：** 10.1002/advs.202518190

### 第一部分 原文与翻译

**英文原标题：** Machine Learning-Enhanced Analysis of Exosomal Surface Sialic Acid Using Surface-Enhanced Raman Spectroscopy for Ovarian Cancer Diagnosis and Therapeutic Monitoring.

> **英文摘要：**
> Currently, the absence of ovarian cancer (OC)-specific biomarkers impedes the development of precise noninvasive diagnostic and monitoring strategies. Exosomal surface sialic acid (SA), a key mediator of intercellular communication and disease progression, emerges as a promising biomarker, though its role in OC remains unclear. Conventional exosome isolation and detection methods exhibit limited clinical utility. Herein, we developed a CD63 aptamer-functionalized gold array chip integrated with a surface-enhanced Raman scattering (SERS) nanosensor for sensitive SA analysis. The chip efficiently isolated exosomes from clinical serum, while the nanosensor selectively bound exosomal SA via molecular recognition, thereby altering the SERS intensity ratio of the nanosensor. More importantly, machine learning can discern SA signatures from SERS spectra, achieving 93% accuracy in OC diagnosis. The longitudinal monitoring of SA throughout the entire treatment period (preoperative, postoperative, and chemotherapy) revealed a potential correlation with treatment response as indicated by clinical markers (CA125, HE4), demonstrating the utility of exosomal SA in precision treatment evaluation. This provides a powerful tool for the diagnosis and treatment monitoring of OC and plays a critical role in precision medicine.

> **中文摘要：**
> 目前，由于缺乏卵巢癌（OC）特异性生物标志物，阻碍了精准无创诊断和监测策略的发展。外泌体表面唾液酸（SA）是细胞间通讯和疾病进展的关键介质，作为一种极具潜力的生物标志物脱颖而出，尽管其在卵巢癌中的作用尚不明确。传统的外泌体分离和检测方法临床应用受限。在此，我们开发了一种功能化CD63适配体的金阵列芯片，集成了表面增强拉曼散射（SERS）纳米传感器，用于灵敏的SA分析。该芯片能高效地从临床血清中分离出外泌体，而纳米传感器通过分子识别选择性地结合外泌体SA，从而改变纳米传感器的SERS强度比。更重要的是，机器学习可以从SERS光谱中识别SA特征，在卵巢癌诊断中实现了93%的准确率。对整个治疗期间（术前、术后和化疗）SA的纵向监测揭示了其与临床指标（CA125、HE4）所指示的治疗反应之间存在潜在关联，证明了外泌体SA在精准治疗评估中的应用价值。这为卵巢癌的诊断和治疗监测提供了一个强有力的工具，并在精准医疗中发挥着关键作用。

### 第二部分 AI 大师评价

本研究通过整合CD63适配体功能化金阵列芯片与SERS技术，开发了一种新型外泌体表面唾液酸（SA）检测平台。研究亮点在于利用机器学习算法对SERS光谱特征进行深度挖掘，在卵巢癌诊断中实现了高达93%的准确率，并成功实现了对患者术前、术后及化疗全周期的纵向动态监测。该研究不仅揭示了SA作为卵巢癌生物标志物的临床价值，还为外泌体分析在精准医疗中的转化应用提供了创新的技术方案。

---

## 16. 异常SUMO化限制了可靶向的癌症免疫肽组

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566667)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41566667
**DOI：** 10.1002/advs.202511449

### 第一部分 原文与翻译

**英文原标题：** Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome.

> **英文摘要：**
> A balanced SUMOylation equilibrium safeguards the functional anti-tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor-immune synapse, we applied HLA class-I-targeted ligandomics and identified a function of activated SUMOylation in restricting the immunopeptidome landscape. Importantly, aberrant SUMOylation suppressed a unique HLA-I peptide and oncoprotein-derived neoepitope repertoire, enabling cancer cells to evade T cell immune surveillance. Mechanistically, SUMOylation impaired the immunoproteasome constitution and proteolytic activity, thus limiting the diversity of the peptide landscape. Further, SUMOylation altered TAP1 transporter binding preferences, thereby mimicking viral immune evasion strategies. As an actionable application, pharmacological inhibition of SUMOylation unmasked the targetable immunopeptidome, enhanced the tumor cell susceptibility to T cell killing and substantially reshaped the immune cell landscape. These findings highlight SUMOylation as a critical regulator of the adaptive anti-tumor immune response. We propose SUMOylation inhibition as a strategy to enhance immunogenic peptide presentation, thereby improving the efficacy of cancer immunotherapies.

> **中文摘要：**
> 平衡的SUMO化稳态保障了功能性抗肿瘤免疫反应。癌基因激活驱动了SUMO化，使得异常SUMO化成为癌症的一个特征。为了描绘活化的SUMO化对肿瘤-免疫突触的影响，我们应用了HLA I类靶向配体组学，并发现了活化的SUMO化在限制免疫肽组景观中的作用。重要的是，异常SUMO化抑制了一套独特的HLA-I肽和癌蛋白衍生的新表位库，使癌细胞能够逃避T细胞免疫监视。从机制上讲，SUMO化损害了免疫蛋白酶体的组成和蛋白水解活性，从而限制了肽景观的多样性。此外，SUMO化改变了TAP1转运蛋白的结合偏好，从而模拟了病毒的免疫逃逸策略。作为一种可行的应用，SUMO化的药理学抑制揭示了可靶向的免疫肽组，增强了肿瘤细胞对T细胞杀伤的敏感性，并显著重塑了免疫细胞景观。这些发现强调了SUMO化是适应性抗肿瘤免疫反应的关键调节因子。我们提出抑制SUMO化作为一种增强免疫原性肽呈递的策略，从而提高癌症免疫疗法的疗效。

### 第二部分 AI 大师评价

本研究深入揭示了异常SUMO化在介导肿瘤免疫逃逸中的关键机制，通过HLA-I类配体组学证实了SUMO化通过干扰免疫蛋白酶体活性及TAP1转运功能来限制新抗原的呈递。研究不仅阐明了活化的SUMO化如何重塑免疫肽组景观以逃避T细胞监控，更提出了药理学抑制SUMO化这一极具前景的临床转化策略。该发现为增强肿瘤免疫原性及提升现有免疫疗法的疗效提供了全新的分子靶点和理论依据。

---

## 17. 微环境引导演化的ssDNA-SWCNT探针用于选择性识别侵袭性前列腺癌表型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566610)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41566610
**DOI：** 10.1002/advs.202518582

### 第一部分 原文与翻译

**英文原标题：** Microenvironment-Guided Evolution of ssDNA-SWCNT Probes for Selective Recognition of Aggressive Prostate Cancer Phenotypes.

> **英文摘要：**
> Despite advances in prostate cancer detection, distinguishing indolent from aggressive phenotypes remains challenging. We report a microenvironment-guided strategy for evolving phenotype-specific molecular probes using single-stranded DNA-functionalized single-walled carbon nanotubes (ssDNA-SWCNTs). Our approach employs 3D tumor models that recapitulate complex cancer microenvironments, enabling identification of ssDNA sequences with differential binding properties. We developed two distinct probes for prostate cancer cells: PC3D2, which preferentially binds hypoxia-adapted stem-like cells associated with treatment resistance, and PC2D2, which shows enhanced binding to mesenchymal-like cells. These probes exhibit characteristic second near-infrared (NIR-II, 1000-1700 nm) fluorescence, enabling non-invasive detection of aggressive phenotypes in heterogeneous tumors using NIR-II optical imaging. We demonstrate their utility for selective drug delivery to prostate cancer spheroids, resulting in enhanced therapeutic efficacy. This platform represents a significant advancement in precision diagnostics and theranostics, potentially transforming prostate cancer management through phenotype-specific targeting. The methodology offers a generalizable approach for developing nanoprobes that recognize clinically relevant cancer phenotypes based on their unique microenvironmental signatures rather than individual biomarkers.

> **中文摘要：**
> 尽管前列腺癌检测取得了进展，但区分惰性与侵袭性表型仍具挑战。我们报告了一种利用单链DNA功能化单壁碳纳米管（ssDNA-SWCNTs）演化表型特异性分子探针的微环境引导策略。我们的方法采用能够模拟复杂癌症微环境的3D肿瘤模型，从而能够鉴定具有差异结合特性的ssDNA序列。我们为前列腺癌细胞开发了两种截然不同的探针：PC3D2，它优先结合与治疗耐药相关的缺氧适应性干细胞样细胞；以及PC2D2，它对间充质样细胞表现出增强的结合能力。这些探针表现出特征性的第二近红外（NIR-II, 1000-1700 nm）荧光，能够利用NIR-II光学成像对异质性肿瘤中的侵袭性表型进行非侵入性检测。我们展示了它们在前列腺癌球体选择性药物递送中的效用，从而提高了治疗效率。该平台代表了精准诊断和诊疗一体化的重大进展，有望通过表型特异性靶向改变前列腺癌的管理。该方法提供了一种通用策略，用于开发基于临床相关癌症表型独特的微环境特征而非单一生物标志物进行识别的纳米探针。

### 第二部分 AI 大师评价

该研究创新性地提出了一种基于微环境引导的ssDNA-SWCNT纳米探针演化平台，成功实现了对侵袭性前列腺癌不同表型（如缺氧干细胞样和间充质样细胞）的选择性识别。通过整合模拟复杂微环境的3D肿瘤模型与NIR-II成像技术，该方案不仅提升了肿瘤异质性识别的精准度，还实现了高效的表型特异性药物递送。其核心突破在于利用微环境特征而非单一生物标志物进行探针筛选，为复杂肿瘤的精准诊疗和临床管理提供了极具潜力的新策略。

---

## 18. 肿瘤细胞外囊泡 lncOSLMT 通过 m6A 依赖的 hnRNPA2B1/COX-2 轴驱动骨肉瘤肺部炎症性转移前生态位形成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566573)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41566573
**DOI：** 10.1002/advs.202519490

### 第一部分 原文与翻译

**英文原标题：** Tumor Extracellular Vesicles lncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A-Dependent hnRNPA2B1/COX-2 Axis.

> **英文摘要：**
> Tumor-derived extracellular vesicles (EVs) play critical roles in premetastatic niche (PMN) formation. Here, we demonstrated that EVs from highly metastatic osteosarcoma cell lines preferentially localized to lung fibroblasts and induce inflammatory PMN formation. High-throughput profiling of EVs-derived long noncoding RNAs (lncRNAs) identified lncOSLMT as a candidate enriched in EVs and markedly upregulated in patient tumors and serum, with elevated levels correlating with poor prognosis. Mechanistically, in EVs, lncOSLMT directly bound the RNA-binding protein hnRNPA2B1. Following internalization by recipient lung fibroblasts, hnRNPA2B1 bound to N-methyladenosine (mA) -modified sites in the 3'UTR of PTGS2 mRNA, leading to transcript stabilization and increased COX-2 expression. For therapeutic intervention, we developed lactoferrin-resveratrol (LF-RES) nanoparticles, which loaded siRNA against lncOSLMT. Intravenous administration of LF-RES-siRNA in mice reduced EVs-induced lung inflammation and suppressed lung metastasis. Combination with EP2/EP4 antagonists produced enhanced anti-metastatic effects. These findings establish EVs-derived lncOSLMT as a key regulator of inflammatory PMN formation in the lung and highlight the potential of LF-RES-siRNA nanoparticles as a targeted anti-metastatic therapy in osteosarcoma.

> **中文摘要：**
> 肿瘤来源的细胞外囊泡（EVs）在转移前生态位（PMN）的形成中起着关键作用。在此，我们证明了来自高转移性骨肉瘤细胞系的 EVs 优先定位于肺成纤维细胞并诱导炎症性 PMN 形成。通过对 EVs 来源的长链非编码 RNAs（lncRNAs）进行高通量分析，鉴定出 lncOSLMT 是一种在 EVs 中富集并在患者肿瘤和血清中显著上调的候选分子，其水平升高与预后不良相关。从机制上讲，在 EVs 中，lncOSLMT 直接结合 RNA 结合蛋白 hnRNPA2B1。被受体肺成纤维细胞内化后，hnRNPA2B1 结合 PTGS2 mRNA 3'UTR 中的 N6-甲基腺苷（m6A）修饰位点，导致转录本稳定和 COX-2 表达增加。为了进行治疗干预，我们开发了装载针对 lncOSLMT 的 siRNA 的乳铁蛋白-白藜芦醇（LF-RES）纳米颗粒。在小鼠中静脉注射 LF-RES-siRNA 减少了 EVs 诱导的肺部炎症并抑制了肺转移。与 EP2/EP4 拮抗剂联合使用产生了增强的抗转移效果。这些发现确立了 EVs 来源的 lncOSLMT 是肺部炎症性 PMN 形成的关键调节因子，并突出了 LF-RES-siRNA 纳米颗粒作为骨肉瘤靶向抗转移疗法的潜力。

### 第二部分 AI 大师评价

本研究深入揭示了骨肉瘤通过细胞外囊泡（EVs）重塑远端器官微环境的分子机制，重点阐述了 lncOSLMT 跨细胞调控肺成纤维细胞的过程。研究亮点在于发现了 m6A 修饰介导的 hnRNPA2B1/COX-2 信号轴在炎症性转移前生态位（PMN）形成中的核心作用。此外，研究者开发的 LF-RES 纳米颗粒递送系统展现了良好的生物相容性与靶向治疗潜力，为骨肉瘤肺转移的临床防治提供了新策略和实验依据。

---

## 19. 超越二元死亡终点：用于胰十二指肠切除术后死亡表型特异性根本原因分析的 T-MOD PD 框架（时间-机制-机会-疾病）：一项回顾性观察性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566535)
**期刊：** Annals of surgery
**PMID：** 41566535
**DOI：** 10.1097/SLA.0000000000007017

### 第一部分 原文与翻译

**英文原标题：** Beyond Binary Mortality Endpoints: The T-MOD PD Framework (Timing-Mechanism-Opportunity-Disease) for Phenotype-Specific Root Cause Analysis of Mortality after Pancreatoduodenectomy A Retrospective Observational Cohort Study.

> **英文摘要：**
> OBJECTIVE: To evaluate the T-MOD PD (Timing-Mechanism-Opportunity-Disease) framework for classifying mortality after pancreatoduodenectomy (PD), focusing on preventability and rescue opportunities. BACKGROUND: Pancreatoduodenectomy mortality (2-10%) is reported as binary endpoints, obscuring distinctions between surgery-related and systemic causes and limiting targeted quality improvement. METHODS: Retrospective analysis of 1,727 consecutive PDs (2014-2024) at a high-volume centre. All 58 deaths (3.4%) were independently adjudicated across four axes: Timing (T1-T3), Mechanism (M1-M3), Opportunity (O1-O4), and Disease (D1-D3). Deaths were categorized as surgery-attributable potentially preventable (SAPM), surgery-attributable non-preventable (SANPM), or non-surgery-attributable mortality (NSAM). RESULTS: Striking phenotypic clustering emerged: 38% of deaths (22/58) converged in T1M1O1D1 (early, surgery-related, strategically modifiable, resectable disease), with 19% (11/58) in T2M1O1D1. Together, these postoperative pancreatic fistula (POPF)-driven phenotypes accounted for 57% of mortality. Domain analysis revealed 66% early deaths (T1), 74% surgery-related mechanisms (M1), and critically, 72% potentially modifiable opportunities (O1: 72%; O2: 22%; O3: 2%; O4: 3%). Overall, 74% were classified as SAPM. Timeline reconstruction identified median 72-hour delays in recognition and escalation despite warning signs at postoperative day 5-6, with 22-day median interval from clinically relevant POPF diagnosis to death, suggesting 35-40% preventability in the dominant phenotype. Perfect interobserver agreement was achieved (κ=1.0). CONCLUSIONS: T-MOD PD provides reproducible mortality phenotyping revealing 72% of deaths are potentially modifiable, with dominant phenotypes sharing POPF pathways and identifiable rescue delays, enabling phenotype-specific quality improvement.

> **中文摘要：**
> 目的：评估 T-MOD PD（时间-机制-机会-疾病）框架在胰十二指肠切除术（PD）后死亡分类中的应用，重点关注可预防性和营救机会。背景：胰十二指肠切除术的死亡率（2-10%）通常以二元终点形式报告，这掩盖了手术相关原因与全身性原因之间的区别，并限制了针对性的质量改进。方法：对一家高业务量中心连续进行的 1,727 例 PD（2014-2024 年）进行回顾性分析。所有 58 例死亡（3.4%）均根据四个轴进行了独立裁定：时间（T1-T3）、机制（M1-M3）、机会（O1-O4）和疾病（D1-D3）。死亡被分为手术相关潜在可预防死亡（SAPM）、手术相关不可预防死亡（SANPM）或非手术相关死亡（NSAM）。结果：出现了显著的表型聚集：38% 的死亡（22/58）集中在 T1M1O1D1（早期、手术相关、战略上可修正、可切除疾病），19%（11/58）集中在 T2M1O1D1。这些由术后胰瘘（POPF）驱动的表型共占死亡总数的 57%。领域分析显示，早期死亡占 66%（T1），手术相关机制占 74%（M1），至关重要的是，潜在可修正机会占 72%（O1：72%；O2：22%；O3：2%；O4：3%）。总体而言，74% 被归类为 SAPM。时间线重建发现，尽管在术后第 5-6 天出现预警信号，但识别和升级的延迟中位数为 72 小时，从临床相关 POPF 诊断到死亡的中位间隔为 22 天，这表明主导表型的可预防性为 35-40%。实现了完美的观察者间一致性（κ=1.0）。结论：T-MOD PD 提供了可重复的死亡表型分析，揭示了 72% 的死亡具有潜在可修正性，其中主导表型具有共同的 POPF 路径和可识别的营救延迟，从而实现了针对特定表型的质量改进。

### 第二部分 AI 大师评价

该研究通过构建创新的 T-MOD PD 四维框架，打破了传统外科死亡率仅作为“生或死”二元指标的局限性，实现了对胰十二指肠切除术后死亡原因的深层解构。研究发现超过 70% 的死亡具有潜在可修正性，尤其是术后胰瘘相关的营救延迟（Failure to Rescue）是关键突破口。其优势在于提供了高度可重复且结构化的临床审计工具，为外科质量改进提供了精准的表型定位；局限性在于该研究基于单中心回顾性数据，其框架在不同资源背景下的普遍适用性仍需进一步验证。

---

## 20. OCTN2 激活非经典肉碱代谢途径以促进 MASH-HCC 进展及免疫治疗耐药

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566533)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41566533
**DOI：** 10.1002/advs.202517054

### 第一部分 原文与翻译

**英文原标题：** OCTN2 Activates a Non-Canonical Carnitine Metabolic Pathway to Promote MASH-HCC Progression and Immunotherapy Resistance.

> **英文摘要：**
> Metabolic dysfunction-associated steatohepatitis related hepatocellular carcinoma (MASH-HCC) is a distinct HCC subtype characterized by lipid accumulation, impaired fatty acid oxidation (FAO), immune evasion, and resistance to immunotherapy. In this study, we observed elevated levels of L-carnitine-a classical FAO activator-and its transporter OCTN2 in MASH-HCC. Mechanistically, L-carnitine is redirected from FAO promotion to buffering intracellular acetyl groups via conversion to acetyl-L-carnitine, leading to acetyl group depletion. This disrupts protein acetylation through two distinct pathways: reduced acetylation of p53 weakens its tumor-suppressive signaling and promotes tumor progression, while decreased acetylation of histone H3 impairs MHC-I antigen presentation, facilitating immune evasion. We further identified that the lncRNA LINCMD1 competitively bound the E3 ligase DZIP3, sequestering it in the nucleus and preventing its interaction with cytoplasmic OCTN2. This inhibited K48-linked ubiquitination of OCTN2 and stabilized its protein expression, further amplifying L-carnitine accumulation. To therapeutically target this axis, we developed a liver-specific lipid nanoparticle (LNP)-delivered antisense oligonucleotide against the DZIP3-binding region of LINCMD1, which restored p53 and MHC-I pathways and enhanced anti-PD-1 efficacy in vivo. Together, our findings uncover a noncanonical carnitine-driven metabolic-epigenetic-immune bypass in MASH-HCC and identify the LINCMD1/DZIP3/OCTN2-L-carnitine axis as a potential therapeutic target.

> **中文摘要：**
> 代谢功能障碍相关脂肪性肝炎相关的肝细胞癌（MASH-HCC）是一种独特的 HCC 亚型，其特征是脂质积累、脂肪酸氧化（FAO）受损、免疫逃逸以及对免疫治疗的耐药性。在本研究中，我们在 MASH-HCC 中观察到 L-肉碱（一种经典的 FAO 激活剂）及其转运蛋白 OCTN2 的水平升高。从机制上讲，L-肉碱的用途发生了改变，从促进 FAO 转向通过转化为乙酰-L-肉碱来缓冲细胞内乙酰基，从而导致乙酰基耗竭。这通过两条截然不同的途径破坏了蛋白质乙酰化：p53 乙酰化水平降低削弱了其肿瘤抑制信号并促进了肿瘤进展，而组蛋白 H3 乙酰化水平降低则损害了 MHC-I 抗原呈递，从而促进了免疫逃逸。我们进一步确定 lncRNA LINCMD1 竞争性结合 E3 连接酶 DZIP3，将其螯合在细胞核中，并阻止其与细胞质中的 OCTN2 发生相互作用。这抑制了 OCTN2 的 K48 连接泛素化并稳定了其蛋白质表达，进一步放大了 L-肉碱的积累。为了靶向该轴线进行治疗，我们开发了一种肝脏特异性脂质纳米颗粒（LNP）递送的反义寡核苷酸，旨在针对 LINCMD1 的 DZIP3 结合区域，该方法恢复了 p53 和 MHC-I 通路，并在体内增强了抗 PD-1 的疗效。总之，我们的研究发现揭示了 MASH-HCC 中一种非经典的肉碱驱动的代谢-表观遗传-免疫旁路，并确定了 LINCMD1/DZIP3/OCTN2-L-肉碱轴为一个潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究深入探讨了 MASH-HCC 中肉碱代谢异常的新机制，揭示了 OCTN2 通过非经典途径耗竭乙酰基，从而在表观遗传水平上抑制抑癌基因 p53 和 MHC-I 介导的抗原呈递。研究通过鉴定 lncRNA LINCMD1 对 OCTN2 的稳定作用，完善了代谢-免疫逃逸的调控网络。其实践意义在于开发了肝脏特异性 LNP-ASO 疗法，为克服肝癌免疫治疗耐药提供了极具前景的代谢-免疫联合治疗新策略。

---

## 21. 人类癌症中的长链非编码RNA PVT1：基因组复杂性、异构体、功能元件、作用机制、亚细胞定位及作为治疗靶点的潜在作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566477)
**期刊：** Molecular cancer
**PMID：** 41566477
**DOI：** 10.1186/s12943-026-02576-y

### 第一部分 原文与翻译

**英文原标题：** LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文综述了长链非编码RNA PVT1在人类癌症中的多重角色，系统阐述了其基因组结构的复杂性以及不同剪接异构体的功能差异。文章详细探讨了PVT1通过表观遗传调节、分子诱饵及亚细胞定位特异性影响肿瘤进展的分子机制。评价认为，该文献全面整合了PVT1从基础生物学到临床应用的最新研究，特别强调了其作为精准医学治疗靶点的潜力，为未来针对非编码RNA的癌症治疗方案设计提供了重要理论依据。

---

## 22. 结直肠癌中癌症干细胞驱动的耐药性：分子机制与治疗潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566465)
**期刊：** Molecular cancer
**PMID：** 41566465
**DOI：** 10.1186/s12943-025-02557-7

### 第一部分 原文与翻译

**英文原标题：** Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials.

> **英文摘要：**
> Colorectal cancer (CRC) remains a major global health burden, with therapeutic resistance accounting for the majority of treatment failures and cancer-related deaths. Cancer stem cells (CSCs), which possess intrinsic drug tolerance and self-renewal capacity, drive both primary and acquired resistance. CSCs maintain drug tolerance through the activation of core signaling cascades, including Wnt/β-catenin, Notch, Hedgehog, PI3K/Akt, and MAPK/ERK pathways, as well as through epithelial-mesenchymal transition (EMT), enhanced DNA repair, and PD-1/PD-L1-mediated immune evasion. These molecular alterations transform the tumor microenvironment (TME) into a stemness-supportive, immunosuppressive niche, thereby promoting tumor recurrence and metastasis. Recent advances in CSCs-directed therapy include monoclonal antibodies targeting stem cell surface antigens, small-molecule inhibitors that disrupt self-renewal pathways, epigenetic agents that reprogram stemness, and immunotherapies aimed at reactivating anti-tumor immune surveillance. Emerging multi-drug regimens that combine CSCs-targeted agents with chemotherapy, pathway inhibitors, or immune checkpoint blockade exhibit synergistic efficacy by simultaneously disrupting multiple resistance mechanisms. Additionally, nanotechnology-based delivery systems further improve drug bioavailability and tumor specificity while reducing systemic toxicity. Despite notable progress, substantial challenges remain, including the pronounced heterogeneity of CSCs, activation of compensatory signaling pathways, and the lack of robust biomarkers for CSCs identification and therapeutic monitoring. Future research should prioritize integrative multi-omics approaches to delineate CSCs-specific vulnerabilities, the rational development of synergistic combination therapies, and the efficient clinical translation of CSCs-directed strategies. This review aims to describe the molecular mechanisms of CSCs-driven drug resistance in CRC, highlighting the current and emerging therapeutic strategies to guide the development of more effective, personalized interventions.

> **中文摘要：**
> 结直肠癌（CRC）仍然是全球主要的健康负担，治疗耐药性是导致大多数治疗失败和癌症相关死亡的原因。具有内在药物耐受性和自我更新能力的癌症干细胞（CSCs）驱动了原发性和获得性耐药。CSCs通过激活核心信号级联反应（包括Wnt/β-catenin、Notch、Hedgehog、PI3K/Akt和MAPK/ERK通路），以及通过上皮-间充质转化（EMT）、增强的DNA修复和PD-1/PD-L1介导的免疫逃逸来维持药物耐受性。这些分子改变将肿瘤微环境（TME）转变为支持干性、免疫抑制的生态位，从而促进肿瘤复发和转移。针对CSCs治疗的最新进展包括靶向干细胞表面抗原的单克隆抗体、破坏自我更新通路的小分子抑制剂、重编程干性的表观遗传药物，以及旨在重新激活抗肿瘤免疫监视的免疫疗法。将靶向CSCs药物与化疗、通路抑制剂或免疫检查点阻断相结合的新型多药方案，通过同时破坏多种耐药机制表现出协同疗效。此外，基于纳米技术的递送系统进一步提高了药物的生物利用度和肿瘤特异性，同时降低了全身毒性。尽管取得了显著进展，但仍存在重大挑战，包括CSCs显著的异质性、补偿性信号通路的激活，以及缺乏用于CSCs识别和治疗监测的可靠生物标志物。未来的研究应优先考虑整合多组学方法以描绘CSCs特有的脆弱性，理性开发协同联合疗法，并有效推进针对CSCs策略的临床转化。本综述旨在描述结直肠癌中CSCs驱动耐药的分子机制，强调当前和新兴的治疗策略，以指导开发更有效、更个性化的干预措施。

### 第二部分 AI 大师评价

本文系统地总结了结直肠癌（CRC）中癌症干细胞（CSCs）驱动耐药的多维分子机制，包括核心信号通路激活、微环境重塑及免疫逃逸。文章亮点在于全面梳理了从单抗、小分子抑制剂到纳米递送系统等前沿治疗手段，并深入探讨了联合用药的协同潜力。尽管全面，但文章也指出了CSCs异质性及缺乏特异性生物标志物等临床转化中的关键障碍，为未来通过多组学技术开发个性化诊疗方案提供了清晰的路径引导。

---

## 23. 癌症中的乳酸化修饰：分子机制及临床研究进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566389)
**期刊：** Molecular cancer
**PMID：** 41566389
**DOI：** 10.1186/s12943-026-02573-1

### 第一部分 原文与翻译

**英文原标题：** Lactylation in cancer: molecular mechanisms and advances in clinical study.

> **英文摘要：**
> Lysine lactylation (Kla), first described in 2019, is an emerging post-translational modification that converts lactate availability into changes in chromatin state and protein function. In cancer, where glycolysis and microenvironmental hypoxia often elevate lactate, lactylation has been linked to transcriptional reprogramming, immune modulation, cellular plasticity, and therapy resistance. Here, we synthesize current evidence across major organ systems to clarify how lactylation is generated, interpreted, and removed, and how it interacts with tumor metabolism and the tumor microenvironment. We summarize enzymatic and non-enzymatic routes to Kla formation, discuss candidate writers, erasers, and readers, and highlight recurring mechanistic patterns spanning histone and non-histone substrates, including regulation of immune-evasive signaling, ferroptosis susceptibility, DNA repair, and stress-adaptation programs. We also integrate translational considerations, outlining druggable nodes within lactate production and transport pathways and within acetyltransferase and deacylase systems, and discuss how lactylation measurements could support patient stratification, pharmacodynamic monitoring, and rational combination strategies. Finally, we identify key open questions that currently limit clinical translation, including site-level causality, cell-type and spatial attribution in patient tissues, assay specificity and quantitative stoichiometry, and the conditions under which lactylation promotes versus restrains tumor progression. Together, this framework aims to guide mechanistic studies and accelerate the development of clinically actionable lactylation-directed interventions.

> **中文摘要：**
> 赖氨酸乳酸化（Kla）于2019年首次被描述，是一种新兴的翻译后修饰，可将乳酸的可获得性转化为染色质状态和蛋白质功能的变化。在癌症中，糖酵解和微环境缺氧通常会导致乳酸升高，乳酸化修饰与转录重编程、免疫调节、细胞可塑性和治疗耐药性密切相关。本文综合了主要器官系统的现有证据，以阐明乳酸化是如何产生、解读和去除的，以及它如何与肿瘤代谢和肿瘤微环境相互作用。我们总结了 Kla 形成的酶促和非酶促途径，讨论了候选的写入蛋白（writers）、擦除蛋白（erasers）和读取蛋白（readers），并重点介绍了涵盖组蛋白和非组蛋白底物的循环机制模式，包括免疫逃逸信号传导、铁死亡敏感性、DNA修复和应激适应程序的调节。我们还整合了转化医学方面的考量，概述了乳酸生成和运输途径以及乙酰转移酶和去酰基酶系统中的成药节点，并讨论了乳酸化测量如何支持患者分层、药效动力学监测和合理的联合治疗策略。最后，我们确定了目前限制临床转化的关键开放性问题，包括位点水平的因果关系、患者组织中的细胞类型和空间归属、检测特异性和定量化学计量比，以及乳酸化促进或抑制肿瘤进展的条件。总之，该框架旨在指导机制研究，并加速临床可行的乳酸化导向干预措施的开发。

### 第二部分 AI 大师评价

本文系统地综述了赖氨酸乳酸化（Kla）在癌症发生发展中的核心地位，将其作为连接肿瘤代谢异常与表观遗传重构的关键纽带。文章不仅详尽归纳了Kla的生化调控机制及其对免疫逃逸、耐药性等恶性表型的驱动作用，还前瞻性地探讨了其在临床诊断、患者分层及靶向药物开发中的应用潜力。综述内容全面且具有高度的跨学科整合性，为从代谢角度破解肿瘤治疗难题提供了清晰的路线图，是该领域极具参考价值的学术文献。

---

## 24. piR-1170 通过 WTAP 介导的 m6A 甲基化重塑驱动三阴性乳腺癌的脑转移和免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566302)
**期刊：** Molecular cancer
**PMID：** 41566302
**DOI：** 10.1186/s12943-026-02568-y

### 第一部分 原文与翻译

**英文原标题：** piR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究揭示了 piRNA 成员 piR-1170 在三阴性乳腺癌（TNBC）恶性演进中的核心作用，特别是其对脑转移及免疫逃逸的驱动机制。研究通过阐明 piR-1170 调节 WTAP 进而诱导 m6A 甲基化水平重塑的通路，为 TNBC 的精准治疗提供了新的分子靶点。这一发现对于理解非编码 RNA 如何通过表观遗传修饰调控肿瘤微环境具有重要的学术价值，尽管目前缺乏摘要细节，但其发表于 Molecular Cancer 证明了该机制研究的深度与前沿性。

---

## 25. 转化研究与创新实验室（TRAIL）模型：通过共享机构资源加速发现

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566041)
**期刊：** Nature medicine
**PMID：** 41566041
**DOI：** 10.1038/s41591-025-04167-8

### 第一部分 原文与翻译

**英文原标题：** The Translational Research and Innovation Laboratory (TRAIL) model for accelerating discovery through a shared institutional resource.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究介绍了转化研究与创新实验室（TRAIL）模型，这是一种通过整合共享机构资源来加速科学发现转化的创新路径。该模型强调了跨学科协作与集中化资源管理在提升研究效率方面的关键作用，为解决生物医学研究中的转化瓶颈提供了制度化方案。其提出的系统性架构对学术医疗中心优化内部创新生态及资源配置具有显著的借鉴意义。

---

## 26. 探究胶质母细胞瘤神经元连接性的跨突触示踪技术

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566037)
**期刊：** Nature protocols
**PMID：** 41566037
**DOI：** 10.1038/s41596-025-01287-w

### 第一部分 原文与翻译

**英文原标题：** Transsynaptic tracing techniques to interrogate neuronal connectivity of glioblastomas.

> **英文摘要：**
> Glioblastomas (GBMs) functionally integrate into diverse neuronal circuits within the central nervous system, which can promote tumor progression and affect neurons via neuron-to-glioma synapses. It remains challenging to identify and manipulate tumor-innervating neurons, which may remain localized or widely distributed throughout the brain. Building on GBM organoids (GBOs) derived from patient-resected surgical tissue, we present here detailed procedures for assessing interactions between tumors and neurons. We first discuss retrograde trans-monosynaptic tracing approaches to study the neuron-tumor connectome by using a rabies viral system in ex vivo human tissue and in xenogenic animal models. As a complementary approach, we then describe the use of anterograde transsynaptic tracing using herpes simplex virus in vivo and ex vivo to assess brain region-specific connectivity in GBMs. In addition, to facilitate the adaptability of these tracing methodologies in diverse systems, we provide procedures for the viral transduction into GBOs, the generation of assembloids comprising GBOs and human induced pluripotent stem cell-derived cortical organoids and the establishment of air-liquid interface cultures from surgical human brain tissue. Together, these techniques permit the flexible characterization and manipulation of tumor-neural circuits and can be easily adapted to other cancers with nervous system involvement. After the generation of GBOs and/or cortical organoids, transsynaptic tracing requires 12-35 d to complete ex vivo or in vivo. The procedure is suitable for users with expertise in human cell and organoid culture, viral production and transduction, rodent surgery and microscopy.

> **中文摘要：**
> 胶质母细胞瘤（GBMs）功能性地整合到中枢神经系统内多种不同的神经回路中，这可以通过神经元-胶质瘤突触促进肿瘤进展并影响神经元。目前，识别和操纵支配肿瘤的神经元仍然具有挑战性，这些神经元可能局限分布或广泛分布于整个大脑。基于从患者手术切除组织中提取的GBM类器官（GBOs），我们在此介绍了评估肿瘤与神经元之间相互作用的详细实验步骤。我们首先讨论了通过在离体人类组织和异种动物模型中使用狂犬病毒系统，来研究神经元-肿瘤连接组的逆行跨单突触示踪方法。作为一种补充方法，我们随后描述了在体内和离体条件下使用单纯疱疹病毒进行顺行跨突触示踪，以评估GBM中特定脑区的连接性。此外，为了提高这些示踪方法在不同系统中的适用性，我们提供了将病毒转导至GBOs、生成由GBOs和人类诱导多能干细胞衍生的皮层类器官组成的组装体（assembloids），以及建立手术切除人类脑组织气液界面培养物的操作流程。总之，这些技术能够实现对肿瘤-神经回路的灵活表征和操纵，并可轻松推广应用于其他涉及神经系统的癌症。在生成GBOs和/或皮层类器官后，跨突触示踪在离体或体内完成需要12至35天。该流程适用于在人类细胞和类器官培养、病毒生产与转导、啮齿动物手术及显微成像方面具有专业知识的研究人员。

### 第二部分 AI 大师评价

本文系统性地介绍了一套针对胶质母细胞瘤（GBM）神经连接性的跨突触示踪技术方案，涵盖了基于狂犬病毒和单纯疱疹病毒的顺行与逆行示踪手段。通过整合患者来源的GBM类器官、脑类器官组装体及气液界面培养等前沿模型，该研究为在细胞和回路层面解析“神经元-肿瘤”相互作用提供了高分辨率的工具箱。该方案的创新之处在于其高度的灵活性和对人类临床样本的适配性，对于深入理解神经系统受累肿瘤的病理机制及开发针对性疗法具有显著的转化医学价值。

---

## 27. 更正：CBX2作为结直肠癌的治疗靶点：通过RUNX1-CBX2-MAP4K1轴对染色质可及性改变的见解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41566000)
**期刊：** Oncogene
**PMID：** 41566000
**DOI：** 10.1038/s41388-026-03677-0

### 第一部分 原文与翻译

**英文原标题：** Correction: CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该条目是针对发表在《Oncogene》杂志上关于CBX2在结直肠癌中作用研究的勘误通知。原研究重点探讨了CBX2如何通过RUNX1-CBX2-MAP4K1轴调控染色质可及性，揭示了其作为结直肠癌潜在治疗靶点的生物学机制。尽管当前文本仅为更正说明且无摘要，但其指向的研究在表观遗传调控和肿瘤精准治疗领域具有重要的学术价值。此类更正对于维护科研数据的准确性和学术严谨性至关重要。

---

## 28. 出版商更正：多胺依赖性代谢屏蔽调节选择性剪接。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565829)
**期刊：** Nature
**PMID：** 41565829
**DOI：** 10.1038/s41586-026-10140-3

### 第一部分 原文与翻译

**英文原标题：** Publisher Correction: Polyamine-dependent metabolic shielding regulates alternative splicing.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是针对《自然》杂志上发表的关于多胺代谢与基因剪接研究的官方出版更正。原研究探讨了代谢产物多胺如何通过“代谢屏蔽”效应来调控细胞内的选择性剪接机制，展现了代谢组学与转录调控之间的深度交互。此类更正通告对于维护顶尖学术期刊数据的严谨性至关重要，确保了科研结论在后续引用中的准确性。

---

## 29. 出版者更正：雌二醇的多重功能抑制铁死亡和急性肾损伤。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565828)
**期刊：** Nature
**PMID：** 41565828
**DOI：** 10.1038/s41586-026-10148-9

### 第一部分 原文与翻译

**英文原标题：** Publisher Correction: Multiple oestradiol functions inhibit ferroptosis and acute kidney injury.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献是发表于《Nature》杂志的一项出版者更正，旨在对先前关于雌二醇抑制铁死亡及急性肾损伤的研究内容进行必要的补充或校正。原研究揭示了雌二醇在肾脏保护中的关键生化机制，其通过多重功能干预铁死亡通路。此类更正文件对于确保科学研究的严谨性与实验数据的准确性至关重要，是维护高水平学术成果完整性的标准程序。

---

## 30. 高塑性细胞状态在肺癌中的关键作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565826)
**期刊：** Nature
**PMID：** 41565826
**DOI：** 10.1038/s41586-025-09985-x

### 第一部分 原文与翻译

**英文原标题：** Critical role for a high-plasticity cell state in lung cancer.

> **英文摘要：**
> Plasticity-the ability of cells to undergo phenotypic transitions-drives cancer progression and therapy resistance. Recent studies have suggested that plasticity in solid tumours is concentrated in a minority subset of cancer cells, yet functional studies examining this high-plasticity cell state (HPCS) in situ are lacking. Here we develop mouse models enabling the detection, longitudinal lineage tracing and ablation of the HPCS in autochthonous lung tumours in vivo. Lineage tracing reveals that the HPCS cells possess a high capacity for cell state transitions, giving rise to both early neoplastic (differentiated) and progressed lung cancer cell states in situ. Longitudinal lineage tracing using secreted luciferases reveals that HPCS-derived cells have a high capacity for growth compared with bulk cancer cells or another cancer cell state with features of differentiated lung epithelium. Ablation of HPCS cells in early neoplasias abrogates benign-to-malignant transition, whereas ablation in established tumours by suicide gene or chimeric antigen receptor (CAR) T cells robustly reduces tumour burden. We further demonstrate that the HPCS gives rise to therapy-resistant cell states, whereas HPCS ablation suppresses resistance to chemotherapy and oncoprotein-targeted therapy. Notably, an HPCS-like state is ubiquitous in regenerating epithelia and in carcinomas of multiple other tissues, revealing a convergence of plasticity programs. Our work establishes the HPCS as a critical hub enabling reciprocal transitions between cancer cell states. Targeting the HPCS in lung cancer and in other carcinomas may suppress cancer progression and eradicate treatment resistance.

> **中文摘要：**
> 塑性——即细胞发生表型转变的能力——驱动着癌症的进展和治疗耐药性。近期研究表明，实体瘤中的塑性集中在少数癌细胞子集中，但目前仍缺乏在原位检查这种高塑性细胞状态（HPCS）的功能性研究。在此，我们开发了小鼠模型，能够对活体自发性肺肿瘤中的 HPCS 进行检测、纵向谱系追踪和消融。谱系追踪揭示，HPCS 细胞具有极强的细胞状态转变能力，能在原位产生早期肿瘤（分化型）和进展期肺癌细胞状态。利用分泌型荧光素酶进行的纵向谱系追踪显示，与整体癌细胞或另一种具有分化肺上皮特征的癌细胞状态相比，HPCS 来源的细胞具有极强的生长能力。在早期肿瘤中消融 HPCS 细胞可阻断良性向恶性的转变，而在已形成的肿瘤中通过自杀基因或嵌合抗原受体（CAR）T 细胞消融 HPCS 细胞可显著减轻肿瘤负荷。我们进一步证明 HPCS 会产生耐药细胞状态，而消融 HPCS 则能抑制对化疗和癌蛋白靶向治疗的耐药性。值得注意的是，类 HPCS 状态在再生上皮和多种其他组织的癌中普遍存在，揭示了塑性程序的趋同性。我们的工作确立了 HPCS 是实现癌细胞状态之间相互转换的关键枢纽。靶向肺癌及其他癌中的 HPCS 可能抑制癌症进展并根除治疗耐药。

### 第二部分 AI 大师评价

本研究通过创新的小鼠模型，首次在体内原位界定了肺癌中的高塑性细胞状态（HPCS），并结合纵向谱系追踪和消融技术验证了其核心功能。研究揭示 HPCS 是肿瘤进展、恶性演变及化疗/靶向治疗耐药的关键驱动枢纽，且这种状态在多种上皮癌中具有普遍性。该发现为开发针对细胞塑性的干预策略提供了坚实的生物学基础，具有极高的临床转化潜力，是肿瘤异质性与可塑性研究领域的重大进展。

---

## 31. 婴儿间的菌株传播塑造发育中的肠道微生物组

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565819)
**期刊：** Nature
**PMID：** 41565819
**DOI：** 10.1038/s41586-025-09983-z

### 第一部分 原文与翻译

**英文原标题：** Baby-to-baby strain transmission shapes the developing gut microbiome.

> **英文摘要：**
> The early infant microbiome is largely primed by microbial transmission from the mother between birth and the first few weeks of life, but how interpersonal transmission further shapes the developing microbiome in the first year remains unexplored. Here we report a metagenomic survey to model microbiome transmission in the nursery setting among babies attending the first year, their educators and their families (n = 134 individuals). We performed dense longitudinal microbiome sampling (n = 1,013 faecal samples) during the first year of nursery and tracked microbial strain transmission within and between nursery groups across 3 different facilities. We detected extensive baby-to-baby microbiome transmission within nursery groups even after only 1 month of nursery attendance, with nursery-acquired strains accounting for a proportion of the infant gut microbiome comparable to that from family by the end of the first term. Baby-to-baby transmission continued to grow over the nursery year, in an increasingly intricate transmission network with single strains spreading in some classes, and with multiple baby-acquisition and species-transmissibility patterns. Having siblings was associated with higher microbiome diversity and reduced strain acquisition from nursery peers, while antibiotic treatment was the condition that most accounted for the increased influx of strains. This study shows that microbiome transmission between babies is extensive during the first year of nursery, and points to social interactions in infancy as crucial drivers of infant microbiome development.

> **中文摘要：**
> 婴儿早期的微生物组主要通过出生至出生后几周内来自母亲的微生物传播来启动，但人际传播在第一年如何进一步塑造发育中的微生物组仍未得到探索。在此，我们报告了一项宏基因组调查，旨在模拟托儿所环境下第一年入托婴儿及其教育工作者和家属（n = 134人）之间的微生物组传播。我们在入托的第一年进行了密集的纵向微生物组采样（n = 1,013份粪便样本），并追踪了3个不同设施内及不同托儿所小组之间的微生物菌株传播情况。我们检测到，在入托仅1个月后，托儿所小组内就存在广泛的婴儿间微生物组传播；到第一学期结束时，从托儿所获得的菌株在婴儿肠道微生物组中所占比例已与来自家庭的比例相当。在整个托儿所年度中，婴儿间的传播持续增长，形成了一个日益复杂的传播网络，表现为单菌株在某些班级中传播，以及多种婴儿获取方式和物种传播模式。拥有兄弟姐妹与较高的微生物组多样性以及减少从托儿所同伴处获取菌株相关，而抗生素治疗是与菌株流入增加最相关的因素。本研究表明，在入托的第一年，婴儿间的微生物组传播是广泛存在的，并指出婴儿期的社会交往是婴儿微生物组发育的关键驱动力。

### 第二部分 AI 大师评价

本研究通过对托儿所环境进行高频次纵向宏基因组采样，揭示了婴儿间菌株传播对肠道微生物组发育的重要影响。研究发现，入托第一年内同龄人间的微生物交换非常活跃，其贡献度甚至可比肩家庭成员。研究不仅识别了抗生素使用及兄弟姐妹情况对菌株获取的影响，还描绘了复杂的传播网络。该成果强调了早期社会接触在塑造人体微生物生态中的核心作用，为理解生命早期健康提供了微生态学视角。

---

## 32. 利用DNA三路连接构建复杂且多样的DNA序列

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565816)
**期刊：** Nature
**PMID：** 41565816
**DOI：** 10.1038/s41586-025-10006-0

### 第一部分 原文与翻译

**英文原标题：** Construction of complex and diverse DNA sequences using DNA three-way junctions.

> **英文摘要：**
> The ability to construct entirely new synthetic DNA sequences de novo is essential to engineering and studying biology. However, the ability to produce long complex synthetic DNA sequences and libraries currently lags behind the ability to sequence and edit DNA. All existing DNA-assembly technologies rely on DNA sequence information found within the final construct to direct assembly between DNA molecules. As a result of this paradigm, these sequences cannot be extensively optimized specifically for assembly without affecting the final sequence. To fundamentally address this challenge, here we show the development of a new DNA assembly technique named Sidewinder that separates the information that guides assembly from the final assembled sequence using DNA three-way junctions. We demonstrate the transformative nature of the Sidewinder technique with highly robust and accurate construction of a 40-piece multifragment assembly, complex DNA sequences of both high GC content and high repeats, parallel assembly of multiple distinct genes in the same reaction and a combinatorial library with a large number of diversified positions across the entire length of the gene for high coverage of a library of 442,368 variants. This technology enables high-fidelity DNA assembly with a misconnection rate at the three-way junction of approximately 1 in 1,000,000.

> **中文摘要：**
> 从头构建全新的合成DNA序列的能力对于工程化和研究生物学至关重要。然而，生产长而复杂的合成DNA序列和文库的能力目前落后于测序和编辑DNA的能力。所有现有的DNA组装技术都依赖于最终构建体中所包含的DNA序列信息来引导DNA分子间的组装。由于这一范式的限制，这些序列无法在不影响最终序列的情况下，专门针对组装过程进行广泛优化。为了从根本上解决这一挑战，我们在此展示了一种名为Sidewinder的新型DNA组装技术的开发，该技术利用DNA三路连接将引导组装的信息与最终组装的序列分离开来。我们通过高度稳健且准确地完成40个片段的多片段组装、构建具有高GC含量和高重复性的复杂DNA序列、在同一反应中并行组装多个不同基因，以及构建在整个基因长度上具有大量多样化位点且覆盖442,368个变体的组合文库，证明了Sidewinder技术的变革性。该技术实现了高保真DNA组装，其在三路连接处的错误连接率仅约为百万分之一。

### 第二部分 AI 大师评价

该研究开发了一种名为Sidewinder的新型DNA组装技术，通过引入DNA三路连接结构，成功实现了组装引导信息与最终目标序列的完全解耦。这一创新突破了传统组装技术受限于目标序列特征的瓶颈，能够高效构建高GC含量、高重复性及超大规模变体文库等极具挑战性的序列。实验证明该方法具有极高的稳健性和精确度，错误连接率低至百万分之一，为合成生物学、基因组工程及高通量筛选研究提供了强有力的底层技术支撑。

---

## 33. 成纤维网状细胞通过CD44引导T细胞应答的启动

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565815)
**期刊：** Nature
**PMID：** 41565815
**DOI：** 10.1038/s41586-025-09988-8

### 第一部分 原文与翻译

**英文原标题：** Fibroblastic reticular cells direct the initiation of T cell responses via CD44.

> **英文摘要：**
> The movement of dendritic cells and T cells within secondary lymphoid organs is critical for the development of adaptive immune responses. Central to this process is the fibroblastic reticular cell (FRC) network, which forms a highly organized conduit system that facilitates the movement of and interactions between dendritic cells and T cells. Previous studies have partly characterized how FRCs support these interactions. However, the molecular mechanisms that operate under physiological conditions remain unknown. Here we show that the viral protein m11, encoded by the herpesvirus murine cytomegalovirus (CMV), inhibits antiviral immunity by targeting the FRC network and interfering with a critical function of cellular CD44. We found that m11 binds to CD44 and established that m11 perturbs the molecular interactions of CD44 with its natural ligand, hyaluronic acid. The interaction of m11 with CD44 impairs the trafficking of dendritic cells within the spleen, thereby impeding efficient priming of naive T cells and the initiation of antiviral CD8 T cell responses. The targeting of CD44 by CMV reveals CD44 as a molecule that is essential to the functioning of the FRC network and uncovers a previously unrecognized stroma-based mechanism that is critical for the generation of effective T cell responses.

> **中文摘要：**
> 树突状细胞和T细胞在次级淋巴器官内的移动对于适应性免疫应答的发展至关重要。这一过程的核心是成纤维网状细胞（FRC）网络，它形成了一个高度有序的导管系统，促进了树突状细胞和T细胞之间的移动和相互作用。以前的研究已部分阐明了FRC如何支持这些相互作用。然而，在生理条件下运行的分子机制仍不清楚。在此，我们展示了由疱疹病毒小鼠巨细胞病毒（CMV）编码的病毒蛋白m11，通过靶向FRC网络并干扰细胞CD44的关键功能，从而抑制抗病毒免疫。我们发现m11与CD44结合，并确定m11扰乱了CD44与其天然配体透明质酸的分子相互作用。m11与CD44的相互作用损害了树突状细胞在脾脏内的运输，从而阻碍了初始T细胞的有效致敏和抗病毒CD8 T细胞应答的启动。CMV对CD44的靶向作用揭示了CD44是FRC网络功能所必需的分子，并发现了一种先前未被认识的、对产生有效T细胞应答至关重要的基于间质的机制。

### 第二部分 AI 大师评价

本研究揭示了成纤维网状细胞（FRC）通过CD44分子引导免疫应答启动的关键机制。通过研究小鼠巨细胞病毒蛋白m11对CD44与透明质酸相互作用的干扰，作者证明了CD44在调节树突状细胞迁移和T细胞致敏中的核心作用。该发现不仅阐明了病毒逃避宿主免疫应答的新策略，还强调了淋巴基质微环境在协调动态免疫相互作用中的重要性，具有高度的创新性和学术价值。

---

## 34. 大脑边界清道夫细胞发育的趋同演化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565812)
**期刊：** Nature
**PMID：** 41565812
**DOI：** 10.1038/s41586-025-10003-3

### 第一部分 原文与翻译

**英文原标题：** Convergent evolution of scavenger cell development at brain borders.

> **英文摘要：**
> The vertebrate central nervous system is protected by the blood-brain barrier and meningeal membranes, which ensure immune privilege. In the mammalian brain, microglia and barrier-associated or border-associated macrophages (BAMs) provide immune surveillance and scavenge wastes, yet how evolution shaped immune-cell diversity and function is not understood. In zebrafish, a vascular-derived mural lymphatic endothelial cell (muLEC) lineage fulfils scavenger cell functions at central nervous system borders. Here we identify the transcription factor odd-skipped related 2 (osr2) as a specific marker and regulator of muLEC differentiation and maintenance. osr2 controls the transition of muLECs from interconnected endothelial cells to individual scavenger cells in part by means of control of cadherin-6. muLECs are more transcriptionally similar to BAMs than to other mammalian meningeal cells and share several functions in tissue homeostasis. However, BAMs are absent from zebrafish and muLECs from mice and humans. Analysis of osr2, lymphatic endothelial cell (LEC) and BAM markers in diverse vertebrate species reveals muLECs as an ancient lineage and BAMs a recent mammalian specialization. muLECs and BAMs share functional analogies but are not homologous, providing an example of convergent evolution. This highlights the physiological importance of meningeal scavenger cells and the developmental plasticity of LECs in generating specialized cell types throughout evolution.

> **中文摘要：**
> 脊椎动物的中枢神经系统受血脑屏障和脑膜的保护，确保了免疫特权。在哺乳动物大脑中，小胶质细胞和屏障相关或边界相关巨噬细胞（BAMs）提供免疫监视并清除废物，然而演化如何塑造免疫细胞的多样性和功能尚不清楚。在斑马鱼中，一种血管来源的壁淋巴内皮细胞（muLEC）谱系在中枢神经系统边界履行清道夫细胞功能。在这里，我们鉴定出转录因子 odd-skipped related 2 (osr2) 是 muLEC 分化和维持的特异性标记物及调节因子。osr2 部分通过控制 cadherin-6 来调控 muLEC 从相互连接的内皮细胞向独立清道夫细胞的转变。muLEC 在转录上与 BAMs 的相似性高于与其他哺乳动物脑膜细胞的相似性，并在组织稳态中具有多项共同功能。然而，斑马鱼中不存在 BAMs，而小鼠和人类中则不存在 muLEC。对多种脊椎动物物种中 osr2、淋巴内皮细胞（LEC）和 BAM 标记物的分析表明，muLEC 是一个古老的谱系，而 BAMs 是近代哺乳动物的特化。muLEC 和 BAMs 具有功能类比性但不具有同源性，这提供了一个趋同演化的范例。这凸显了脑膜清道夫细胞的生理重要性，以及 LEC 在整个演化过程中产生特化细胞类型的发育可塑性。

### 第二部分 AI 大师评价

本研究通过比较斑马鱼与哺乳动物的大脑边界免疫细胞，揭示了清道夫细胞在脊椎动物演化中的高度复杂性。研究确定了转录因子 osr2 是调控斑马鱼壁淋巴内皮细胞（muLEC）发育的关键因子，并发现其与哺乳动物边界相关巨噬细胞（BAMs）在功能和转录层面表现出惊人的相似性，但二者起源不同，属于典型的趋同演化。该发现不仅深化了对中枢神经系统免疫监视演化历程的理解，也突显了淋巴内皮细胞在产生特化功能细胞方面的强大发育可塑性。

---

## 35. 鸟类内层视网膜由梳膜支持的无氧代谢

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565811)
**期刊：** Nature
**PMID：** 41565811
**DOI：** 10.1038/s41586-025-09978-w

### 第一部分 原文与翻译

**英文原标题：** Oxygen-free metabolism in the bird inner retina supported by the pecten.

> **英文摘要：**
> Neural tissues are exceptionally sensitive to oxygen deprivation and rely on a dense network of blood vessels to support their extraordinarily high metabolic demands for oxygen, nutrients and clearance of waste products. In birds, one of the metabolically most demanding neural tissue-the retina-lacks internal blood vessels. This raises the question of how such a metabolically demanding neural tissue can function without blood perfusion. Here we show that, while the photoreceptor outer segments in the outer retina have access to oxygen, the inner bird retina operates under chronic anoxia, supported by anaerobic glycolysis in the retinal neurons. We provide evidence that the pecten oculi-a uniquely vascularized structure in the vitreous humour of birds, the function of which has been debated for centuries-supplies the anoxic inner retina with glucose and removes lactic acid. We suggest that the pecten's metabolic support of the bird retina's anoxia tolerance enabled first the evolution of a thick cell-dense, avascular retina, which secondarily served as an exaptation enabling retinal function during high-altitude migrations.

> **中文摘要：**
> 神经组织对缺氧异常敏感，并依赖密集的血管网络来支持其对氧气、营养物质以及代谢产物清除的极高代谢需求。在鸟类中，代谢需求最高的神经组织之一——视网膜——缺乏内部血管。这提出了一个问题：这种代谢需求极高的神经组织如何在没有血流灌注的情况下运作？在此，我们展示了虽然视网膜外层的光感受器外段可以获取氧气，但鸟类视网膜内层则在慢性缺氧状态下运行，由视网膜神经元中的无氧糖酵解提供支持。我们提供证据表明，梳膜（pecten oculi）——一种位于鸟类玻璃体中、其功能已被争论数百年的独特血管化结构——为缺氧的视网膜内层提供葡萄糖并清除乳酸。我们认为，梳膜对鸟类视网膜耐氧性提供的代谢支持，首先使厚实、细胞密集且无血管的视网膜得以进化，其次作为一种外适性（exaptation），使视网膜在高海拔迁徙期间能够发挥功能。

### 第二部分 AI 大师评价

本文揭示了鸟类视网膜在缺乏内部血管的情况下，如何通过独特的代谢机制维持高强度神经活动。研究发现，鸟类内层视网膜处于慢性缺氧状态，主要依赖无氧糖酵解，而长期功能不明的梳膜（pecten oculi）则发挥了关键作用，负责转运葡萄糖和清除代谢产物乳酸。这一发现不仅解决了生物学界关于梳膜功能的百年争议，还阐明了该代谢策略在促进厚实视网膜进化及支持高海拔迁徙中的重要性，是演化生物学与生理学结合的卓越范例。

---

## 36. 单核细胞向组织驻留巨噬细胞的转变需要DHPS

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565804)
**期刊：** Nature
**PMID：** 41565804
**DOI：** 10.1038/s41586-025-09972-2

### 第一部分 原文与翻译

**英文原标题：** The transition from monocyte to tissue-resident macrophage requires DHPS.

> **英文摘要：**
> Tissue-resident macrophages (RTMs) form during embryogenesis, self-renew locally, and regulate tissue homeostasis by clearing dead cells and debris. During tissue damage, however, bone-marrow-derived monocytes enter tissues and differentiate into RTMs, repairing the tissue and replenishing macrophages in the niche. The universal cell-intrinsic mechanisms that control the monocyte-to-RTM transition and the maintenance of mature RTMs across tissues remain elusive. Here we show that deoxyhypusine synthase (DHPS), an enzyme that mediates spermidine-dependent hypusine modification of translation factor eIF5A, is required for RTM differentiation and maintenance. Mice with myeloid cell lack of DHPS (Dhps-ΔM mice) had a global defect in RTMs across tissues, resulting in persistent but ultimately futile monocyte influx. Transcriptional analyses of DHPS-deficient macrophages indicated a block in their ability to differentiate into mature RTMs, whereas proteomics revealed defects in cell adhesion and signalling pathways. Sequencing of ribosome-engaged transcripts identified a subset of mRNAs involved in cell adhesion and signalling that rely on DHPS for efficient translation. Imaging of DHPS-deficient macrophages in tissues showed differences in morphology and tissue interactions, which were correlated with their failed RTM differentiation. DHPS-deficient macrophages were also defective in critical homeostatic RTM functions including efferocytosis and tissue maintenance. Together, our results demonstrate a cell-intrinsic, tissue-agnostic pathway that drives differentiation of monocyte-derived macrophages into RTMs.

> **中文摘要：**
> 组织驻留巨噬细胞（RTMs）在胚胎发育期间形成，在局部自我更新，并通过清除死细胞和碎片来调节组织稳态。然而，在组织损伤期间，骨髓来源的单核细胞进入组织并分化为RTMs，修复组织并补充微环境中的巨噬细胞。控制单核细胞向RTM转变以及跨组织维持成熟RTM的通用细胞内在机制仍不清楚。在这里，我们表明脱氧羟丁胺酸合酶（DHPS）是RTM分化和维持所必需的，该酶介导亚精胺依赖性的翻译因子eIF5A的羟丁胺酸修饰。髓系细胞缺失DHPS的小鼠（Dhps-ΔM小鼠）在各组织的RTM中存在全局性缺陷，导致持续但最终无效的单核细胞涌入。对DHPS缺陷巨噬细胞的转录分析表明其分化为成熟RTM的能力受阻，而蛋白质组学研究则揭示了细胞粘附和信号通路的缺陷。核糖体结合转录本测序鉴定出了一组涉及细胞粘附和信号传导的mRNA，它们依赖DHPS进行有效翻译。对组织中DHPS缺陷巨噬细胞的成像显示，其形态和组织相互作用存在差异，这与其RTM分化失败相关。DHPS缺陷的巨噬细胞在关键的稳态RTM功能（包括胞葬作用和组织维持）方面也存在缺陷。总之，我们的结果证明了一种细胞内在的、与组织无关的通路，它驱动单核细胞来源的巨噬细胞向RTM分化。

### 第二部分 AI 大师评价

本研究利用髓系特异性缺失小鼠模型，首次揭示了脱氧羟丁胺酸合酶（DHPS）介导的eIF5A羟丁胺酸修饰在单核细胞向组织驻留巨噬细胞（RTM）转化中的关键作用。通过整合转录组学、蛋白质组学及核糖体测序技术，作者发现DHPS缺失会导致细胞粘附和信号通路相关mRNA的翻译效率下降，进而阻断RTM的成熟与稳态功能。该成果确定了驱动巨噬细胞分化的通用细胞内在通路，为理解组织修复及稳态维持提供了新的代谢-翻译控制视角。

---

## 37. 从空间快照揭示组织的时间动力学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565801)
**期刊：** Nature
**PMID：** 41565801
**DOI：** 10.1038/s41586-025-09876-1

### 第一部分 原文与翻译

**英文原标题：** Temporal tissue dynamics from a spatial snapshot.

> **英文摘要：**
> Physiological and pathological processes such as inflammation and cancer emerge from interactions between cells over time. However, methods to follow cell populations over time within the native context of a human tissue are lacking because a biopsy offers only a single snapshot. Here we present one-shot tissue dynamics reconstruction (OSDR), an approach to estimate a dynamical model of cell populations based on a single tissue sample. OSDR uses spatial proteomics to learn how the composition of cellular neighbourhoods influences division rate, providing a dynamical model of cell population change over time. We apply OSDR to human breast cancer data, and reconstruct two fixed points of fibroblasts and macrophage interactions. These fixed points correspond to hot and cold fibrosis, in agreement with co-culture experiments that measured these dynamics directly. We then use OSDR to discover a pulse-generating excitable circuit of T and B cells in the tumour microenvironment, suggesting temporal flares of anticancer immune responses. Finally, we study longitudinal biopsies from a triple-negative breast cancer clinical trial, in which OSDR predicts the collapse of the tumour cell population in responders but not in non-responders, based on early-treatment biopsies. OSDR can be applied to a wide range of spatial proteomics assays to enable analysis of tissue dynamics based on patient biopsies.

> **中文摘要：**
> 炎症和癌症等生理与病理过程起源于细胞随时间推移而产生的相互作用。然而，由于活检仅能提供单一的快照，目前尚缺乏在人体组织原生背景下追踪细胞群体随时间变化的方法。在此，我们提出了单次组织动力学重建（OSDR），这是一种基于单一组织样本估算细胞群体动力学模型的方法。OSDR 利用空间蛋白质组学来学习细胞邻域构成如何影响分裂率，从而提供细胞群体随时间变化的动力学模型。我们将 OSDR 应用于人类乳腺癌数据，并重建了成纤维细胞与巨噬细胞相互作用的两个不动点。这些不动点对应于热纤维化和冷纤维化，与直接测量这些动力学的共培养实验结果一致。随后，我们利用 OSDR 发现了肿瘤微环境中 T 细胞和 B 细胞形成的脉冲产生可激发回路，这暗示了抗肿瘤免疫反应的时间性爆发。最后，我们研究了来自三阴性乳腺癌临床试验的纵向活检，OSDR 基于治疗早期的活检结果，预测了响应者中肿瘤细胞群体的崩溃，但在非响应者中则不然。OSDR 可应用于广泛的空间蛋白质组学分析，从而实现基于患者活检的组织动力学分析。

### 第二部分 AI 大师评价

该研究开发了名为 OSDR 的创新算法，突破了临床活检样本仅能反映静态时间点的局限，实现了从单次空间快照中推断复杂的组织动力学。通过在乳腺癌中识别纤维化反馈环路和免疫反应脉冲电路，展示了该方法在揭示细胞间长期相互作用规律方面的卓越性能。最显著的创新在于其临床应用价值，即通过治疗早期的单次活检即可准确预测患者的治疗响应，为精准医疗下的预后评估提供了全新的时空组学计算框架。

---

## 38. 通过动态位错进行可弯曲有机晶体的矢量非共价合成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565711)
**期刊：** Nature communications
**PMID：** 41565711
**DOI：** 10.1038/s41467-026-68783-9

### 第一部分 原文与翻译

**英文原标题：** Vectorial noncovalent synthesis of bendable organic crystals through dynamic dislocation.

> **英文摘要：**
> Organic molecular crystals with controllable bending angles are crucial interconnectors in integrated optoelectronic chips, which can precisely guide optical signals along a predetermined path to achieve effective optical path steering. Nevertheless, current methods of tailoring molecular crystals with desired bent geometric features yet without fractured bending interface has not yet been fully realized. Here, we addresses this issue by proposing a universal "molecular cocrystal" strategy that introduces directional charge-transfer non-covalent interactions into molecular systems to weaken the original interactions, thereby triggering the spontaneous deformation transition from crystal slippage to bending. Significantly, a diverse range of self-assembled bent crystals with accurate angles ranging from 61.8° to 85.0° have been synthesized without destroying the structural integrity of the crystals. The proposed strategy is also applied to construct hierarchical bent microstructures with 2 to 6 bends. These as-prepared bent crystals exhibit excitation position-dependent anisotropic optical behaviors, which are applied into the photonics switch with adjustable on/off ratio. This methodology offers a versatile pathway to purposely design bent crystals with tailored angles, thereby laying a structural foundation for the on-chip organic optoelectronics.

> **中文摘要：**
> 具有可控弯曲角度的有机分子晶体是集成光电子芯片中关键的互连组件，能够沿着预定路径精确引导光信号，从而实现有效的光路转向。然而，目前在定制具有理想弯曲几何特征且不产生断裂弯曲界面的分子晶体方面，尚未完全实现。在此，我们通过提出一种通用的“分子共晶”策略来解决这一问题，该策略将定向电荷转移非共价相互作用引入分子系统中以削弱原始相互作用，从而触发从晶体滑移到弯曲的自发变形转变。值得注意的是，在不破坏晶体结构完整性的情况下，已合成出角度在61.8°至85.0°之间的多种自组装弯曲晶体。该策略还被应用于构建具有2到6个弯曲的层次化弯曲微结构。这些制备的弯曲晶体表现出依赖于激发位置的各向异性光学行为，并被应用于具有可调开关比的光子开关中。该方法为有目的地设计具有定制角度的弯曲晶体提供了一条通用的途径，从而为片上有机光电子学奠定了结构基础。

### 第二部分 AI 大师评价

该研究针对集成光电子芯片中分子晶体弯曲角度精确控制困难且易断裂的挑战，提出了一种创新的“分子共晶”策略。通过引入定向电荷转移非共价相互作用诱导动态位错，研究团队成功实现了角度在61.8°至85.0°范围内的自发、无损弯曲变形。该方法不仅证明了构建多弯曲层次化微结构的可行性，还展示了其在高性能光子开关中的应用潜力。这一成果为定制化设计有机晶体光路互连结构提供了重要的方法学指导，在有机光电子学领域具有显著的创新性和实用价值。

---

## 39. 原位自组装细胞库水凝胶用于调控多阶段放射免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565700)
**期刊：** Nature communications
**PMID：** 41565700
**DOI：** 10.1038/s41467-026-68490-5

### 第一部分 原文与翻译

**英文原标题：** In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy.

> **英文摘要：**
> Radiotherapy (RT) is a clinical mainstay of cancer treatment that triggers tumor-specific immune responses. However, the effectiveness is usually hampered due to the hypoxic tumor microenvironment (TME) and the ambivalent impact of RT on the immune landscape of tumors. Herein, we develop an injectable hydrogel encapsulating interleukin-12 (IL-12)/anti-CTLA-4 (aCTLA-4) co-engineered red blood cells (RBC), which is in situ self-assembled within the TME to increase oxygen supply and instigate sequential aCTLA-4/IL-12 release, thus achieving Ba/O self-compensated radiosensitization and activating multistage immune responses. Once in the acidic TME, the in situ injected BaO undergoes hydrolysis to generate HO and Ba, followed by the rapid reaction of Ba with sodium alginate to afford a biocompatible hydrogel. Meanwhile, catalase presented on RBC converts HO into O, thereby alleviating hypoxia-induced radioresistance and inducing O-mediated pore formation on RBC membrane for rapid release of aCTLA-4 to relieve tumor immunosuppression. Subsequently, IL-12 anchored on RBC is dilatorily released and interacts with T/NK cells within the TME to induce IFN-γ-dependent antitumor immunity. Taken together, the in situ self-assembled cell reservoir hydrogel offers a futuristic avenue to realize multistage radioimmunotherapy for effective tumor regression by programmable immunoregulation with significant clinical value.

> **中文摘要：**
> 放射治疗（RT）是癌症治疗的临床支柱，能够触发肿瘤特异性免疫反应。然而，其疗效通常因低氧肿瘤微环境（TME）以及放疗对肿瘤免疫格局的双重影响而受限。在此，我们开发了一种封装白细胞介素-12 (IL-12)/抗CTLA-4 (aCTLA-4) 共修饰红细胞 (RBC) 的可注射水凝胶，该凝胶在肿瘤微环境内原位自组装，以增加氧气供应并诱发 aCTLA-4/IL-12 的顺序释放，从而实现钡/氧 (Ba/O) 自补偿放疗增敏并激活多阶段免疫反应。一旦进入酸性肿瘤微环境，原位注射的过氧化钡 (BaO2) 发生水解产生过氧化氢 (H2O2) 和钡离子 (Ba2+)，随后钡离子与海藻酸钠快速反应生成具有生物相容性的水凝胶。同时，红细胞上表达的过氧化氢酶将 H2O2 转化为 O2，从而缓解低氧诱导的放射耐药性，并诱导氧气介导的红细胞膜造孔，以快速释放 aCTLA-4 从而解除肿瘤免疫抑制。随后，锚定在红细胞上的 IL-12 缓慢释放，并与肿瘤微环境中的 T/NK 细胞相互作用，诱导干扰素-γ (IFN-γ) 依赖性抗肿瘤免疫。总之，这种原位自组装细胞库水凝胶通过程序化免疫调节，为实现多阶段放射免疫治疗以有效促进肿瘤消退提供了一条极具前景的途径，具有重要的临床价值。

### 第二部分 AI 大师评价

本研究创新性地提出了一种基于过氧化钡原位水解成胶的“细胞库”水凝胶系统，巧妙地解决了放疗中低氧耐药与免疫抑制的双重挑战。通过红细胞负载并程控释放 aCTLA-4 与 IL-12，该系统实现了从氧气增敏到级联免疫激活的精准时空调控。这种整合了化学驱动组装与生物工程化细胞载体的策略，为开发多阶段协同抗肿瘤治疗平台提供了极具启发性的思路，具有显著的临床转化潜力和科学价值。

---

## 40. ZNF683+ NK 细胞通过重塑免疫微环境调控晚期下咽鳞状细胞癌的化疗敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565699)
**期刊：** Nature communications
**PMID：** 41565699
**DOI：** 10.1038/s41467-026-68676-x

### 第一部分 原文与翻译

**英文原标题：** ZNF683 NK cells govern chemotherapy sensitivity in advanced HPSCC via reshaping immune microenvironment.

> **英文摘要：**
> Hypopharyngeal squamous cell carcinoma (HPSCC), an aggressive head and neck cancer with dismal prognosis, faces persistent chemoresistance to standard TPF (docetaxel, cisplatin, 5-fluorouracil) regimen. However, the immunological mechanisms underlying chemoresistance remain undefined. Here, we perform longitudinal single-cell RNA sequencing (scRNA-seq) profiling of paired pre-/post-TPF HPSCC specimens, mapping immune cell dynamics underlying chemoresistance. Our study identifies ZNF683 natural killer (NK) cells as a gatekeeper of chemotherapy efficacy through integrated single-cell transcriptomics, spatial multiplex immunohistochemistry and functional validation. Moreover, pretreatment baseline enrichment of ZNF683 NK cells predicts TPF response, while GZMKCD8 effector memory T cells function as the predominant immunologic effector to successful TPF intervention. Mechanistically, bioinformatics and in vitro coculture data reveal that ZNF683 NK cells directly interact with CD8 T cells, and drive an MHC-I-dependent licensing of polyfunctional GZMKCD8 effector memory T cells. Collectively, this NK-CD8 axis provides a potential predictive biomarker and therapeutic target to overcome chemoresistance in patients with HPSCC.

> **中文摘要：**
> 下咽鳞状细胞癌（HPSCC）是一种预后极差的侵袭性头颈部肿瘤，临床上面临着对标准 TPF（多西他赛、顺铂、5-氟尿嘧啶）方案持续产生化疗耐药的挑战。然而，化疗耐药背后的免疫机制仍不明确。在此，我们对配对的 TPF 治疗前/后 HPSCC 标本进行了纵向单细胞 RNA 测序（scRNA-seq）分析，描绘了化疗耐药背后的免疫细胞动态。通过整合单细胞转录组学、空间多重免疫组化和功能验证，我们的研究确定 ZNF683+ 自然杀伤（NK）细胞是化疗疗效的守护者。此外，治疗前基线 ZNF683+ NK 细胞的富集可预测 TPF 反应，而 GZMK+CD8+ 效应记忆 T 细胞则是 TPF 干预成功的核心免疫效应细胞。从机制上讲，生物信息学和体外共培养数据表明，ZNF683+ NK 细胞直接与 CD8+ T 细胞相互作用，并驱动 MHC-I 依赖性的多功能 GZMK+CD8+ 效应记忆 T 细胞许可。总而言之，这种 NK-CD8+ 轴为克服 HPSCC 患者的化疗耐药提供了潜在的预测性生物标志物和治疗靶点。

### 第二部分 AI 大师评价

该研究通过纵向单细胞测序技术，深入揭示了下咽鳞状细胞癌在 TPF 化疗过程中的免疫微环境演变规律。研究创新性地确定了 ZNF683+ NK 细胞作为化疗敏感性的关键调控者，并阐明了其通过 MHC-I 依赖方式激活 GZMK+CD8+ T 细胞的跨细胞通讯机制。这一发现在临床上为化疗疗效评估提供了高价值的预测标志物，并为克服头颈部鳞癌耐药提供了新的潜在治疗靶点，具有较强的转化医学意义。

---

## 41. PURE-seq：整合FACS与PIP-seq用于极稀有细胞单细胞基因组学研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565684)
**期刊：** Nature communications
**PMID：** 41565684
**DOI：** 10.1038/s41467-025-68146-w

### 第一部分 原文与翻译

**英文原标题：** PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

> **英文摘要：**
> Single-cell transcriptomics is valuable for uncovering individual cell properties, particularly in heterogeneous systems. However, this technique often results in the reanalysis of many well-characterized cells, increasing costs and diluting rare cell populations. To address this, we develop PIP-seq for Rare-cell Enrichment and Sequencing (PURE-seq). PURE-seq allows direct FACS sorting of cells into PIP-seq reactions, minimizing handling and reducing cell loss. PURE-seq reliably sequences ultrarare cells, with 1 hour of sorting capturing tens of target cells at a rarity of 1 in 1,000,000. Leveraging this extreme sensitivity, we use PURE-seq to isolate and single-cell sequence circulating tumor cells from metastatic melanoma patient blood, obtaining detailed single cancer cell gene expression profiles. Additionally, we use PURE-seq to examine hematopoietic stem and progenitor cells from young, old and middle-aged mice. Transcriptomic analysis identifies Egr1 as a putative master regulator of murine hematopoietic stem and progenitor cell aging, demonstrating PURE-seq's utility as a discovery platform for basic science applications. PURE-seq offers a simple and highly sensitive method for single-cell sequencing ultra-rare cells.

> **中文摘要：**
> 单细胞转录组学对于揭示个体细胞特性非常有价值，特别是在异质系统中。然而，这项技术通常会导致对许多已充分表征的细胞进行重复分析，从而增加成本并稀释稀有细胞群。为了解决这一问题，我们开发了用于稀有细胞富集与测序的PIP-seq（简称PURE-seq）。PURE-seq允许将细胞直接通过FACS分选到PIP-seq反应体系中，最大限度地减少了操作流程并减少了细胞损失。PURE-seq能够可靠地对极稀有细胞进行测序，在1小时的分选内即可捕捉到稀有度为百万分之一的数十个目标细胞。利用这种极高的灵敏度，我们使用PURE-seq从转移性黑色素瘤患者血液中分离并进行了循环肿瘤细胞的单细胞测序，获得了详细的单癌细胞基因表达谱。此外，我们使用PURE-seq检测了来自年轻、年老和中年小鼠的造血干细胞及祖细胞。转录组分析确定Egr1是小鼠造血干细胞和祖细胞衰老的推测主调控因子，证明了PURE-seq作为基础科学应用发现平台的实用性。PURE-seq为极稀有细胞的单细胞测序提供了一种简单且高度敏感的方法。

### 第二部分 AI 大师评价

PURE-seq通过将流式细胞分选（FACS）与PIP-seq液滴技术深度集成，有效解决了传统单细胞测序在处理百万分之一级别极稀有细胞时面临的高损耗与高成本难题。该研究不仅在临床层面实现了对转移性黑色素瘤循环肿瘤细胞（CTC）的精准转录组刻画，还在基础研究中发现了调控造血干细胞衰老的关键因子Egr1。其核心创新在于极简化的操作流程与极高的富集灵敏度，为罕见细胞群体的生物学功能解析提供了强有力的技术支撑。

---

## 42. 肺成纤维细胞表达的 Versican 抑制肺纤维化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565682)
**期刊：** Nature communications
**PMID：** 41565682
**DOI：** 10.1038/s41467-026-68377-5

### 第一部分 原文与翻译

**英文原标题：** Versican expression from lung fibroblasts suppresses pulmonary fibrosis.

> **英文摘要：**
> The activation and accumulation of lung fibroblasts, leading to excessive ECM deposition, is a pathogenic hallmark of Idiopathic Pulmonary Fibrosis, a lethal and currently untreatable disease. In this report, increased expression of Versican, a multifunctional ECM proteoglycan, is detected in both human and mouse pulmonary fibrosis, mainly in monocytic cells and fibroblasts. Ubiquitous genetic reduction of Versican expression in mice promotes collagen expression and polymerisation, alters pulmonary ECM composition and structure, and exacerbates pulmonary fibrosis, delaying its resolution. Moreover, the decrease in Versican in the ECM and the ensuing reorganisation stimulate Tenascin-C expression from fibroblasts, which is further shown to be a potent Toll-like receptor 4-dependent podosome inducer, promoting ECM invasion. Thus, fibroblast-expressed Versican regulates the underlying ECM composition and structure and suppresses autologous podosome formation, limiting ECM invasion and pulmonary fibrosis.

> **中文摘要：**
> 肺成纤维细胞的激活和积聚导致细胞外基质（ECM）过度沉积，是特发性肺纤维化（IPF）的病理学特征，这是一种致命且目前无法治愈的疾病。在本报告中，研究人员在人类和小鼠的肺纤维化中均检测到多功能 ECM 蛋白聚糖 Versican 的表达增加，其主要分布在单核细胞和成纤维细胞中。在小鼠中普遍通过遗传手段降低 Versican 的表达会促进胶原蛋白的表达和聚合，改变肺部 ECM 的组成和结构，并加剧肺纤维化，延迟其消退。此外，ECM 中 Versican 的减少及其随后的重组会刺激成纤维细胞表达 Tenascin-C，研究进一步表明 Tenascin-C 是一种强效的 Toll 样受体 4 依赖性伪足小体诱导剂，能够促进 ECM 侵袭。因此，成纤维细胞表达的 Versican 通过调节基础 ECM 的组成和结构，并抑制自体伪足小体的形成，从而限制 ECM 侵袭和肺纤维化。

### 第二部分 AI 大师评价

本研究深入探讨了细胞外基质蛋白聚糖 Versican 在特发性肺纤维化（IPF）中的保护机制，挑战了“所有 ECM 成分均促进纤维化”的传统认知。研究人员通过遗传敲除模型证实，Versican 的缺失会诱导 Tenascin-C 高表达并触发 TLR4 介导的伪足小体形成，从而显著增强成纤维细胞的侵袭力并恶化病情。该发现揭示了 Versican 作为肺部微环境稳定器的关键作用，为针对病理性 ECM 重塑的精准治疗提供了重要的科学支撑和新靶点。

---

## 43. SAMSN1 抑制肝细胞癌中 NK 细胞介导的抗肿瘤免疫

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565668)
**期刊：** Nature communications
**PMID：** 41565668
**DOI：** 10.1038/s41467-026-68661-4

### 第一部分 原文与翻译

**英文原标题：** SAMSN1 restrains NK cell mediated anti-tumor immunity in hepatocellular carcinoma.

> **英文摘要：**
> NK cells are critical mediators of anti-tumor immunity whose function is frequently compromised in the tumor microenvironment. Here we identify SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1) as a previously unrecognized immune checkpoint that predominantly regulates NK cell function in hepatocellular carcinoma (HCC). Single-cell RNA sequencing (scRNA-seq) analysis reveals significant SAMSN1 upregulation in intratumoral NK cells from HCC patients, correlating with reduced granzyme B expression and poor prognosis. In orthotopic Hepa1-6 hepatocellular carcinoma models, global Samsn1 knockout (Samsn1) mice exhibits 34% tumor burden reduction with enhanced NK cell granzyme B production (P = 0.0002). Critically, NK cell-specific deletion alone (Samsn1-Ncr1) recapitulates this therapeutic effect (41% tumor burden reduction, P = 0.0017), demonstrating that SAMSN1 functions predominantly through intratumoral NK cells rather than other immune populations in the HCC microenvironment. Mechanistically, SAMSN1 suppresses NK cell activation, proliferation, and granzyme B production. These findings indicate SAMSN1 as a targetable NK cell checkpoint with direct therapeutic implications for HCC immunotherapy.

> **中文摘要：**
> NK 细胞是抗肿瘤免疫的关键介质，其功能在肿瘤微环境中经常受损。在此，我们确定 SAM 结构域、SH3 结构域和核定位信号 1 (SAMSN1) 是一个此前未被识别的免疫检查点，它主要调节肝细胞癌 (HCC) 中的 NK 细胞功能。单细胞 RNA 测序 (scRNA-seq) 分析显示，HCC 患者瘤内 NK 细胞中 SAMSN1 显著上调，这与颗粒酶 B 表达降低和预后不良相关。在原位 Hepa1-6 肝细胞癌模型中，全身性 Samsn1 敲除 (Samsn1) 小鼠表现出肿瘤负荷减少 34%，并伴有 NK 细胞颗粒酶 B 产量的增强 (P = 0.0002)。至关重要的是，仅 NK 细胞特异性缺失 (Samsn1-Ncr1) 即可重现这种治疗效果（肿瘤负荷减少 41%，P = 0.0017），这表明 SAMSN1 主要通过瘤内 NK 细胞而非 HCC 微环境中的其他免疫群体发挥作用。从机制上讲，SAMSN1 抑制 NK 细胞的活化、增殖和颗粒酶 B 的产生。这些发现表明 SAMSN1 是一个可作为靶点的 NK 细胞检查点，对 HCC 免疫治疗具有直接的治疗意义。

### 第二部分 AI 大师评价

本研究通过单细胞测序与基因敲除小鼠模型，首次揭示了 SAMSN1 是调节肝细胞癌内 NK 细胞功能的核心免疫检查点。研究严谨地证明了 SAMSN1 的上调与患者预后不良及 NK 细胞细胞毒性受损直接相关，且 NK 细胞特异性敲除该基因可显著抑制肿瘤进展。这一发现突破了传统 T 细胞免疫检查点的局限，为开发针对 HCC 的 NK 细胞靶向免疫疗法提供了强有力的理论支撑和实验依据。

---

## 44. 患者来源的 R252C 突变通过一种替代性的 EGFR 激活方式促进癌症进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565660)
**期刊：** Nature communications
**PMID：** 41565660
**DOI：** 10.1038/s41467-026-68699-4

### 第一部分 原文与翻译

**英文原标题：** An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.

> **英文摘要：**
> Mutations in the extracellular or intracellular domains of epidermal growth factor receptor (EGFR) are implicated in the development of various cancers. While the intracellular mutations of EGFR have been extensively studied, the function of extracellular mutations remains poorly understood. In this study, we identify an EGFR mutant (EGFR R252C) in a patient with multifocal lung cancer and glioma, in which arginine (R) 252 is mutated to cysteine (C) in the EGFR extracellular domain. This mutation promotes C252-C252 disulfide-mediated EGFR dimerization and induces a conformational change of EGFR, leading to absent autophosphorylation and enhanced direct interaction between EGFR and extracellular signal-regulated protein kinase 1/2 (ERK1/2). Importantly, EGFR directly phosphorylates ERK1/2 at threonine (T) 202 / tyrosine (Y) 204 and activates ERK1/2, thereby promoting tumor cell proliferation and tumor growth in vivo. Afatinib, a second-generation EGFR tyrosine kinase inhibitor, effectively suppresses primary tumor growth and extends progression-free survival in the patient with multifocal lung cancer and glioma driven by EGFR R252C. Our finding elucidates the activation mechanism of this extracellular EGFR mutation and demonstrates the efficacy of afatinib in treating lung cancer or glioma patients with this variant.

> **中文摘要：**
> 表皮生长因子受体（EGFR）胞外域或胞内域的突变与多种癌症的发展有关。虽然 EGFR 的胞内突变已得到广泛研究，但胞外突变的功能仍知之甚少。在本研究中，我们在一名患有多灶性肺癌和神经胶质瘤的患者中鉴定出一种 EGFR 突变体（EGFR R252C），其中 EGFR 胞外域的第 252 位精氨酸（R）突变为半胱氨酸（C）。该突变促进了 C252-C252 二硫键介导的 EGFR 二聚化并诱导了 EGFR 的构象改变，导致自磷酸化缺失，并增强了 EGFR 与细胞外信号调节激酶 1/2（ERK1/2）之间的直接相互作用。重要的是，EGFR 直接磷酸化 ERK1/2 的苏氨酸（T）202 / 酪氨酸（Y）204 位点并激活 ERK1/2，从而促进体内肿瘤细胞增殖和肿瘤生长。阿法替尼（Afatinib）作为第二代 EGFR 酪氨酸激酶抑制剂，能有效抑制原发肿瘤生长，并延长了由 EGFR R252C 驱动的多灶性肺癌和神经胶质瘤患者的无进展生存期。我们的发现阐明了这种胞外 EGFR 突变的激活机制，并证明了阿法替尼在治疗携带该变异的肺癌或神经胶质瘤患者中的疗效。

### 第二部分 AI 大师评价

本研究通过临床病例鉴定出一种罕见的 EGFR 胞外域 R252C 突变，并揭示了其独特的非典型激活机制：该突变通过二硫键介导二聚化，跳过经典的自磷酸化过程，直接磷酸化并激活 ERK1/2 信号通路。研究不仅在分子水平上阐明了胞外突变如何驱动肿瘤进展，还通过临床数据证实了第二代 TKI 药物阿法替尼对该特定突变的显著疗效。这一发现为携带 EGFR 胞外突变的精准医疗提供了重要的理论依据和临床指导方案。

---

## 45. 结核菌素皮肤试验的演变揭示了具有普适性的结核分枝杆菌反应性T细胞元克隆

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565657)
**期刊：** Nature communications
**PMID：** 41565657
**DOI：** 10.1038/s41467-026-68678-9

### 第一部分 原文与翻译

**英文原标题：** Evolution of the tuberculin skin test reveals generalisable Mtb-reactive T cell metaclones.

> **英文摘要：**
> T cells contribute to immune protection and pathogenesis in tuberculosis, but measurements of polyclonal responses have failed to resolve correlates of outcome. We report the temporal evaluation of the human in vivo clonal repertoire of Mycobacterium tuberculosis (Mtb)-reactive T cell responses, by T cell receptor (TCR) sequencing at the site of the tuberculin skin test, as a model for a standardised antigenic challenge. Initial non-selective recruitment of T cells is followed by enrichment of Mtb-reactive clones arising from oligoclonal T cell proliferation. We introduce a modular computational pipeline, Metaclonotypist, to sensitively cluster distinct TCRs with shared epitope specificity, which we apply here to establish a catalogue of public Mtb-reactive HLA-restricted T cell metaclones. Although most in vivo Mtb-reactive T cells are private, 10 metaclones were sufficient to identify Mtb-T cell reactivity across our study population (N≥128), indicating striking population level immunodominance of specific TCR-peptide interactions that may inform patient stratification and vaccine development.

> **中文摘要：**
> T细胞在结核病的免疫保护和发病机制中发挥作用，但对多克隆反应的测量未能明确与预后相关的指标。我们通过在结核菌素皮肤试验部位进行T细胞受体（TCR）测序，作为标准化抗原挑战的模型，报告了人类体内结核分枝杆菌（Mtb）反应性T细胞反应克隆库的时间动态评估。研究发现，T细胞最初的非选择性招募随后伴随着源于寡克隆T细胞增殖的Mtb反应性克隆的富集。我们推出了一套模块化计算流程Metaclonotypist，用于灵敏地聚类具有共享表位特异性的不同TCR，并在此将其应用于建立公共Mtb反应性HLA限制性T细胞元克隆目录。尽管大多数体内Mtb反应性T细胞是私有的，但仅10个元克隆就足以在我们的研究群体（N≥128）中识别Mtb-T细胞反应性，这表明特定TCR-肽相互作用在人群水平上具有显著的免疫显性，可能为患者分层和疫苗开发提供重要参考。

### 第二部分 AI 大师评价

该研究利用结核菌素皮肤试验作为体内免疫模型，结合时序性TCR测序和创新的Metaclonotypist计算工具，系统地解析了人体对结核分枝杆菌的T细胞免疫演变。研究的核心创新在于打破了T细胞反应高度个体化的传统认知，成功识别出具有群体普适性的“元克隆”，证明了特定TCR-肽相互作用存在显著的免疫显性。这些发现不仅为理解结核病的免疫保护机制提供了新维度，也为开发基于公共克隆的疫苗和精准诊断工具奠定了分子基础。

---

## 46. 靶向截断型降钙素原可减轻脓毒症中的内皮细胞反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565647)
**期刊：** Nature communications
**PMID：** 41565647
**DOI：** 10.1038/s41467-025-68199-x

### 第一部分 原文与翻译

**英文原标题：** Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin.

> **英文摘要：**
> Sepsis is associated with hypotension, vascular leakage, vasoplegia and microvascular dysfunction. Therefore, the endothelium is a target for sepsis therapies. Since truncated procalcitonin exerts vascular activity, we here evaluated the efficacy of targeting procalcitonin for vascular integrity and sepsis outcomes. Sepsis up-regulated >2000 genes involved in pro-inflammatory responses while similar numbers of genes involving cell growth and maintenance were down-regulated. Transcriptomic changes in endothelial cells diminished by >50% by anti-procalcitonin antibodies and this was functionally associated with preserved vascular barrier integrity in lungs and intestines, reduced sepsis-induced vasoplegia, preserved endothelial nitric oxide bioavailability, improved organ integrity and reduced sepsis severity in mice. Mechanistically, procalcitonin neutralization was associated with reduced signaling of the interleukin-17 pathway. We here show sepsis induces substantial changes to the endothelial transcriptome and vascular integrity and neutralizing procalcitonin is a suitable means to preserve endothelial homeostasis at a transcriptomic and functional level that could translate into organ protection during sepsis.

> **中文摘要：**
> 脓毒症与低血压、血管渗漏、血管麻痹和微血管功能障碍密切相关。因此，内皮系统是脓毒症治疗的一个重要靶点。由于截断型降钙素原具有血管活性，本研究评估了靶向降钙素原对维持血管完整性和改善脓毒症预后的疗效。研究发现，脓毒症上调了2000多个涉及促炎反应的基因，同时下调了类似数量的涉及细胞生长和维持的基因。应用抗降钙素原抗体使内皮细胞中的转录组变化减少了50%以上，这在功能上与肺部和肠道血管屏障完整性的保留、脓毒症诱导的血管麻痹减轻、内皮一氧化氮生物利用度的维持、器官完整性的改善以及小鼠脓毒症严重程度的降低相关。机制上，中和降钙素原与白细胞介素-17（IL-17）通路信号传导的减弱有关。研究表明，脓毒症会诱导内皮转录组和血管完整性发生显著改变，而中和降钙素原是在转录组和功能水平上维持内皮稳态的有效手段，这可能转化为脓毒症期间的器官保护作用。

### 第二部分 AI 大师评价

本研究深入探讨了截断型降钙素原（PCT）在脓毒症诱导的内皮功能障碍中的致病作用。通过转录组学和功能实验，研究证明了中和PCT能显著抑制内皮细胞的炎症反应并维持血管屏障完整性，其机制与下调IL-17信号通路密切相关。该研究的创新之处在于将PCT从传统的生物标志物重新定义为脓毒症微血管衰竭的治疗靶点，为缓解脓毒症引起的器官损伤提供了新的干预策略。

---

## 47. WDR5重塑NANOG凝聚体以驱动转录程序并维持干细胞特性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565645)
**期刊：** Nature communications
**PMID：** 41565645
**DOI：** 10.1038/s41467-026-68623-w

### 第一部分 原文与翻译

**英文原标题：** WDR5 remodels NANOG condensates to drive transcriptional programs and sustain stem cell identity.

> **英文摘要：**
> Stem cell pluripotency relies on a finely tuned interplay between transcription factors and epigenetic regulators. Here, we identify a direct interaction between NANOG, a master pluripotency transcription factor, and WDR5, a core chromatin regulator essential for maintaining stem cell identity. Mechanistically, WDR5 remodels irregular NANOG aggregates into dynamic, liquid-liquid phase-separated condensates at pluripotency-associated promoters to activate target genes. Structural analyses show that the NANOG homeodomain engages WDR5 through an extended interface distinct from previously characterized short linear motifs. The NANOG R153A mutation disrupts this interaction, leading to impaired condensate formation, reduced chromatin co-occupancy, and diminished levels of active histone marks, ultimately compromising embryonic stem cell pluripotency. Pharmacological inhibition of the WDR5-NANOG interaction suppresses leukemia stem cell expansion in vivo, highlighting its therapeutic potential. Collectively, this study reveals that WDR5-dependent regulation of NANOG condensate dynamics links phase-separated assemblies to transcriptional control of stem cell identity in physiological and pathological contexts.

> **中文摘要：**
> 干细胞多能性依赖于转录因子与表观遗传调节因子之间精细调节的相互作用。在这里，我们鉴定出了NANOG（一种核心多能性转录因子）与WDR5（一种维持干细胞特性所必需的核心染色质调节因子）之间的直接相互作用。从机制上讲，WDR5将不规则的NANOG聚集体重塑为多能性相关启动子处动态的液-液相分离凝聚体，以激活靶基因。结构分析表明，NANOG同源结构域通过一种不同于以往表征的短线性基序的扩展界面与WDR5结合。NANOG R153A突变破坏了这种相互作用，导致凝聚体形成受损、染色质共同占据减少以及活性组蛋白标记水平降低，最终损害了胚胎干细胞的多能性。药理学抑制WDR5-NANOG相互作用可在体内抑制白血病干细胞的扩增，凸显了其治疗潜力。总之，本研究揭示了WDR5依赖的NANOG凝聚体动力学调节将相分离组装与生理和病理背景下干细胞特性的转录控制联系起来。

### 第二部分 AI 大师评价

本研究揭示了核心染色质调节因子WDR5通过介导关键转录因子NANOG的液-液相分离（LLPS）来调控干细胞多能性的分子机制。研究不仅确定了两者结合的独特结构界面及关键突变位点R153A，还阐明了这种凝聚体重塑对染色质开放性和活性组蛋白标记的重要性。此外，通过在白血病模型中验证该相互作用的干预效果，为靶向干细胞特性的治疗策略提供了新的理论依据，系统展示了相分离在生理与病理转录调控中的关键作用。

---

## 48. INCENP和CDCA8预测食管鳞状细胞癌的新辅助化疗反应和预后

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565643)
**期刊：** Nature communications
**PMID：** 41565643
**DOI：** 10.1038/s41467-026-68371-x

### 第一部分 原文与翻译

**英文原标题：** INCENP and CDCA8 predict neoadjuvant chemotherapy response and outcomes in esophageal squamous cell carcinoma.

> **英文摘要：**
> Neoadjuvant chemotherapy (NACT), a key strategy for various cancers, markedly improves patient prognosis and 5-year survival rates. However, numerous patients develop resistance to NACT and thus fail to benefit from it. Therefore, identifying reliable biomarkers to predict patient responsiveness to NACT remains a critical challenge. Here, we demonstrate that elevated expression of INCENP and CDCA8 contributes to poor NACT responsiveness across multiple cancers. Mechanistically, the 5'UTR (GGACT at position 113) of INCENP and the 3'UTR (GGACT at position 1041) of CDCA8 undergo m⁶A methylation and are recognized by YTHDF3, which facilitates their translation through interaction with eIF3A, ultimately driving poor response to NACT. Moreover, inhibition of INCENP and CDCA8 enhances NACT sensitivity by promoting multipolar spindle formation. Collectively, our findings establish that INCENP and CDCA8 serve as crucial biomarkers for predicting NACT responsiveness and as potential therapeutic targets for combination therapy with NACT to improve patient survival.

> **中文摘要：**
> 新辅助化疗（NACT）作为多种癌症的关键治疗策略，显著改善了患者的预后和5年生存率。然而，许多患者对NACT产生了耐药性，因此无法从中获益。因此，寻找可靠的生物标志物来预测患者对NACT的反应性仍是一项关键挑战。在此，我们证明了INCENP和CDCA8的高表达与多种癌症中较差的NACT反应性有关。从机制上讲，INCENP的5'UTR（113位的GGACT）和CDCA8的3'UTR（1041位的GGACT）会发生m⁶A甲基化并被YTHDF3识别，后者通过与eIF3A相互作用促进它们的翻译，最终导致对NACT的反应不佳。此外，抑制INCENP和CDCA8通过促进多极纺锤体形成来增强NACT的敏感性。总而言之，我们的研究结果确立了INCENP和CDCA8可作为预测NACT反应性的关键生物标志物，并可作为与NACT联合治疗以提高患者生存率的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究深入探讨了食管鳞状细胞癌中INCENP和CDCA8作为新辅助化疗（NACT）耐药标志物的生物学功能与分子机制。研究揭示了m⁶A阅读器YTHDF3通过识别特定的甲基化位点并结合eIF3A，促进了这两个关键蛋白的翻译，从而驱动化疗耐药。通过抑制INCENP/CDCA8诱导纺锤体极性异常可有效提高NACT敏感性，具有重要的临床转化价值。这项工作不仅从表观转录组层面阐明了癌症耐药的新机制，也为精准预测NACT疗效及制定联合治疗策略提供了强有力的理论支撑。

---

## 49. 未产与经产乳腺的差异性衰老揭示了 IL33+ 杂合上皮细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565642)
**期刊：** Nature communications
**PMID：** 41565642
**DOI：** 10.1038/s41467-026-68611-0

### 第一部分 原文与翻译

**英文原标题：** Divergent aging of nulliparous and parous mammary glands reveals IL33+ hybrid epithelial cells.

> **英文摘要：**
> Aging increases breast cancer risk while an early first pregnancy reduces a woman's life-long risk. Several studies have explored the effect of either aging or pregnancy on mammary stem/progenitor cells, however, the combined effect of both remains unclear. Here, we interrogate the functional and transcriptomic changes at single-cell resolution in the mammary gland of aged nulliparous and parous mice to discover that pregnancy normalizes age-related imbalances in lineage composition, while also inducing a differentiated cell state. Importantly, we uncover a minority population of Il33-expressing epithelial cells that express both luminal and basal markers (i.e. hybrid), which accumulate in aged nulliparous mice but are significantly reduced in aged parous mice. Functionally, IL33 treatment of mammary epithelial cells from young mice phenocopies aged nulliparous epithelial cells, induces proliferation and promotes formation of organoids with Trp53 knockdown. Collectively, our study demonstrates that pregnancy blocks the age-associated imbalances in lineage integrity in the basal layer, including a decrease in Il33+ hybrid cells, that could potentially contribute to pregnancy-induced breast cancer protection.

> **中文摘要：**
> 衰老会增加患乳腺癌的风险，而早期首次怀孕则会降低女性的终生风险。已有若干研究探讨了衰老或怀孕对乳腺干/祖细胞的影响，然而，这两者的共同作用仍不清楚。在本研究中，我们在单细胞分辨率下探究了高龄未产小鼠和经产小鼠乳腺的功能及转录组变化，发现怀孕使与年龄相关的谱系组成失衡恢复正常，同时也诱导了分化的细胞状态。重要的是，我们发现了一小部分表达 Il33 的上皮细胞，这些细胞同时表达管腔和基底标记物（即杂合细胞），它们在老龄未产小鼠中积累，但在老龄经产小鼠中显著减少。在功能上，对年轻小鼠的乳腺上皮细胞进行 IL33 处理会模拟老龄未产上皮细胞的表型，诱导增殖并促进 Trp53 敲低后的类器官形成。总而言之，我们的研究表明，怀孕阻断了基底层中与年龄相关的谱系完整性失衡，包括 Il33+ 杂合细胞的减少，这可能有助于怀孕诱导的乳腺癌保护作用。

### 第二部分 AI 大师评价

本研究利用单细胞转录组技术对比了未产与经产乳腺在衰老过程中的细胞动力学差异，揭示了怀孕通过重塑谱系平衡产生保护作用的机制。研究通过鉴定出一类随衰老积累且具有致癌潜能的 IL33+ 杂合上皮细胞，精准解释了经产如何通过清除此类风险细胞来降低乳腺癌风险。该发现不仅深化了对乳腺衰老的认知，也为乳腺癌的预防提供了新的细胞靶点和理论依据。

---

## 50. 丝氨酸通过抑制颗粒细胞铁死亡维持卵巢功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565641)
**期刊：** Nature communications
**PMID：** 41565641
**DOI：** 10.1038/s41467-026-68440-1

### 第一部分 原文与翻译

**英文原标题：** Serine inhibits granulosa cell ferroptosis to maintain ovarian function.

> **英文摘要：**
> Cyclophosphamide (CTX) is a primary medicine for curing breast cancer which often causes premature ovarian insufficiency (POI). Our recent publication reveals that CTX induces POI by promoting the expression of SLC1A4, a transporter of serine efflux, in ovarian granulosa cells (GCs). Here, we report that there is a closed connection between the reduction of serum serine and ovarian hypofunction in the breast cancer patients treated with CTX or women of childbearing age who are suffered from the staying-up-late. Additionally, we observe that dietary serine supplementation protects mice from CTX-induced POI without altering its anti-breast cancer. Furthermore, we demonstrate that the elevated serine promotes S1P synthesis, and in turn, inhibits the nuclear translocation of Nrf2 and consequent HO-1 expression, to suppress ferroptosis in GCs. Our study reveals that the chemotherapy-induced or idiopathic POI share the same mechanisms, indicating that serine is a critical factor for maintaining ovarian function.

> **中文摘要：**
> 环磷酰胺（CTX）是治疗乳腺癌的主要药物，但常引起卵巢早衰（POI）。我们最近发表的研究显示，CTX通过促进卵巢颗粒细胞（GCs）中丝氨酸外排转运蛋白SLC1A4的表达来诱导POI。在此，我们报道了在接受CTX治疗的乳腺癌患者或长期熬夜的育龄女性中，血清丝氨酸的减少与卵巢功能减退之间存在密切联系。此外，我们观察到膳食补充丝氨酸可以保护小鼠免受CTX诱导的POI，且不影响其抗乳腺癌活性。此外，我们证实升高的丝氨酸促进了1-磷酸鞘氨醇（S1P）的合成，进而抑制Nrf2的核转位及随后的HO-1表达，从而抑制GCs中的铁死亡。我们的研究揭示了化疗诱导的或特发性的POI具有相同的机制，表明丝氨酸是维持卵巢功能的关键因子。

### 第二部分 AI 大师评价

该研究深入探讨了氨基酸代谢在卵巢保护中的关键作用，揭示了丝氨酸缺乏是化疗药物及不良生活习惯（如熬夜）导致卵巢功能损伤的共同病理基础。通过临床数据与动物实验，研究者精准定位了S1P/Nrf2/HO-1这一调控颗粒细胞铁死亡的分子轴，证实了膳食补充丝氨酸的干预潜力。该发现不仅为化疗引发的生殖损伤提供了新的防治策略，也为非疾病因素导致的卵巢早衰提供了重要的营养学干预思路。

---

## 51. 新辅助放化疗联合信迪利单抗治疗具有中/高免疫评分的错配修复完整型局部晚期直肠癌（SILAR）：一项单臂II期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565630)
**期刊：** Nature communications
**PMID：** 41565630
**DOI：** 10.1038/s41467-025-65162-8

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR): a single-arm phase II trial.

> **英文摘要：**
> There is an urgent need to identify those who may benefit from immunotherapy-based chemoradiotherapy (CRT) for patients with locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR). This single-arm, phase-II trial (NCT05450029), enrolled 46 treatment-naïve patients with histologically confirmed TNM or TNM LARC with intermediate or high Immunoscore. Patients received 6 cycles of mFOLFOX6 and long-course radiotherapy (50 Gy in 25 fractions) followed by surgery. Sintilimab was added during CRT (2nd-6th cycle). The primary endpoint, pathologic complete response (pCR) rate, was 65.2% [30/46, 95%CI: 49.7-78.6], with 85.7% (6/7) in high and 61.5% (24/39) in intermediate Immunoscore, meeting the pre-specified primary endpoint. Secondary endpoints included R0 resection rate (97.8%), the clinical tumor response (ORR 93.5%), the complication rate and safety, 3-year event-free survival rate, and 3-year overall survival rate (immature). The most common treatment related adverse event (TRAE) was leukopenia (69.6%, 32/46). The TRAE of Grade 3 occurred in 7 patients (15.2%). Four patients had postoperative complications (all grade ≤2). Here, we showed that PD-1 blockade combined with long-course CRT yielded promising therapeutic effects with a favorable pCR rate and acceptable safety profile among patients with intermediate/high-Immunoscore pMMR LARC.

> **中文摘要：**
> 对于错配修复完整（pMMR）的局部晚期直肠癌（LARC）患者，迫切需要识别出那些可能从基于免疫疗法的放化疗（CRT）中获益的人群。这项单臂、II期试验（NCT05450029）招募了46名经组织学证实为TNM II期或III期、且具有中或高免疫评分（Immunoscore）的初治LARC患者。患者接受了6个周期的mFOLFOX6方案和长程放疗（50 Gy，分25次），随后进行手术。在放化疗期间（第2至第6周期）加入了信迪利单抗。主要终点病理完全缓解（pCR）率为65.2% [30/46, 95% CI: 49.7-78.6]，其中高免疫评分组为85.7% (6/7)，中免疫评分组为61.5% (24/39)，达到了预设的主要终点。次要终点包括R0切除率（97.8%）、临床肿瘤缓解率（ORR 93.5%）、并发症发生率与安全性、3年无事件生存率和3年总生存率（数据尚不成熟）。最常见的治疗相关不良事件（TRAE）为白细胞减少症（69.6%, 32/46）。3级TRAE发生在7名患者（15.2%）中。4名患者出现术后并发症（均为≤2级）。本研究表明，PD-1抑制剂联合长程放化疗在具有中/高免疫评分的pMMR LARC患者中产生了令人鼓舞的治疗效果，具有优异的pCR率和可接受的安全性。

### 第二部分 AI 大师评价

本研究（SILAR试验）创新性地利用免疫评分（Immunoscore）作为生物标志物，成功筛选出能从免疫联合放化疗中获益的pMMR局部晚期直肠癌患者，打破了传统认为pMMR人群对免疫治疗不敏感的局限。结果显示，信迪利单抗联合长程放化疗实现了高达65.2%的pCR率，显著优于既往标准治疗数据，且安全风险可控。尽管该研究为单臂设计且样本量较小，但其为pMMR直肠癌的精准免疫治疗提供了高质量证据，具有重要的临床转化价值。

---

## 52. 更正：IFN-γ 与 TNF-α 联合处理可增强乳腺癌细胞和球状体对自然杀伤细胞介导杀伤作用的敏感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565626)
**期刊：** Cell death & disease
**PMID：** 41565626
**DOI：** 10.1038/s41419-025-08381-7

### 第一部分 原文与翻译

**英文原标题：** Correction: Combined IFN-γ and TNF-α treatment enhances the susceptibility of breast cancer cells and spheroids to Natural Killer cell-mediated killing.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献属于学术勘误（Correction），旨在对原发表研究中关于IFN-γ和TNF-α联合应用增强乳腺癌免疫杀伤敏感性的实验数据或描述进行修正。原研究重点探讨了细胞因子诱导对提升NK细胞杀伤效率的协同作用，特别是在模拟肿瘤微环境的三维球状体模型中。此类文件对于维持学术严谨性和确保后续肿瘤免疫治疗研究的准确性具有重要意义。

---

## 53. 奥希替尼通过抑制 MYLK4 介导的 CDKAL1 磷酸化以抑制横纹肌肉瘤的干性和化疗耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565624)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41565624
**DOI：** 10.1038/s41392-025-02548-6

### 第一部分 原文与翻译

**英文原标题：** Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究揭示了第三代 EGFR 抑制剂奥希替尼在横纹肌肉瘤（RMS）治疗中的新机制，即通过阻断 MYLK4 介导的 CDKAL1 磷酸化来抑制肿瘤干性和克服化疗耐药。这一发现不仅拓展了奥希替尼的临床应用潜力，也为开发针对 RMS 信号转导通路的新型靶向策略提供了重要实验依据。研究聚焦于解决横纹肌肉瘤临床治疗中常见的耐药难题，具有较高的临床转化参考价值。

---

## 54. 表观遗传控制的CEBPB通过GPD1L介导的醚脂合成调节肾癌的发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565622)
**期刊：** Cell death & disease
**PMID：** 41565622
**DOI：** 10.1038/s41419-025-08403-4

### 第一部分 原文与翻译

**英文原标题：** Epigenetically-controlled CEBPB regulates kidney cancer tumorigenesis via GPD1L-mediated ether lipid synthesis.

> **英文摘要：**
> Clear cell renal cell carcinoma (ccRCC) is characterized by disrupted lipid metabolism, traditionally attributed to VHL mutations and HIF stabilization. Here, we identified CEBPB as an epigenetically upregulated, VHL-independent transcription factor driving ccRCC tumorigenesis. CEBPB was regulated by H3K27ac and H3K4me and transcriptionally repressed the tumor-suppressive glycerol-3-phosphate dehydrogenase 1-like protein (GPD1L), thereby elevating dihydroxyacetone phosphate (DHAP)-derived ether lipid synthesis and enhancing Akt signaling. This activation suppressed CPT1A expression, inhibiting fatty acid oxidation (FAO) and leading to lipid accumulation, as found by lipidomics and isotope tracing. Loss of CEBPB reduced ether lipids, reactivated CPT1A, and impaired Akt signaling, diminishing tumor growth and lipid content in vitro and in vivo. Restoration of ether lipids or Akt activity rescued these effects. Importantly, CEBPB expression and enhancer activation were not modulated by VHL status and it could be targeted pharmacologically. The CEBPB-GPD1L-ether lipid-Akt-CPT1A axis is proposed as a new druggable driver in ccRCC integrating epigenetics, transcription, intermediary metabolism and oncogenic signaling.

> **中文摘要：**
> 透明细胞肾细胞癌（ccRCC）的特征是脂质代谢紊乱，传统上这被归因于VHL突变和HIF稳定。在本研究中，我们鉴定出CEBPB是一种受表观遗传上调、非VHL依赖性的转录因子，驱动ccRCC的发生。CEBPB受H3K27ac和H3K4me调节，并在转录水平上抑制肿瘤抑制因子甘油-3-磷酸脱氢酶1样蛋白（GPD1L），从而增加了磷酸二羟丙酮（DHAP）衍生的醚脂合成并增强了Akt信号传导。脂质组学和同位素示踪研究发现，这种激活抑制了CPT1A的表达，从而阻断脂肪酸氧化（FAO）并导致脂质积累。缺失CEBPB会减少醚脂产生、重新激活CPT1A并削弱Akt信号传导，进而在体内外抑制肿瘤生长并降低脂质含量。恢复醚脂水平或Akt活性可逆转这些效应。重要的是，CEBPB的表达和增强子激活不受VHL状态的调节，且可以作为药物干预的靶点。本研究提出的CEBPB-GPD1L-醚脂-Akt-CPT1A轴整合了表观遗传学、转录、中间代谢和致癌信号，是ccRCC中一个新的可成药驱动机制。

### 第二部分 AI 大师评价

本研究揭示了ccRCC中一种独立于经典VHL-HIF轴的新型代谢重编程机制，具有显著的科学价值。作者通过整合表观基因组学、脂质组学和同位素示踪技术，论证了转录因子CEBPB如何通过调控GPD1L介导的醚脂合成来激活Akt信号并抑制脂肪酸氧化。该研究不仅拓宽了对肾癌脂质蓄积机制的理解，还为临床上开发针对VHL非依赖型肾癌的靶向疗法提供了坚实的理论依据。

---

## 55. USP8与Hippo/YAP轴之间的正反馈调节驱动三阴性乳腺癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565619)
**期刊：** Cell death & disease
**PMID：** 41565619
**DOI：** 10.1038/s41419-025-08356-8

### 第一部分 原文与翻译

**英文原标题：** Positive feedback regulation between USP8 and Hippo/YAP axis drives triple-negative breast cancer progression.

> **英文摘要：**
> The hyper-activation of the Hippo/YAP axis was observed in triple-negative breast cancer (TNBC), which was crucial for tumor progression. The over-activation of YAP in TNBC remains unexplained, despite the continued functionality of the inhibitory phospho-cascade. Recently, studies revealed that the ubiquitin modifications of YAP also play important roles in the Hippo/YAP axis and cancer progression. In order to understand the potential mechanisms of ubiquitination and deubiquitination process in YAP function, we carried out siRNA screening for critical deubiquitinases in TNBC. Via the deubiquitinases (DUB) library, we identified Ubiquitin Specific Peptidase 8 (USP8) as an important effector in YAP function and TNBC progression. Inhibition of USP8 hampered TNBC progression via Hippo signaling. Clinical data revealed that USP8 expression correlated with YAP protein level and poor survival in TNBC patients. Biochemical evaluations revealed that USP8 has the ability to connect with YAP and suppress K48-linked polyubiquitination, thereby enhancing the stability of YAP. Interestingly, YAP directly binds to the USP8 promoter region, enhancing its transcription in TNBC. Our study revealed a forward feedback loop between USP8 and Hippo signaling in TNBC, indicating USP8 as a potential therapeutic drug targets in TNBC.

> **中文摘要：**
> 在三阴性乳腺癌（TNBC）中观察到Hippo/YAP轴的过度激活，这对于肿瘤进展至关重要。尽管抑制性磷酸化级联反应仍在发挥作用，但TNBC中YAP过度激活的原因仍不明确。最近的研究表明，YAP的泛素化修饰在Hippo/YAP轴和癌症进展中也发挥着重要作用。为了了解YAP功能中泛素化和去泛素化过程的潜在机制，我们对TNBC中关键的去泛素酶进行了siRNA筛选。通过去泛素酶（DUB）库，我们鉴定出泛素特异性肽酶8（USP8）是YAP功能和TNBC进展中的重要效应因子。抑制USP8可通过Hippo信号通路阻碍TNBC的进展。临床数据表明，USP8的表达与TNBC患者的YAP蛋白水平及不良生存率相关。生化评估显示，USP8能够与YAP结合并抑制K48连接的多泛素化，从而增强YAP的稳定性。有趣的是，YAP直接结合USP8启动子区域，增强其在TNBC中的转录。我们的研究揭示了TNBC中USP8与Hippo信号通路之间的正反馈环路，表明USP8是TNBC中一个潜在的治疗药物靶点。

### 第二部分 AI 大师评价

本研究通过siRNA文库筛选，鉴定出USP8是驱动三阴性乳腺癌（TNBC）进展的关键去泛素酶。研究揭示了USP8通过抑制K48位点泛素化来稳定YAP蛋白，而YAP又能直接促进USP8转录，形成了一个维持肿瘤恶性表型的正反馈环路。该发现不仅深化了对TNBC中Hippo通路异常激活机制的理解，也为USP8作为临床治疗TNBC的潜在分子靶点提供了坚实的实验依据。

---

## 56. 仑伐替尼联合经动脉化疗栓塞及PD-1抑制剂作为不可切除中晚期肝细胞癌转化治疗的2期临床试验及探索性生物分子研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565617)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41565617
**DOI：** 10.1038/s41392-025-02498-z

### 第一部分 原文与翻译

**英文原标题：** Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.

> **英文摘要：**
> Conversion therapy remains an uncommon strategy for managing unresectable hepatocellular carcinoma (uHCC) due to limited evidence supporting its efficacy. To address this gap, we initiated a prospective phase 2 multicenter trial (NCT04997850) comparing the LEN-TAP regimen, combining lenvatinib, transarterial chemoembolization (TACE), and PD-1 inhibitors, against TACE alone in uHCC patients. The study's primary outcome was salvage liver resection (SLR) rate; secondary measures included objective response rate (ORR), overall survival (OS), event-free survival (EFS), recurrence-free survival (RFS), and safety profile. From October 2020 to November 2021, 142 eligible participants were assigned to LEN-TAP (n = 71) or TACE monotherapy (n = 71). At a median follow-up of 24.2 months, the LEN-TAP cohort exhibited a significantly higher SLR rate (59.2% vs. 18.3%, P < 0.001) and ORR (78.9% vs. 16.9%, P < 0.001). Median OS, EFS, and RFS were also substantially prolonged in the LEN-TAP cohort (not reached vs. 23.0 months, P < 0.001; 20.03 vs. 6.52 months, P < 0.001; 36.6 vs. 19.0 months, P = 0.048). Although grade 3 treatment-related AEs occurred more frequently with LEN-TAP (60.6% vs. 21.1%, P < 0.001), no grade 4 or higher toxicities were observed. Exploratory biomarker assessments via single-cell sequencing and flow cytometry linked elevated levels of circulating HLA-DRCD38CD8 T cells with improved treatment response. These T cells appear to mediate antitumor activity potentially through the CXCR6-PI3K-AKT signaling axis. In summary, the LEN-TAP protocol demonstrates promising efficacy and acceptable tolerability as a conversion therapy in uHCC, with peripheral HLA-DRCD38CD8 T cell abundance serving as a potential predictor of therapeutic benefit.

> **中文摘要：**
> 转化治疗由于支持其有效性的证据有限，目前仍是管理不可切除肝细胞癌（uHCC）的一种非主流策略。为填补这一空白，我们发起了一项前瞻性、2期、多中心临床试验（NCT04997850），旨在比较结合了仑伐替尼、经动脉化疗栓塞（TACE）和PD-1抑制剂的LEN-TAP方案与单纯TACE在uHCC患者中的疗效。该研究的主要终点是挽救性肝切除（SLR）率；次要指标包括客观缓解率（ORR）、总生存期（OS）、无事件生存期（EFS）、无复发生存期（RFS）以及安全性概况。从2020年10月至2021年11月，142名符合条件的受试者被分配至LEN-TAP组（n=71）或TACE单药组（n=71）。在中位随访24.2个月时，LEN-TAP组表现出显著更高的SLR率（59.2% vs. 18.3%，P < 0.001）和ORR（78.9% vs. 16.9%，P < 0.001）。LEN-TAP组的中位OS、EFS和RFS也显著延长（未达到 vs. 23.0个月，P < 0.001；20.03 vs. 6.52个月，P < 0.001；36.6 vs. 19.0个月，P = 0.048）。虽然LEN-TAP组发生3级治疗相关不良事件（AE）的频率更高（60.6% vs. 21.1%，P < 0.001），但未观察到4级或更高级别的毒性。通过单细胞测序和流式细胞术进行的探索性生物标志物评估显示，循环中HLA-DR+CD38+CD8+ T细胞水平的升高与更好的治疗反应相关。这些T细胞似乎可能通过CXCR6-PI3K-AKT信号轴介导抗肿瘤活性。总之，LEN-TAP方案作为uHCC的转化治疗表现出极具前景的疗效和可接受的耐受性，外周血HLA-DR+CD38+CD8+ T细胞丰度可作为治疗获益的潜在预测指标。

### 第二部分 AI 大师评价

这项前瞻性2期多中心研究有力证明了LEN-TAP三联方案在不可切除中晚期肝癌转化治疗中的卓越临床价值，显著提升了手术切除率和患者生存期。研究不仅提供了高质量的循证医学证据，还通过单细胞测序深入揭示了外周血HLA-DR+CD38+CD8+ T细胞及其介导的CXCR6-PI3K-AKT信号轴在预测疗效中的关键作用。尽管三联疗法增加了3级不良反应的风险，但整体安全性可控，为晚期肝癌的综合治疗模式优化提供了重要的生物分子机制支持和实践参考。

---

## 57. SNORA49 通过抑制 SOX9 转录负向调节肝癌干细胞的自我更新和肝癌发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41565615)
**期刊：** Nature communications
**PMID：** 41565615
**DOI：** 10.1038/s41467-025-66486-1

### 第一部分 原文与翻译

**英文原标题：** SNORA49 negatively regulates self-renewal of liver cancer stem cells and hepatocarcinogenesis via suppressing SOX9 transcription.

> **英文摘要：**
> Cancer stem cells (CSCs) play a critical role in tumor initiation, progression, and recurrence. How liver CSCs initiate their self-renewal remains elusive. Here we identify a conserved small nucleolar RNA (snoRNA), SNORA49, which is lowly expressed in liver CSCs, as a negative regulator of CSC self-renewal. SNORA49 knockout enhances the self-renewal capacity of liver CSCs and accelerates hepatocellular carcinoma (HCC) tumorigenesis, whereas overexpression of SNORA49 suppresses tumor formation. Mechanistically, in non-CSCs, SNORA49 is specifically localized in the nucleoplasm to associate with HNRNPU, blocking its interaction with ZC3H18, resulting in inhibition of SOX9 transcription. In liver CSCs, lowly expressed SNORA49 releases HNRNPU to engage with ZC3H18 and enrich on the promoter of SOX9, leading to its transcription. Of note, lipid nanoparticle (LNP)-mediated delivery of SNORA49 RNAs and antisense oligonucleotides (ASOs) targeting SOX9 exerts potent synergistic anti-tumor effect on HCC tumors. Our findings define SNORA49 as a tumor suppressor in liver CSCs, and restoring SNORA49 levels and silencing SOX9 with LNP-delivered system may provide therapeutic strategy for clinical intervention to HCC patients.

> **中文摘要：**
> 癌症干细胞 (CSCs) 在肿瘤的启动、进展和复发中起着关键作用。肝癌 CSCs 如何启动其自我更新仍不清楚。在这里，我们鉴定出一种在肝癌 CSCs 中低表达的保守小核仁 RNA (snoRNA)——SNORA49，它是 CSC 自我更新的负调节因子。敲除 SNORA49 会增强肝癌 CSCs 的自我更新能力并加速肝细胞癌 (HCC) 的发生，而过表达 SNORA49 则会抑制肿瘤形成。在机制上，在非 CSCs 中，SNORA49 特异性定位于核质中并与 HNRNPU 结合，从而阻断其与 ZC3H18 的相互作用，导致 SOX9 转录受到抑制。在肝癌 CSCs 中，低表达的 SNORA49 释放了 HNRNPU，使其与 ZC3H18 结合并富集在 SOX9 的启动子上，进而引导其转录。值得注意的是，利用脂质纳米颗粒 (LNP) 介导递送 SNORA49 RNA 和靶向 SOX9 的反义寡核苷酸 (ASOs) 对 HCC 肿瘤展现出强大的协同抗肿瘤作用。我们的研究结果将 SNORA49 定义为肝癌 CSCs 中的一种抑癌因子，通过 LNP 递送系统恢复 SNORA49 水平并沉默 SOX9，可能为 HCC 患者的临床干预提供治疗策略。

### 第二部分 AI 大师评价

该研究深入探讨了小核仁RNA（snoRNA）成员 SNORA49 在肝癌干细胞（CSCs）自更新中的关键抑癌作用，揭示了其通过调控 HNRNPU/ZC3H18 轴抑制 SOX9 转录的精确分子机制。研究的创新性在于阐明了核质定位的 SNORA49 如何在非干细胞中维持 SOX9 的低表达，并验证了 LNP 递送 SNORA49 联合 SOX9 沉默在体内实验中的强大协同抗肿瘤潜力。这一发现不仅完善了非编码 RNA 调控肿瘤干性的理论体系，还为肝细胞癌的临床治疗提供了极具前景的核酸药物联合策略。

---

## 58. POT1介导的长端粒综合征中的淋巴恶性肿瘤和克隆性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564438)
**期刊：** Blood
**PMID：** 41564438
**DOI：** 10.1182/blood.2025031287

### 第一部分 原文与翻译

**英文原标题：** Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.

> **英文摘要：**
> Long telomere length (TL) extends replicative capacity in vitro, and predisposes to clonal hematopoiesis. We characterized the cancer phenotype in 51 individuals from 24 families with mutant POT1, a negative regulator of telomerase elongation (median age 51, range 5-94). Hematologic malignancies were second in prevalence after melanoma (27%), and lymphoid subsets were more common. They clustered with history of sarcoma, thyroid cancer and chronic myeloproliferative neoplasms. UKB participants with pathogenic POT1 variants had long TL and higher lymphoid malignancy rates (45% by age 80, Hazard ratio 8.28, 95% CI, 5.29-13.0). Across cohorts, diagnoses encompassed acute lymphoblastic leukemia and Hodgkin lymphoma in children/young adults, and chronic lymphocytic leukemia/multiple myeloma in adults. They clustered in families manifesting as autosomal dominant pan-lymphoma with genetic anticipation at times. Lymphocyte TL was longer than granulocytes at baseline (age-adjusted mean +1 kb, P<0.0001), and was preserved longitudinally with aging. Ultra-long lymphocyte TL >99th percentile was more sensitive for identifying pathogenic variants (58% vs. 38% for granulocytes). Among asymptomatic POT1 variant carriers, 60% (12 of 20) had immunophenotype-detected B and/or T cell clonality with complete penetrance after age 65 (7 of 7). IGH CDR3 sequencing supported age-dependent pruning of the B cell repertoire, and cytogenetic and next-generation analyses uncovered preclinical clonal lymphoma-associated changes in nearly all POT1 variant carriers older than 60 (9 of 10). Our data identify extended cellular longevity due to long TL as an inherited risk factor for lymphoma explaining its syndromic association with solid tumors, and in some cases, myeloproliferative neoplasms.

> **中文摘要：**
> 体外实验显示，长端粒长度（TL）可延长细胞复制能力，并导致克隆性造血倾向。我们对来自24个携带POT1突变（一种端粒酶延长的负调节因子）家族的51名个体（中位年龄51岁，范围5-94岁）的癌症表型进行了表征。血液系统恶性肿瘤的患病率（27%）仅次于黑色素瘤，其中淋巴亚群更为常见。这些恶性肿瘤常与肉瘤、甲状腺癌和慢性骨髓增殖性肿瘤病史聚集出现。携带致病性POT1变异的英国生物样本库（UKB）参与者具有较长的端粒和较高的淋巴恶性肿瘤发病率（到80岁时为45%，风险比8.28，95% CI 5.29-13.0）。在不同队列中，诊断包括儿童和青少年的急性淋巴细胞白血病和霍奇金淋巴瘤，以及成人的慢性淋巴细胞白血病和多发性骨髓瘤。这些疾病在家族中呈常染色体显性“全淋巴瘤”表现，有时伴有遗传早现现象。基线时淋巴细胞的TL比粒细胞长（年龄校正后的均值+1 kb，P<0.0001），且在衰老过程中呈现纵向保持特征。超过第99百分位数的超长淋巴细胞TL在识别致病变异方面比粒细胞更敏感（58%对38%）。在无症状的POT1变异携带者中，60%（20人中的12人）通过免疫表型检测发现存在B细胞和/或T细胞克隆性，且在65岁以后表现为完全外显（7人中的7人）。IGH CDR3测序支持B细胞谱系存在随年龄增长的精简现象，细胞遗传学和二代测序分析在几乎所有60岁以上的POT1变异携带者（10人中的9人）中发现了临床前克隆性淋巴瘤相关的改变。我们的数据表明，长端粒导致的细胞寿命延长是淋巴瘤的一种遗传性危险因素，这解释了其与实体瘤以及在某些情况下与骨髓增殖性肿瘤的综合征关联。

### 第二部分 AI 大师评价

本研究通过结合家族队列分析与英国生物样本库大数据，深入揭示了POT1介导的长端粒综合征与淋巴恶性肿瘤之间的遗传关联与病理机制。研究发现POT1变异不仅显著提升了淋巴系统肿瘤的患病风险，还呈现出高外显率和年龄依赖性的克隆性演变特征。其创新性在于将“细胞长寿”转化为“肿瘤易感性”的生物学视角，并提出超长淋巴细胞端粒作为致病变异筛查的新型标志物。该研究为遗传性端粒疾病谱系提供了关键补充，对淋巴瘤的早期预警和精准筛查具有重要的临床意义。

---

## 59. 脑叶酸缺乏症、自闭症及亚叶酸钙的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564421)
**期刊：** The New England journal of medicine
**PMID：** 41564421
**DOI：** 10.1056/NEJMp2516268

### 第一部分 原文与翻译

**英文原标题：** Cerebral Folate Deficiency, Autism, and the Role of Leucovorin.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文探讨了脑叶酸缺乏症与自闭症谱系障碍之间的病理关联，并重点论述了亚叶酸钙在改善患者神经发育症状中的临床作用。文章旨在揭示叶酸代谢异常对自闭症发病机制的影响，为这一复杂疾病的精准干预提供了生化维度的重要视角。尽管该篇文献为观点类文章且未提供摘要，但其核心价值在于强调了早期识别代谢异常及靶向药物干预在神经发育障碍管理中的潜力，对临床诊疗具有重要的启发性。

---

## 60. 医学影像检查与儿童及青少年血液癌症风险：作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564412)
**期刊：** The New England journal of medicine
**PMID：** 41564412
**DOI：** 10.1056/NEJMc2515877

### 第一部分 原文与翻译

**英文原标题：** Medical Imaging and Hematologic Cancer Risk among Children and Teens. Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献属于《新英格兰医学杂志》（NEJM）中的通讯类文章，是作者针对此前发表的关于儿童及青少年医学影像暴露与血液肿瘤风险研究的正式回复。此类回复通常针对读者对原始研究的方法学、混杂因素控制或统计效力的质疑进行深度澄清。作为学术闭环的重要组成部分，它对于准确理解放射流行病学数据及完善儿科临床决策路径具有重要参考价值。

---

## 61. 医学成像与儿童及青少年血液系统癌症风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564411)
**期刊：** The New England journal of medicine
**PMID：** 41564411
**DOI：** 10.1056/NEJMc2515877

### 第一部分 原文与翻译

**英文原标题：** Medical Imaging and Hematologic Cancer Risk among Children and Teens.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究聚焦于探讨医疗成像暴露与儿童及青少年血液系统癌症风险之间的潜在关联。该课题是儿科放射防护和公共卫生领域的核心关注点，旨在评估诊断性电离辐射暴露的长期安全性。虽然目前暂无详细摘要，但鉴于其发表于顶级医学期刊《新英格兰医学杂志》，该研究可能为临床医生在平衡影像检查的诊断获益与潜在致癌风险方面提供关键的循证依据，对于优化儿科临床转诊流程具有重要意义。

---

## 62. 儿童与青少年医学影像检查与血液系统癌症风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564410)
**期刊：** The New England journal of medicine
**PMID：** 41564410
**DOI：** 10.1056/NEJMc2515877

### 第一部分 原文与翻译

**英文原标题：** Medical Imaging and Hematologic Cancer Risk among Children and Teens.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究深入探讨了儿童及青少年时期接受涉及电离辐射的医学影像检查与后续血液系统癌症风险之间的流行病学关联。作为发表在NEJM上的论著性信函，其核心价值在于提供了关于低剂量辐射暴露在未成年人群中长期安全性的关键证据。研究强调了在临床实践中对儿科影像检查进行放射防护及必要性评估的重要性，以权衡诊断获益与潜在的致癌风险。尽管文中未提供详细摘要，但其针对敏感人群的风险评估对公共卫生策略和临床影像操作规范具有显著的指导意义。

---

## 63. 儿童和青少年医学影像检查与血液系统癌症风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564409)
**期刊：** The New England journal of medicine
**PMID：** 41564409
**DOI：** 10.1056/NEJMc2515877

### 第一部分 原文与翻译

**英文原标题：** Medical Imaging and Hematologic Cancer Risk among Children and Teens.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文探讨了儿童及青少年时期接受医学影像检查（涉及电离辐射暴露）与后续发生血液系统癌症之间的风险关联。该研究聚焦于儿科放射防护的核心议题，旨在量化低剂量辐射对处于发育敏感期人群的长期致癌效应。作为发表在顶级期刊NEJM的通信类文章，其对优化临床影像诊断的获益-风险比评估以及完善放射剂量管理策略具有极高的指导价值。尽管目前无详细摘要，但其研究结论对于降低未成年人医源性辐射风险及加强血液系统恶性肿瘤预防具有重要的循证医学意义。

---

## 64. 欧洲前列腺癌筛查研究——23年随访。答复。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564408)
**期刊：** The New England journal of medicine
**PMID：** 41564408
**DOI：** 10.1056/NEJMc2517122

### 第一部分 原文与翻译

**英文原标题：** European Study of Prostate Cancer Screening - 23-Year Follow-up. Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本篇文献为《新英格兰医学杂志》（NEJM）刊发的针对“欧洲前列腺癌筛查研究（ERSPC）23年随访结果”的作者答复。ERSPC是全球衡量前列腺癌筛查价值的最重要研究之一，其长达23年的数据为评估PSA筛查在降低死亡率方面的长期获益提供了核心证据。该回复旨在针对同行评议中关于研究设计、数据解读或临床应用等方面的争议点进行澄清与深度探讨。这类学术互动对于在公共卫生层面权衡前列腺癌筛查的获益与过度诊断风险具有重要的指导意义。

---

## 65. 欧洲前列腺癌筛查研究：23年随访结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564407)
**期刊：** The New England journal of medicine
**PMID：** 41564407
**DOI：** 10.1056/NEJMc2517122

### 第一部分 原文与翻译

**英文原标题：** European Study of Prostate Cancer Screening - 23-Year Follow-up.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要内容。

### 第二部分 AI 大师评价

本研究报告了欧洲前列腺癌筛查随机研究（ERSPC）长达23年的随访结果，是目前全球关于PSA筛查领域观察周期最长的证据之一。23年的数据进一步验证了筛查对降低前列腺癌死亡率的长期获益，同时为评估过度诊断与死亡获益之间的利弊平衡提供了关键依据。作为NEJM发布的最新随访通讯，该研究对完善全球前列腺癌早期筛查指南和公共卫生策略具有极高的学术价值和临床参考意义。

---

## 66. 欧洲前列腺癌筛查研究：23年随访结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564406)
**期刊：** The New England journal of medicine
**PMID：** 41564406
**DOI：** 10.1056/NEJMc2517122

### 第一部分 原文与翻译

**英文原标题：** European Study of Prostate Cancer Screening - 23-Year Follow-up.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究提供了欧洲随机前列腺癌筛查研究（ERSPC）长达23年的随访数据，是目前该领域随访时间最长的核心文献之一。其核心目的在于通过超长周期的观察，进一步量化基于PSA的早期筛查对降低前列腺癌死亡率的实际获益及其持续性。该研究结果对评估筛查带来的长期生存优势与过度诊断风险之间的平衡具有至关重要的学术价值，为全球前列腺癌筛查策略的长期演进提供了决定性的循证支持。

---

## 67. Sacituzumab Govitecan 联合帕博利珠单抗治疗晚期三阴性乳腺癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564397)
**期刊：** The New England journal of medicine
**PMID：** 41564397
**DOI：** 10.1056/NEJMoa2508959

### 第一部分 原文与翻译

**英文原标题：** Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.

> **英文摘要：**
> BACKGROUND: Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer. METHODS: In this phase 3, open-label, international trial, we randomly assigned patients in a 1:1 ratio to receive sacituzumab govitecan plus pembrolizumab or chemotherapy plus pembrolizumab. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included overall survival, objective response (complete or partial response) and duration of response as assessed by blinded independent central review, and safety. RESULTS: A total of 443 patients were randomly assigned to receive sacituzumab govitecan plus pembrolizumab (221 patients) or chemotherapy plus pembrolizumab (222 patients). The median progression-free survival was 11.2 months (95% confidence interval [CI], 9.3 to 16.7) with sacituzumab govitecan plus pembrolizumab and 7.8 months (95% CI, 7.3 to 9.3) with chemotherapy plus pembrolizumab (hazard ratio for disease progression or death, 0.65; 95% CI, 0.51 to 0.84; two-sided P<0.001). Data for overall survival were immature. The percentage of patients with an objective response was 60% (95% CI, 53 to 66) with sacituzumab govitecan plus pembrolizumab and 53% (95% CI, 46 to 60) with chemotherapy plus pembrolizumab; among patients with a response, the median duration of response was 16.5 months (95% CI, 12.7 to 19.5) and 9.2 months (95% CI, 7.6 to 11.3), respectively. Adverse events of grade 3 or higher occurred in 71% of the patients receiving sacituzumab govitecan plus pembrolizumab and in 70% of those receiving chemotherapy plus pembrolizumab; the incidence of treatment discontinuation due to adverse events was 12% and 31%, respectively. Adverse events leading to death occurred in 3% of the patients in each group. CONCLUSIONS: Sacituzumab govitecan plus pembrolizumab led to significantly longer progression-free survival than chemotherapy plus pembrolizumab among patients with previously untreated, PD-L1-positive, advanced triple-negative breast cancer. (Funded by Gilead Sciences; ASCENT-04/KEYNOTE-D19 ClinicalTrials.gov number, NCT05382286.).

> **中文摘要：**
> 背景：三阴性乳腺癌是一种侵袭性乳腺癌亚型，对于既往未接受过治疗、程序性死亡配体 1 (PD-L1) 阳性的局部晚期不可切除或转移性三阴性乳腺癌患者，仍存在改善预后的未满足需求。
> 
> 方法：在这项 3 期、开放标签、国际性试验中，我们将患者按 1:1 的比例随机分配，分别接受 sacituzumab govitecan 联合帕博利珠单抗或化疗联合帕博利珠单抗治疗。主要终点是由盲态独立中央审查委员会评估的无进展生存期。次要终点包括总生存期、由盲态独立中央审查委员会评估的客观缓解（完全或部分缓解）和缓解持续时间，以及安全性。
> 
> 结果：共有 443 名患者被随机分配接受 sacituzumab govitecan 联合帕博利珠单抗（221 名患者）或化疗联合帕博利珠单抗（222 名患者）治疗。sacituzumab govitecan 联合帕博利珠单抗组的中位无进展生存期为 11.2 个月（95% 置信区间 [CI] 为 9.3 至 16.7），而化疗联合帕博利珠单抗组为 7.8 个月（95% CI 为 7.3 至 9.3）（疾病进展或死亡的风险比为 0.65；95% CI 为 0.51 至 0.84；双侧 P<0.001）。总生存期数据尚不成熟。sacituzumab govitecan 联合帕博利珠单抗组获得客观缓解的患者比例为 60%（95% CI 为 53 至 66），化疗联合帕博利珠单抗组为 53%（95% CI 为 46 至 60）；在产生缓解的患者中，中位缓解持续时间分别为 16.5 个月（95% CI 为 12.7 至 19.5）和 9.2 个月（95% CI 为 7.6 至 11.3）。sacituzumab govitecan 联合帕博利珠单抗组中 71% 的患者发生了 3 级或更高水平的不良事件，化疗联合帕博利珠单抗组中该比例为 70%；因不良事件导致治疗中断的发生率分别为 12% 和 31%。每组均有 3% 的患者发生了导致死亡的不良事件。
> 
> 结论：在既往未接受过治疗、PD-L1 阳性的晚期三阴性乳腺癌患者中，sacituzumab govitecan 联合帕博利珠单抗治疗导致的无进展生存期显著长于化疗联合帕博利珠单抗。（由吉利德科学公司资助；ASCENT-04/KEYNOTE-D19 ClinicalTrials.gov 编号为 NCT05382286。）

### 第二部分 AI 大师评价

本研究（ASCENT-04/KEYNOTE-D19）是一项具有里程碑意义的 3 期临床试验，首次在 PD-L1 阳性的晚期三阴性乳腺癌（TNBC）一线治疗中证明了抗体偶联药物（ADC）联合免疫检查点抑制剂优于传统化疗方案。结果显示该联合疗法显著延长了无进展生存期并使缓解持续时间翻倍，且在保持相似安全性谱的同时，显著降低了因不良事件导致的治疗中断率。尽管总生存期数据尚不成熟，但其强效的抗肿瘤活性及更优的耐受性为晚期 TNBC 的一线标准治疗提供了新的证据支持。

---

## 68. 在造血细胞移植临床试验中，是否到了超越“无移植物抗宿主病且无复发生存率”作为主要终点的时候了？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564387)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41564387
**DOI：** 10.1200/JCO-25-02130

### 第一部分 原文与翻译

**英文原标题：** Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

这篇发表于《临床肿瘤学杂志》（JCO）的述评文章聚焦于造血细胞移植临床试验设计的核心度量指标。文章深入探讨了目前广泛采用的复合终点“无移植物抗宿主病且无复发生存率（GRFS）”的局限性，并提出了对于更具临床代表性终点的需求。这种讨论反映了移植领域从单纯追求生存数据向更全面衡量患者长期生存质量与疾病控制平衡的转变，对未来临床试验方案的优化具有重要的指导意义。

---

## 69. AXSANA/EUBREAST-03/AGO-B-053研究中接受新辅助治疗的淋巴结阳性乳腺癌患者目标淋巴结标记技术研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564379)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41564379
**DOI：** 10.1200/JCO-25-01921

### 第一部分 原文与翻译

**英文原标题：** Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study.

> **英文摘要：**
> PURPOSE: Surgical axillary staging in patients with node-positive breast cancer (BC) who converted to clinical node negativity through neoadjuvant chemotherapy (NACT) has changed significantly in recent years. Targeted axillary dissection (TAD) and target lymph node (TLN) biopsy (TLNB) became increasingly popular. However, data comparing marking techniques for the TLN are limited. Here, we evaluate marking techniques in the largest prospective cohort worldwide. MATERIALS AND METHODS: Among patients from the ongoing prospective multicenter AXSANA (EUBREAST-03) study who received TLN marking and TAD/TLNB, we evaluated different marking methods with respect to detection and removal rates and clinical performance. RESULTS: Until January 6, 2025, 6,129 patients from 26 countries were enrolled. Of these patients, 2,596 had ≥1 TLN marked before NACT and completed surgery; 13.3% of the patients had ≥4 suspicious nodes at diagnosis. Pre-NACT TLN marking used a clip in 2,003 patients (77.2%), magnetic seed in 287 (11.1%), carbon ink in 192 (7.4%), radar marker in 119 (4.6%), radioactive seed in 18 (0.7%), radiofrequency identification device (RFID) in 12 (0.5%), or other methods in two (0.1%). One TLN was marked in 2,427 patients (93.5%), two TLNs in 138 (5.3%), and ≥3 in 27 patients (1%). Targeted removal of the TLN was planned in 2,100 patients (80.9%; TAD in 2,076 [80.0%] and TLNB in 24 [0.9%]). The TLN was detected and removed by TAD/TLNB in 1,915 patients (91.2%). TLN detection rate was the highest in patients whose TLNs were marked pre-NACT with markers suitable for probe-guided detection (96.6%; radioactive seed: 100%, magnetic seed: 96.9%, radar marker: 96.1%, RFID: 90%), followed by carbon ink (94.9%) and clip (89.6%; P < .001). CONCLUSION: This large prospective analysis of patients with initially clinically node-positive BC receiving NACT demonstrates that probe-guided detection markers used to mark metastatic nodes before NACT provide superior detection rates.

> **中文摘要：**
> 目的：近年来，通过新辅助化疗（NACT）转为临床淋巴结阴性的淋巴结阳性乳腺癌（BC）患者的手术腋窝分期发生了重大变化。靶向腋窝清扫术（TAD）和目标淋巴结（TLN）活检（TLNB）日益普及。然而，比较TLN标记技术的数据有限。在此，我们在全球最大的前瞻性队列中评估了标记技术。材料与方法：在正在进行的AXSANA（EUBREAST-03）前瞻性多中心研究中，我们评估了接受TLN标记和TAD/TLNB患者的不同标记方法在检出率、切除率及临床表现方面的差异。结果：截至2025年1月6日，共纳入来自26个国家的6,129名患者。其中，2,596名患者在NACT前标记了至少1个TLN并完成了手术；13.3%的患者在诊断时有4个或更多可疑淋巴结。NACT前的TLN标记方法包括：2,003名患者（77.2%）使用金属夹，287名（11.1%）使用磁子，192名（7.4%）使用碳素墨水，119名（4.6%）使用雷达标记物，18名（0.7%）使用放射性粒子，12名（0.5%）使用射频识别（RFID）设备，另有2名（0.1%）使用其他方法。2,427名患者（93.5%）标记了1个TLN，138名（5.3%）标记了2个，27名（1%）标记了3个或更多。2,100名患者计划进行目标TLN切除（80.9%；其中2,076名[80.0%]行TAD，24名[0.9%]行TLNB）。1,915名患者（91.2%）通过TAD/TLNB成功检出并切除了TLN。在使用适合探头引导检测的标记物在NACT前进行标记的患者中，TLN检出率最高（96.6%；其中放射性粒子：100%，磁子：96.9%，雷达标记物：96.1%，RFID：90%），其次是碳素墨水（94.9%）和金属夹（89.6%；P < .001）。结论：这项针对初始临床淋巴结阳性且接受NACT的乳腺癌患者的大规模前瞻性分析表明，在NACT前使用探头引导检测标记物标记转移淋巴结可提供更优越的检出率。

### 第二部分 AI 大师评价

该研究基于AXSANA全球最大规模的前瞻性队列，系统对比了多种目标淋巴结（TLN）标记技术在乳腺癌新辅助治疗后的临床表现。研究发现，放射性粒子、磁子和雷达标记物等“探头引导型”技术在术中检出率方面显著优于传统的金属夹，具有极高的临床参考价值。这项研究为优化靶向腋窝清扫术（TAD）提供了强有力的循证医学支持，尽管不同标记物的使用样本量存在差异，但其结论对于推动乳腺癌腋窝精准手术的标准化具有重要意义。

---

## 70. 肝切除术后联合 mFOLFOX6 辅助化疗对比单纯肝切除治疗结直肠癌肝转移的随机 II/III 期试验：JCOG0603 研究的长期结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564372)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41564372
**DOI：** 10.1200/JCO-25-01231

### 第一部分 原文与翻译

**英文原标题：** Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.

> **英文摘要：**
> JCOG0603 demonstrated improved disease-free survival (DFS) with adjuvant mFOLFOX6 after hepatectomy compared with hepatectomy alone in colorectal liver-only metastasis (CRLM), but the overall survival (OS) data were immature. Here, we report OS after long-term follow-up. Eligible patients with colorectal adenocarcinoma and an unlimited number of liver metastases were randomized to adjuvant mFOLFOX6 or hepatectomy alone. DFS was the primary endpoint, and OS was a secondary endpoint. Between March 2007 and January 2019, 151 and 149 patients were randomized to adjuvant chemotherapy and hepatectomy alone, respectively. At a median follow-up of 7.7 years for disease-free surviving patients, 54 (35.8%) and 51 (34.2%) patients had died in the respective arms, (hazard ratio [HR], 1.07 [95% CI, 0.73 to 1.57]). Five-year OS was 73.4% (95% CI, 65.5 to 79.7) and 80.1% (95% CI, 72.6 to 85.7) and 7-year OS was 69.4% (95% CI, 61.2 to 76.2) and 72.4% (95% CI, 64.2 to 79.1), respectively. One patient in the adjuvant chemotherapy arm possibly died of protocol treatment-related toxicity, and one in the hepatectomy-alone arm died of post-protocol treatment complications. Five-year DFS was respectively 49.7% (95% CI, 41.5 to 57.3) and 40.5% (95% CI, 32.5 to 48.3) in the adjuvant chemotherapy and hepatectomy-alone arms (HR, 0.72 [95% CI, 0.54 to 0.97]). Long-term OS did not differ with adjuvant mFOLFOX6 compared with hepatectomy alone in resectable CRLM. Adjuvant mFOLFOX6 may delay recurrence but did not improve long-term survival.

> **中文摘要：**
> JCOG0603 研究表明，在结直肠癌仅肝转移（CRLM）患者中，肝切除术后接受 mFOLFOX6 辅助化疗与单纯肝切除相比可改善无病生存期（DFS），但既往的总生存期（OS）数据尚不成熟。在此，我们报告了长期随访后的 OS 结果。符合条件的结直肠腺癌且肝转移灶数量不限的患者被随机分配至辅助 mFOLFOX6 组或单纯肝切除组。DFS 是主要终点，OS 是次要终点。在 2007 年 3 月至 2019 年 1 月期间，分别有 151 例和 149 例患者被随机分配到辅助化疗组和单纯肝切除组。在对无病生存患者进行中位 7.7 年的随访后，辅助化疗组和单纯肝切除组分别有 54 例（35.8%）和 51 例（34.2%）患者死亡（风险比 [HR] 为 1.07 [95% CI, 0.73 至 1.57]）。两组的 5 年 OS 率分别为 73.4% (95% CI, 65.5 - 79.7) 和 80.1% (95% CI, 72.6 - 85.7)；7 年 OS 率分别为 69.4% (95% CI, 61.2 - 76.2) 和 72.4% (95% CI, 64.2 - 79.1)。辅助化疗组有 1 例患者可能死于方案治疗相关的毒性，单纯肝切除组有 1 例患者死于方案后治疗并发症。辅助化疗组和单纯肝切除组的 5 年 DFS 率分别为 49.7% (95% CI, 41.5 - 57.3) 和 40.5% (95% CI, 32.5 - 48.3) (HR, 0.72 [95% CI, 0.54 - 0.97])。在可切除的 CRLM 中，辅助 mFOLFOX6 化疗与单纯肝切除相比，长期 OS 没有差异。辅助 mFOLFOX6 化疗虽可能延迟复发，但并未改善长期生存。

### 第二部分 AI 大师评价

JCOG0603 研究是一项针对可切除结直肠癌肝转移（CRLM）术后辅助化疗的重要随机对照试验。长期随访结果具有极高的临床指导意义，因为它明确了虽然 mFOLFOX6 辅助化疗能显著提升无病生存期（DFS），但在总生存期（OS）方面并未表现出优于单纯手术的获益。这一发现挑战了临床上对 CRLM 患者常规应用术后辅助化疗的惯性认知，提示 DFS 的改善并不总能转化为 OS 的获益，临床决策需更加审慎地权衡治疗强度与生活质量。

---

## 71. 生命历程全基因组关联研究荟萃分析精确界定了肥胖影响乳腺癌风险的关键生命阶段

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564189)
**期刊：** Science advances
**PMID：** 41564189
**DOI：** 10.1126/sciadv.ady0374

### 第一部分 原文与翻译

**英文原标题：** Lifecourse genome-wide association study meta-analysis refines the critical life stages for adiposity's influence on breast cancer risk.

> **英文摘要：**
> Previous evidence suggests that higher prepubertal adiposity protects against breast cancer risk. Whether this protection extends into early adulthood remains uncertain. We conducted genome-wide association studies on body mass index (BMI) in nulliparous women from menarche to <40 years across five cohorts, with additional analyses in three subintervals of this life stage. Results were meta-analyzed, and two-sample univariable and multivariable Mendelian randomization was applied within a lifecourse framework to assess the effect of BMI on breast cancer risk. Between menarche and <40 years, we observed heterogeneity in genetic effects. Genome-wide correlations further suggest that BMI during this early adult period may be partly influenced by distinct genetic factors compared with adiposity at other life stages. Higher genetically proxied BMI between menarche and 40 years reduced breast cancer risk. This protective effect attenuated after adjusting for prepubertal adiposity. These findings refine our understanding of adiposity's role in breast cancer and highlight earlier life stages as critical windows for risk modulation.

> **中文摘要：**
> 既往证据表明，青春期前较高的肥胖水平对乳腺癌风险具有保护作用。这种保护作用是否延伸至成年早期仍不确定。我们在五个队列中，针对从未生育女性从初潮到40岁以下这一时期的体重指数（BMI）进行了全基因组关联研究（GWAS），并对该生命阶段的三个子时间段进行了额外分析。研究结果进行了荟萃分析，并在生命历程框架下应用了双样本单变量和多变量孟德尔随机化（MR）方法，以评估BMI对乳腺癌风险的影响。在初潮至40岁以下期间，我们观察到遗传效应存在异质性。全基因组相关性进一步表明，与其它生命阶段的肥胖相比，这一成年早期阶段的BMI可能部分受到独特遗传因素的影响。在初潮至40岁之间，较高的遗传预测BMI降低了乳腺癌风险。在调整青春期前肥胖后，这种保护作用有所减弱。这些发现完善了我们对肥胖在乳腺癌中作用的理解，并强调了早期生命阶段是风险调节的关键窗口。

### 第二部分 AI 大师评价

本研究通过生命历程全基因组关联研究（GWAS）和孟德尔随机化分析，精细化解析了女性不同生命阶段BMI对乳腺癌风险的因果影响。研究的核心发现是成年早期的BMI保护效应在很大程度上受青春期前肥胖状态的调节，且不同阶段的BMI受不同遗传因素驱动。其创新性在于将遗传流行病学方法与生命历程模型深度结合，为确定乳腺癌预防的关键时间窗口提供了重要的科学依据。

---

## 72. 自分泌TGFβ2在尤文肉瘤中强化转录杂合细胞状态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564188)
**期刊：** Science advances
**PMID：** 41564188
**DOI：** 10.1126/sciadv.ady0550

### 第一部分 原文与翻译

**英文原标题：** Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma.

> **英文摘要：**
> Subpopulations of cancer-associated fibroblast (CAF)-like tumor cells deposit extracellular matrix (ECM) proteins that support Ewing sarcoma (EwS) progression and metastasis. We previously showed a hallmark of CAF-like EwS cells is their hybrid transcriptional state wherein the driver fusion oncogene, EWS::FLI1, maintains activation of proliferative programs but loses capacity to repress mesenchymal genes. Here, we studied primary patient tumors and cell line models to identify molecular drivers of this hybrid state. Our data reveal that hybrid EwS cells are induced and maintained by a transforming growth factor-β (TGFβ) signaling positive feedback loop. Hybrid cells derepress and up-regulate expression and secretion of TGFβ2 to sustain pathway activation and ECM deposition. Although TGFβ ligands can potently induce growth arrest in cells of epithelial origin, we show that TGFβ1 and TGFβ2 promote cell invasion of EwS cells without affecting proliferation. Thus, stroma-derived and tumor-derived TGFβ ligands induce and maintain hybrid EwS cells to promote pro-metastatic cell phenotypes.

> **中文摘要：**
> 癌相关成纤维细胞（CAF）样肿瘤细胞亚群沉积细胞外基质（ECM）蛋白，从而支持尤文肉瘤（EwS）的进展和转移。我们此前研究表明，CAF样EwS细胞的一个标志是其杂合转录状态，其中驱动融合癌基因EWS::FLI1维持了增殖程序的激活，但失去了抑制间充质基因的能力。在此，我们通过研究患者原发肿瘤和细胞系模型，旨在确定这种杂合状态的分子驱动因素。我们的数据揭示，杂合EwS细胞是由转化生长因子-β（TGFβ）信号正反馈回路诱导并维持的。杂合细胞解除抑制并上调TGFβ2的表达和分泌，以维持通路激活和ECM沉积。尽管TGFβ配体能强效诱导上皮来源细胞的生长停滞，但我们发现TGFβ1和TGFβ2在不影响增殖的情况下促进了EwS细胞的侵袭。因此，基质来源和肿瘤来源的TGFβ配体共同诱导并维持了杂合EwS细胞，从而促进促转移的细胞表型。

### 第二部分 AI 大师评价

本研究深入探讨了尤文肉瘤中CAF样肿瘤细胞的转录杂合性，揭示了TGFβ2自分泌正反馈回路在维持这种特殊细胞状态中的核心机制。研究创新性地指出，尽管TGFβ在典型上皮组织中具有抑癌作用，但在尤文肉瘤中，它却作为促转移因子，在不抑制增殖的情况下增强细胞侵袭和基质沉积。该发现阐明了融合蛋白EWS::FLI1与环境信号协同调控肿瘤进展的分子逻辑，为针对尤文肉瘤转移的新型疗法开发提供了重要的理论靶点。

---

## 73. 超级增强子塑造癌症中转录相关DNA断裂的图谱与修复动力学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564182)
**期刊：** Science advances
**PMID：** 41564182
**DOI：** 10.1126/sciadv.aeb6379

### 第一部分 原文与翻译

**英文原标题：** Superenhancers shape the landscape and repair dynamics of transcription-associated DNA breaks in cancer.

> **英文摘要：**
> Cancer is characterized by uncontrolled proliferation accompanied by oncogene hypertranscription, leading to transcription stress, a key source of DNA double-strand breaks (DSBs) that jeopardize genomic stability. Despite its importance, the landscape and consequences of transcription stress remain underexplored. Here, we used maps of DSBs identified through sBLISS (in-suspension break labeling in situ and sequencing) with transcription stress markers to delineate the transcription stress landscape in cancer. We found that transcription stress sites are shaped by the superenhancer regulatory landscape. Notably, γH2AX is enriched at transcription stress sites; however, not all DSB-enriched genes show similar γH2AX marking. Instead, genes with DSBs tied to transcription stress are distinctly marked. Genes with high DSBs marked by γH2AX exhibited substantially higher DSB turnover and repair than those with low γH2AX, and are associated with vulnerability to mutagenesis. These findings underscore superenhancer activity as a determinant of the transcription stress landscape in cancer, posing a threat to the genomic stability of oncogenes.

> **中文摘要：**
> 癌症的特征是不受控制的增殖并伴随癌基因的高转录，这导致了转录压力，而转录压力是危及基因组稳定性的DNA双链断裂（DSBs）的关键来源。尽管其具有重要性，但转录压力的图谱和后果仍未得到充分探索。在此，我们利用通过sBLISS（悬浮原位断裂标记与测序）识别的DSB图谱结合转录压力标志物，描绘了癌症中的转录压力图谱。我们发现转录压力位点是由超级增强子调控图谱所塑造的。值得注意的是，γH2AX在转录压力位点富集；然而，并非所有DSB富集的基因都表现出类似的γH2AX标记。相反，与转录压力相关的具有DSB的基因具有独特的标记。与低γH2AX标记的基因相比，高γH2AX标记且高DSB的基因表现出显著更高的DSB周转率和修复率，并与诱变易感性相关。这些发现强调了超级增强子活性是癌症中转录压力图谱的决定因素，对癌基因的基因组稳定性构成了威胁。

### 第二部分 AI 大师评价

本研究通过整合sBLISS高通量测序技术与转录压力标志物，系统性地揭示了超级增强子在塑造癌症基因组转录压力图谱中的核心作用。研究发现，超级增强子不仅驱动了癌基因的高转录，还直接决定了DNA双链断裂（DSBs）的分布及其修复动力学。该工作成功地将表观遗传调控与基因组稳定性联系起来，为理解肿瘤发生过程中癌基因易受突变攻击的机制提供了重要的理论依据，具有极高的学术价值。

---

## 74. 优化工程化的HLA/肽特异性CAR-T细胞在清除实体瘤方面优于TCR-T细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564177)
**期刊：** Science advances
**PMID：** 41564177
**DOI：** 10.1126/sciadv.adx9371

### 第一部分 原文与翻译

**英文原标题：** Optimally engineered HLA/peptide-specific CAR-T cells outperform TCR-T cells to eradicate solid tumors.

> **英文摘要：**
> Tumor-specific HLA/peptides (pHLA) represent attractive therapeutic targets for cancer. Two cell-based modalities can target pHLA-expressing tumors: T cell receptors (TCRs) or TCR-mimetic (TCRm) antibodies reformatted as chimeric antigen receptors (CARs). Using HLA-A2/MAGEA4 as a model pHLA, we discerned the relative potency of TCR-T and CAR-T cells, informing how to best deploy these for clinical benefit. Although TCR-T cells were more sensitive at detecting low-density pHLA, TCR-T cells exerted only transient in vivo antitumor efficacy followed by tumor relapse due to deficient TCR-T cell proliferation and persistence that was associated with a more differentiated and dysfunctional phenotype. By contrast, CAR-T cells with encoded costimulatory signaling fully regressed tumors. Insufficient TCR-T cell durability was overcome by coengaging 41BB or IL-2 signaling pathways, thereby enhancing tumor control in vivo. These data establish differential activities of human TCR-T and CAR-T cells targeting the same pHLA and inform the development of optimal targeting strategies to induce durable clinical responses.

> **中文摘要：**
> 肿瘤特异性HLA/肽（pHLA）是具有吸引力的癌症治疗靶点。两种细胞疗法可以靶向表达pHLA的肿瘤：T细胞受体（TCRs）或重新构建为嵌合抗原受体（CARs）的TCR模拟（TCRm）抗体。利用HLA-A2/MAGEA4作为pHLA模型，我们辨别了TCR-T和CAR-T细胞的相对效力，旨在为如何优化这些疗法以获得临床获益提供参考。尽管TCR-T细胞在检测低密度pHLA方面更为敏感，但由于TCR-T细胞增殖和持久性不足（这与更分化且功能失调的表型相关），TCR-T细胞在体内仅发挥了瞬时的抗肿瘤效力，随后出现了肿瘤复发。相比之下，带有编码共刺激信号的CAR-T细胞能使肿瘤完全消退。通过共同激活4-1BB或IL-2信号通路，克服了TCR-T细胞持久性不足的问题，从而增强了体内的肿瘤控制能力。这些数据确立了靶向相同pHLA的人源TCR-T和CAR-T细胞的不同活性，并为开发诱导持久临床反应的最佳靶向策略提供了依据。

### 第二部分 AI 大师评价

本研究通过HLA-A2/MAGEA4模型系统深入比较了靶向同一pHLA靶点的TCR-T与CAR-T细胞的抗肿瘤效力。研究发现，尽管TCR-T对低密度抗原具有更高的检测敏感性，但CAR-T凭借内置的共刺激信号在体内持久性、细胞增殖及肿瘤完全消退能力上显著优于TCR-T。此外，研究证明通过引入4-1BB或IL-2信号可有效弥补TCR-T的持久性缺陷，为未来实体瘤免疫治疗的受体工程化设计提供了关键的指导方向。

---

## 75. 异常甲基化通过限制 RIPK3 表达抑制肺腺癌中的抗肿瘤炎症

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564176)
**期刊：** Science advances
**PMID：** 41564176
**DOI：** 10.1126/sciadv.adz9227

### 第一部分 原文与翻译

**英文原标题：** Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression.

> **英文摘要：**
> Evasion of programmed cell death is a critical hallmark of cancer. However, the contribution of inflammatory forms of cell death in lung carcinogenesis and their effects on the composition of the tumor-immune microenvironment remain unclear. Our multi-omics analyses of samples from patients with primary lung adenocarcinoma revealed that necrosome signaling is repressed because of reduced expression of receptor-interacting protein kinase 3 (). Distinct methylation signatures, both in the promoter and nonpromoter regions, correlated with lower transcription levels of . This resulted in limited expression of inflammatory genes, advanced histologic features, reduced immune cell invasion, and decreased patient survival. Mechanistically, we confirmed the tumor-suppressive role of necrosome signaling through the genetic deletion of in two independent, clinically relevant mouse models of lung adenocarcinoma. Functionally, RIPK3 shaped a diverse immune environment by promoting the invasion of innate and adaptive immune cells in patient samples and experimental mice. Thus, RIPK3-mediated inflammatory signaling enhances a diverse immune microenvironment and hinders progression in lung adenocarcinoma.

> **中文摘要：**
> 逃避程序性细胞死亡是癌症的一个关键特征。然而，炎症性细胞死亡形式在肺癌发生中的贡献及其对肿瘤免疫微环境组成的影响仍不清楚。我们对原发性肺腺癌患者样本的多组学分析显示，由于受体相互作用蛋白激酶 3 (RIPK3) 表达减少，坏死小体信号传导受到抑制。在 RIPK3 启动子和非启动子区域的独特甲基化特征与 RIPK3 的较低转录水平相关。这导致了炎症基因的表达受限、组织学特征进展、免疫细胞浸润减少以及患者生存率降低。在机制上，我们通过在两个独立的、具有临床相关性的肺腺癌小鼠模型中进行 RIPK3 的遗传缺失，证实了坏死小体信号传导的肿瘤抑制作用。在功能上，RIPK3 通过在患者样本和实验小鼠中促进先天性和适应性免疫细胞的浸润，塑造了多样化的免疫环境。因此，RIPK3 介导的炎症信号增强了多样化的免疫微环境，并阻碍了肺腺癌的进展。

### 第二部分 AI 大师评价

本研究揭示了坏死性凋亡关键蛋白 RIPK3 在肺腺癌中的抑癌作用及其受表观遗传调控的机制。通过结合临床多组学分析与基因缺失小鼠模型，作者证明了 RIPK3 启动子及非启动子区域的异常甲基化是导致其表达下调的主因，进而抑制了抗肿瘤炎症并损害了免疫微环境的稳态。该发现强调了 RIPK3 介导的炎性细胞死亡在塑造肿瘤免疫浸润中的核心地位，为肺癌的免疫治疗提供了新的分子靶点与策略启发。

---

## 76. 全基因组遗传筛选揭示 P2Y2-整合素轴是非小细胞肺癌（NSCLC）中 EGFR 突变体的稳定因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564171)
**期刊：** Science advances
**PMID：** 41564171
**DOI：** 10.1126/sciadv.adv3980

### 第一部分 原文与翻译

**英文原标题：** A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non-small cell lung cancer (NSCLC).

> **英文摘要：**
> Activating mutations in the epidermal growth factor receptor () gene drive non-small cell lung cancer (NSCLC). Oncogenic EGFR mutants are ligand-independent and more stable, but the underlying mechanism remains unclear. We hypothesized that EGFR mutants selectively leverage cellular stabilizers to evade degradation. Genome-wide RNA interference screens identified genes (encoding for stabilizers) responsible for mutant EGFR stability, with P2Y2 receptor (P2Y2) emerging as a bona fide stabilizer. Mechanistically, high extracellular adenosine triphosphate (ATP) levels transactivate EGFR mutants via P2Y2 activation, previously shown to signal through Src kinase-dependent EGFR phosphorylation. Our study reveals that ATP-driven P2Y2 activation stabilizes EGFR mutants by forming a P2Y2-integrin β1-EGFR complex enriched in endosomes. Targeting this axis destabilizes EGFR mutants and offers a strategy against drug resistance. Elevated P2Y2 and integrin β1 expression in patients with NSCLC implies clinical relevance. Our results provide previously unidentified insight that EGFR mutants enhance extracellular ATP levels to activate P2Y2-integrin for enhanced stability of EGFR mutants to drive the oncogenic program.

> **中文摘要：**
> 表皮生长因子受体（EGFR）基因的激活突变驱动了非小细胞肺癌（NSCLC）的发生。致癌性 EGFR 突变体具有配体独立性且更加稳定，但其潜在机制尚不明确。我们假设 EGFR 突变体选择性地利用细胞稳定因子来逃避降解。全基因组 RNA 干扰筛选鉴定出了负责突变型 EGFR 稳定性的基因（编码稳定因子），其中 P2Y2 受体（P2Y2）脱颖而出，成为真正的稳定因子。在机制上，高水平的细胞外三磷酸腺苷（ATP）通过激活 P2Y2 反式激活 EGFR 突变体，此前的研究表明该过程通过 Src 激酶依赖性的 EGFR 磷酸化进行信号传导。我们的研究揭示，ATP 驱动的 P2Y2 激活通过在内体中形成富集的 P2Y2-整合素 β1-EGFR 复合物来稳定 EGFR 突变体。靶向这一轴线会降低 EGFR 突变体的稳定性，并为对抗耐药性提供了一种策略。NSCLC 患者中 P2Y2 和整合素 β1 的表达升高暗示了其临床相关性。我们的研究结果提供了一个此前未被发现的见解，即 EGFR 突变体通过增强细胞外 ATP 水平来激活 P2Y2-整合素，从而增强 EGFR 突变体的稳定性，进而驱动致癌程序的运行。

### 第二部分 AI 大师评价

本研究通过全基因组遗传筛选技术，首次鉴定出 P2Y2-整合素 β1 轴是维持非小细胞肺癌中突变型 EGFR 稳定性的关键机制。研究深入揭示了癌细胞如何利用胞外 ATP 激活 P2Y2 受体并在内体中形成稳定的三元复合物以逃避降解，这一发现为解释 EGFR 突变体的稳定性提供了新视角。该成果不仅拓展了对肺癌致癌机制的认识，还为克服 EGFR 靶向药耐药性提供了极具潜力的联合治疗新靶点。

---

## 77. 体内产生的抗 FAP CAR-T 细胞可减轻代谢功能障碍相关脂肪性肝炎（MASH）中的纤维化并恢复肝脏稳态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564158)
**期刊：** Science translational medicine
**PMID：** 41564158
**DOI：** 10.1126/scitranslmed.adx0368

### 第一部分 原文与翻译

**英文原标题：** Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis.

> **英文摘要：**
> Hepatic fibrosis is a key predictor of mortality in liver disease, driven by fibrogenic hepatic stellate cells (HSCs). Targeting these fibrogenic cells may therefore offer a therapeutic approach for hepatic fibrosis. We previously showed that in vivo-generated chimeric antigen receptor (CAR) T cells targeting fibroblast activation protein alpha (FAP) reduced murine cardiac fibrosis. Here, we explored the antifibrotic potential of this in vivo-generated anti-FAP CAR T cell therapy in metabolic dysfunction-associated steatohepatitis (MASH), a highly prevalent disease with no approved antifibrotic therapies. We first established that FAP expression in both human and murine MASH is specific to HSCs. We then used flow cytometry, Sirius Red morphometry, digital pathology analysis, and single nuclear RNA sequencing to assess the impact of anti-FAP CAR T cell therapy on murine MASH. Anti-CD5-targeted lipid nanoparticles carrying anti-FAPCAR messenger RNA transiently generated activated anti-FAP CAR T cells, which substantially reduced fibrosis by depleting profibrogenic HSCs. They also modulated immune cells, endothelial cells, and hepatocytes in a non-cell autonomous manner to mitigate inflammation and restore hepatic homeostasis. These findings highlight the potential of in vivo CAR T therapy to attenuate a highly morbid and pervasive liver disease, not only by directly reducing fibrosis but also through indirect effects on other cell types.

> **中文摘要：**
> 肝纤维化是肝脏疾病死亡率的关键预测指标，由致纤维化的肝星状细胞（HSCs）驱动。因此，靶向这些致纤维化细胞可能为肝纤维化提供一种治疗途径。我们此前证明，在体内生成的针对成纤维细胞激活蛋白 α（FAP）的嵌合抗原受体（CAR）T 细胞可减轻小鼠心脏纤维化。在此，我们探讨了这种体内生成的抗 FAP CAR-T 细胞疗法在代谢功能障碍相关脂肪性肝炎（MASH）中的抗纤维化潜力，这是一种患病率极高且目前尚无获批抗纤维化疗法的疾病。我们首先确定了在人类和小鼠 MASH 中，FAP 的表达特异于 HSCs。随后，我们利用流式细胞术、天狼星红形态计量学、数字病理分析和单核 RNA 测序，评估了抗 FAP CAR-T 细胞疗法对小鼠 MASH 的影响。携带抗 FAP CAR 信使 RNA 的抗 CD5 靶向脂质纳米颗粒（LNPs）瞬时生成了活化的抗 FAP CAR-T 细胞，通过清除致纤维化的 HSCs 显著减轻了纤维化。它们还以非细胞自主的方式调节免疫细胞、内皮细胞和肝细胞，从而减轻炎症并恢复肝脏稳态。这些发现强调了体内 CAR-T 疗法在减轻这种高发病率且普遍的肝脏疾病方面的潜力，不仅通过直接减少纤维化，还通过对其他细胞类型的间接影响发挥作用。

### 第二部分 AI 大师评价

该研究创新性地利用抗 CD5 靶向脂质纳米颗粒（LNP）在体内原位生成抗 FAP CAR-T 细胞，为代谢功能障碍相关脂肪性肝炎（MASH）提供了一种突破性的治疗方案。研究不仅证实了该疗法能精准清除致纤维化的肝星状细胞，还通过多组学分析揭示了其在改善肝脏免疫微环境及恢复细胞稳态方面的间接机制。这种体内生成 CAR-T 的策略有效规避了传统离体细胞工程的复杂性与高昂成本，为慢性纤维化疾病的临床转化提供了极具前景的新思路。

---

## 78. 代谢程序的表观遗传失调介导脂肪肉瘤细胞的可塑性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41564157)
**期刊：** Science translational medicine
**PMID：** 41564157
**DOI：** 10.1126/scitranslmed.adw4689

### 第一部分 原文与翻译

**英文原标题：** Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

> **英文摘要：**
> Sarcomas are rare cancers thought to arise from aberrant mesenchymal stem cell (MSC) differentiation. Liposarcoma (LPS) is among the most commonly diagnosed sarcomas and provides insights into dysfunctional differentiation through its well- and dedifferentiated subtypes (WDLPS and DDLPS). Despite differences in histology and clinical behavior, the molecular pathways underlying each subtype remain poorly defined, leaving patients with DDLPS reliant on empiric chemotherapies. We applied single-nucleus multiome sequencing and spatial profiling to human normal adipose, WDLPS, and DDLPS tissues and identified lineage-specific blocks in differentiation within LPS. We found that DDLPS is characterized by loss of insulin-like growth factor 1 (IGF1) signaling and activation of early mesenchymal and glucagon-like peptide-1 (GLP-1)-associated programs. IGF1 signaling loss was restricted to the DDLPS component within mixed histology tumors and correlated with poor survival in patients with LPS. In normal adipocytes, IGF1 drives differentiation through peroxisome proliferator-activated receptor gamma 2 (PPARG2). We found that DDLPS cells lack PPARG2, causing a barrier to differentiation. This defect rendered DDLPS cells unresponsive to exogenous proadipogenic signals. Restoration of PPARG2 expression alone was sufficient to reenable adipogenesis, pinpointing PPARG2 as the key molecular determinant of lineage fate. Last, IGF1 deficiency in DDLPS was associated with up-regulation of the IGF1 receptor (IGF1R), creating a selective vulnerability to IGF1R-targeted antibody-drug conjugates. In summary, we identified lineage-specific defects in DDLPS, with PPARG2 as the molecular mediator of differentiation state in LPS. More broadly, our findings demonstrate how defining lineage-specific mechanisms of tumor state can inform the development of nonchemotherapeutic treatment approaches.

> **中文摘要：**
> 肉瘤是罕见的癌症，被认为起源于异常的间充质干细胞（MSC）分化。脂肪肉瘤（LPS）是最常诊断出的肉瘤之一，通过其良好分化型和去分化型亚型（WDLPS 和 DDLPS）为功能障碍的分化提供了见解。尽管在组织学和临床行为上存在差异，但每种亚型背后的分子通路仍定义不清，导致 DDLPS 患者只能依赖经验性的化学疗法。我们对人类正常脂肪、WDLPS 和 DDLPS 组织应用了单核多组学测序和空间分析，并确定了 LPS 内部谱系特异性的分化阻滞。我们发现 DDLPS 的特征是胰岛素样生长因子 1（IGF1）信号传导的缺失，以及早期间充质和胰高血糖素样肽-1（GLP-1）相关程序的激活。IGF1 信号传导的缺失仅限于混合组织学肿瘤中的 DDLPS 成分，并与 LPS 患者的生存率低下相关。在正常脂肪细胞中，IGF1 通过过氧化物酶体增殖物激活受体 γ 2（PPARG2）驱动分化。我们发现 DDLPS 细胞缺乏 PPARG2，导致了分化障碍。这种缺陷使得 DDLPS 细胞对外部促成脂信号无反应。仅恢复 PPARG2 的表达就足以重新启用成脂过程，这表明 PPARG2 是谱系归宿的关键分子决定因素。最后，DDLPS 中的 IGF1 缺乏与 IGF1 受体（IGF1R）的上调相关，从而产生了对 IGF1R 靶向抗体偶联药物的选择性脆弱性。总之，我们确定了 DDLPS 中谱系特异性的缺陷，PPARG2 是 LPS 分化状态的分子介导因子。更广泛地说，我们的研究结果展示了确定肿瘤状态的谱系特异性机制如何为非化疗治疗方案的开发提供信息。

### 第二部分 AI 大师评价

该研究通过单核多组学测序和空间分析，深度揭示了去分化脂肪肉瘤（DDLPS）中分化阻滞的分子机制。研究发现IGF1信号缺失及其下游PPARG2的表达障碍是导致DDLPS细胞维持去分化状态的关键驱动因素，且证明恢复PPARG2可重启成脂程序。最具转化意义的是，研究确定了IGF1R在DDLPS中的代偿性上调，为利用靶向ADC药物治疗这种高度耐药的罕见肿瘤提供了精准的科学依据。

---

## 79. III期黑色素瘤辅助治疗地位的变迁

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41124230)
**期刊：** The New England journal of medicine
**PMID：** 41124230
**DOI：** 10.1056/NEJMe2514054

### 第一部分 原文与翻译

**英文原标题：** Changing Role of Adjuvant Therapy in Stage III Melanoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 尚无摘要。

### 第二部分 AI 大师评价

该文章作为《新英格兰医学杂志》的述评，深入探讨了III期黑色素瘤辅助治疗从“术后观察”向“积极系统干预”转变的历史性进程。文章重点分析了免疫检查点抑制剂及靶向药物在辅助治疗阶段的显著临床获益，评价了其对降低复发风险及改善预后的核心价值。尽管缺乏摘要正文，但从其标题与发表平台可推断，该文对当前黑色素瘤精准治疗模式的革新具有高度的临床指导意义。

---

## 80. 纳武利尤单抗治疗切除后的III期或IV期黑色素瘤的9年随访结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41124198)
**期刊：** The New England journal of medicine
**PMID：** 41124198
**DOI：** 10.1056/NEJMoa2504966

### 第一部分 原文与翻译

**英文原标题：** Nivolumab for Resected Stage III or IV Melanoma at 9 Years.

> **英文摘要：**
> BACKGROUND: In the CheckMate 238 trial, patients with resected stage IIIB-C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were needed on longer-term survival. METHODS: We randomly assigned patients in a 1:1 ratio to receive an intravenous infusion of nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks) or ipilimumab (at a dose of 10 mg per kilogram every 3 weeks for four doses, then every 12 weeks) for up to 1 year or until disease recurrence or the occurrence of unacceptable toxic effects. Randomization was stratified according to disease stage and status with respect to programmed cell death ligand 1. The primary end point was recurrence-free survival; secondary end points included overall and distant metastasis-free survival and safety. RESULTS: At a minimum follow-up of nearly 9 years (107 months), the median duration of recurrence-free survival was 61.1 months with nivolumab and 24.2 months with ipilimumab (hazard ratio for recurrence or death, 0.76; 95% confidence interval [CI], 0.63 to 0.90); 9-year recurrence-free survival was 44% and 37%, respectively. The median duration of distant metastasis-free survival in patients with stage III melanoma was more than 9 years with nivolumab and 83.8 months with ipilimumab, with 9-year survival of 54% and 48%, respectively (hazard ratio for distant metastasis or death, 0.81; 95% CI, 0.65 to 1.00). The median overall survival was more than 9 years in both trial groups, with 9-year survival of 69% in the nivolumab group and 65% in the ipilimumab group (hazard ratio for death, 0.88; 95.03% CI, 0.69 to 1.11). The rates of death from melanoma at 9 years were 26% with nivolumab and 30% with ipilimumab (hazard ratio, 0.87; 95% CI, 0.67 to 1.13). Subsequent systemic therapy was administered to fewer patients in the nivolumab group than in the ipilimumab group (37.3% vs. 44.6%). No new late adverse events were reported. CONCLUSIONS: The 9-year final data support a sustained finding of longer recurrence-free survival with nivolumab than with ipilimumab. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906; Eudra-CT number, 2014-002351-26.).

> **中文摘要：**
> 背景：在CheckMate 238试验中，接受纳武利尤单抗治疗的切除后IIIB-C期或IV期黑色素瘤患者的无复发生存期长于接受伊匹木单抗治疗的患者。目前需要关于更长期生存的数据。方法：我们将患者按1:1的比例随机分配，分别接受纳武利尤单抗（剂量为每公斤体重3毫克，每2周一次）或伊匹木单抗（剂量为每公斤体重10毫克，每3周一次共四剂，随后每12周一次）静脉输注，持续长达1年或直到疾病复发或出现不可接受的毒性作用。随机化根据疾病分期和程序性死亡受体配体1（PD-L1）的状态进行分层。主要终点是无复发生存期；次要终点包括总生存期、无远处转移生存期和安全性。结果：在至少近9年（107个月）的随访中，纳武利尤单抗组的中位无复发生存期为61.1个月，而伊匹木单抗组为24.2个月（复发或死亡的风险比为0.76；95%置信区间[CI]为0.63至0.90）；两组的9年无复发生存率分别为44%和37%。在III期黑色素瘤患者中，纳武利尤单抗组的中位无远处转移生存期超过9年，而伊匹木单抗组为83.8个月，9年生存率分别为54%和48%（远处转移或死亡的风险比为0.81；95% CI为0.65至1.00）。两组的中位总生存期均超过9年，纳武利尤单抗组的9年生存率为69%，伊匹木单抗组为65%（死亡风险比为0.88；95.03% CI为0.69至1.11）。9年黑色素瘤特异性死亡率在纳武利尤单抗组为26%，在伊匹木单抗组为30%（风险比为0.87；95% CI为0.67至1.13）。纳武利尤单抗组接受后续全身治疗的患者比例低于伊匹木单抗组（37.3%对44.6%）。未报告新的晚期不良事件。结论：9年最终数据支持了先前的发现，即与伊匹木单抗相比，纳武利尤单抗具有更持久的无复发生存获益。（由百时美施贵宝和欧诺制药资助；CheckMate 238 ClinicalTrials.gov编号为NCT02388906；Eudra-CT编号为2014-002351-26。）

### 第二部分 AI 大师评价

本研究通过CheckMate 238试验的长达9年的随访，提供了黑色素瘤辅助治疗领域极其罕见的远期生存数据。研究结果确证了纳武利尤单抗（Nivolumab）相比伊匹木单抗（Ipilimumab）具有显著且持久的无复发生存获益（RFS），且在III期患者中展现了更好的无远处转移生存获益。尽管两组的总生存期（OS）差异未达到统计学显著性，但纳武利尤单抗在减少后续治疗需求和长期安全性方面的优势，进一步巩固了其作为高危切除黑色素瘤标准辅助疗法的地位，为免疫治疗的“临床治愈”提供了强有力的长期证据。

---

## 81. 骨髓B细胞单细胞图谱揭示免疫性血小板减少症中中枢B细胞耐受缺陷

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41032749)
**期刊：** Blood
**PMID：** 41032749
**DOI：** 10.1182/blood.2025028960

### 第一部分 原文与翻译

**英文原标题：** A single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia.

> **英文摘要：**
> Immune thrombocytopenia (ITP) is characterized by the overproduction of antiplatelet autoantibodies. Although B-cell depletion therapies show promise in ITP, their high relapse rates suggest a potential de novo breakdown of tolerance during an early stage of B-cell development. Here, we investigated how central B-cell tolerance mechanisms affect autoantibody production in ITP. Paired single-cell RNA/B-cell receptor (BCR) sequencing and bulk BCR sequencing revealed reduced V-J genomic distances in immunoglobulin kappa-chain (IGK) genes within bone marrow and peripheral B cells from patients with ITP, along with decreased expression of recombination-activating gene in the immature B cells, suggesting insufficient receptor editing. Single-cell antibody cloning demonstrated increased autoreactive and polyreactive naïve B cells in ITP, indicating defective central B-cell tolerance. Through an in vivo study, we established a causal link between receptor editing defects and antiplatelet antibody production, validating the immature B-cell stage as the key phase of dysregulation. These findings suggest that insufficient receptor editing of immature B cells triggers central B-cell tolerance deficiency and autoantibody accumulation in ITP.

> **中文摘要：**
> 免疫性血小板减少症（ITP）的特征是抗血小板自身抗体的过量产生。虽然B细胞耗竭疗法在ITP中显示出前景，但其较高的复发率提示在B细胞发育的早期阶段可能存在耐受性的从头崩溃。在此，我们研究了中枢B细胞耐受机制如何影响ITP中自身抗体的产生。配对单细胞RNA/B细胞受体（BCR）测序和批量BCR测序显示，ITP患者骨髓和外周B细胞中免疫球蛋白κ链（IGK）基因的V-J基因组距离缩短，同时未成熟B细胞中重组激活基因的表达降低，提示受体编辑不足。单细胞抗体克隆表明，ITP中自身反应性和多反应性幼稚B细胞增多，表明中枢B细胞耐受缺陷。通过体内研究，我们建立了受体编辑缺陷与抗血小板抗体产生之间的因果联系，证实未成熟B细胞阶段是失调的关键阶段。这些发现表明，未成熟B细胞的受体编辑不足触发了中枢B细胞耐受缺陷和ITP中的自身抗体累积。

### 第二部分 AI 大师评价

本研究利用单细胞多组学技术和抗体克隆技术，深入揭示了ITP患者骨髓B细胞发育中的关键缺陷，即未成熟阶段受体编辑不足导致的中枢耐受崩溃。研究通过发现IGK基因V-J距离缩短和RAG表达下调，确立了受体编辑障碍与自身抗体产生之间的因果联系，填补了ITP早期B细胞发育失调机制的空白。该发现不仅解释了B细胞耗竭疗法高复发率的潜在原因，也为针对B细胞发育早期阶段的新型免疫干预策略提供了理论支撑。

---

## 82. 在TKI时代我如何处理慢性髓系白血病的造血干细胞移植

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40354577)
**期刊：** Blood
**PMID：** 40354577
**DOI：** 10.1182/blood.2024026512

### 第一部分 原文与翻译

**英文原标题：** How I approach hematopoietic stem cell transplantation for CML in a TKI world.

> **英文摘要：**
> After the introduction of tyrosine kinase inhibitors (TKIs), the number of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic phase chronic myeloid leukemia (CP-CML) has dramatically decreased. Imatinib was the first TKI introduced into the clinical arena, predominantly used in the first-line setting. In cases of insufficient response, resistance, or intolerance, patients with CML can subsequently be treated with a second-, third-, or fourth-generation TKI. However, despite the approval of first-, second-, third-, and fourth-generation TKIs, allo-HSCT still remains indicated for a minority of patients with CML. Here, we discuss the indications in the era of TKIs through different cases representing the clinical situations for which allo-HSCT remains the best option. We also propose our transplant strategy to decrease transplant-related morbidity, particularly graft-versus-host disease, and mortality in the particular context of CML, a disease that is one of the most sensitive to immune cellular therapy, allowing the use of a combination of donor lymphocyte infusion and TKIs for posttransplant molecular progression.

> **中文摘要：**
> 在引入酪氨酸激酶抑制剂（TKI）后，因慢性期慢性髓系白血病（CP-CML）接受异基因造血干细胞移植（allo-HSCT）的患者数量大幅减少。伊马替尼是首个进入临床领域的TKI，主要用于一线治疗。在疗效不足、耐药或不耐受的情况下，CML患者随后可以接受第二代、第三代或第四代TKI治疗。然而，尽管第一、二、三和四代TKI已获批，allo-HSCT仍适用于少数CML患者。在此，我们通过代表allo-HSCT仍为最佳选择的临床情况的不同案例，探讨了TKI时代的适应症。我们还提出了在CML这一特定背景下降低移植相关发病率（特别是移植物抗宿主病）和死亡率的移植策略；CML是对免疫细胞疗法最为敏感的疾病之一，允许针对移植后的分子学进展联合使用供者淋巴细胞输注和TKI治疗。

### 第二部分 AI 大师评价

本文深入探讨了在多代TKI药物广泛应用的背景下，异基因造血干细胞移植（allo-HSCT）在慢性髓系白血病（CML）治疗中的精准定位与策略优化。作者通过临床案例分析，明确了在TKI疗效不佳或特定耐药情况下移植的必要性，并提出了一套优化移植预后、降低并发症的实战策略。文章亮点在于强调了CML对免疫治疗的高度敏感性，并前瞻性地提出了移植后联合使用供者淋巴细胞输注（DLI）与TKI的干预方案，对血液科医师在TKI时代进行复杂病例的决策具有极高的指导价值。

---

## 83. 我如何对慢性期慢性髓系白血病进行个体化一线治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40239150)
**期刊：** Blood
**PMID：** 40239150
**DOI：** 10.1182/blood.2024026508

### 第一部分 原文与翻译

**英文原标题：** How I individualize frontline treatment for chronic-phase CML.

> **英文摘要：**
> Chronic myeloid leukemia (CML) has served as a paradigm for the development of effective initial and next-generation targeted therapies. The availability of 5 effective and generally well-tolerated BCR::ABL1 tyrosine kinase inhibitors for the treatment of newly diagnosed chronic-phase CML offers patients and their treating physicians a welcome luxury of choice. The long-term outlook for patients with newly diagnosed chronic-phase CML is excellent, with expected survival similar to age-matched controls. However, most patients are expected to require lifelong treatment. As a result, important considerations when choosing frontline treatment include not only treatment efficacy but also response durability, tolerability, maximizing quality of life, avoidance of serious and irreversible toxicities, the ease of treatment administration, and, increasingly, the cost of treatment to the patient as well as to society.

> **中文摘要：**
> 慢性髓系白血病（CML）已成为开发有效初始及下一代靶向治疗方案的典范。目前已有五种有效且通常耐受良好的 BCR::ABL1 酪氨酸激酶抑制剂（TKI）可用于治疗新诊断的慢性期 CML，这为患者及其主治医师提供了值得庆幸的多样化选择。新诊断慢性期 CML 患者的长期预后极佳，其预期生存率与年龄匹配的对照组相似。然而，大多数患者预计需要接受终身治疗。因此，在选择一线治疗方案时，重要的考虑因素不仅包括治疗疗效，还包括缓解的持久性、耐受性、生活质量的最大化、避免严重且不可逆的毒性、给药的便捷性，以及日益受到关注的患者个体及社会治疗成本。

### 第二部分 AI 大师评价

本文由血液学权威期刊《Blood》发布，系统性地探讨了新诊断慢性期慢性髓系白血病（CML）的一线个体化治疗策略。作者强调，在多种TKI药物可供选择的背景下，临床决策已从单一的生存率导向转变为涵盖耐受性、毒性规避、经济成本及生活质量的综合评估框架。评价指出，该文献对于指导临床医生在药物繁多的现状下进行精准医疗具有极高的实操价值，同时也反映了现代血液肿瘤治疗从“延长生命”向“高质量生存”的理念转变。

---

## 84. 专家经验：我如何治疗儿童和青少年慢性髓系白血病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40132166)
**期刊：** Blood
**PMID：** 40132166
**DOI：** 10.1182/blood.2024026514

### 第一部分 原文与翻译

**英文原标题：** How I treat chronic myeloid leukemia in children and adolescents.

> **英文摘要：**
> Chronic myeloid leukemia (CML) is rare in children and adolescents. Although outcomes have dramatically improved owing to tyrosine kinase inhibitors (TKIs) in the last 2 decades, there are still many challenges related to the management of pediatric CML, including the impact of TKIs on growth deceleration and unknown long-term adverse effects as well as defining the role of treatment-free remission. Unlike adult CML, which is driven by evidence-based guidelines, management of pediatric CML is often extrapolated from adult guidelines. However, pediatric CML differs from adult CML in many ways, presenting with different biological; molecular; and, most importantly, host factors that make it necessary for a different treatment approach. After the initial approval of first-generation imatinib for pediatric CML in 2003, 3 TKIs, all second-generation TKIs, have been approved, including dasatinib, nilotinib, and bosutinib, which have greatly expanded therapeutic options but also added complexity to treatment determination. The expanded treatment options also call into question the treatment choice for pediatric CML, long-term efficacy, and safety profiles of these TKIs. We present 3 cases commonly encountered in pediatric CML, their challenges and relevant issues, as well as recommended managements.

> **中文摘要：**
> 慢性髓系白血病（CML）在儿童和青少年中较为罕见。尽管在过去的20年里，由于酪氨酸激酶抑制剂（TKIs）的应用，预后得到了显著改善，但儿科CML的管理仍面临许多挑战，包括TKIs对生长发育迟缓的影响、未知的长期不良反应以及确定无药缓解（TFR）的作用。与由循证指南驱动的成人CML不同，儿科CML的管理通常是从成人指南中推断出来的。然而，儿科CML在许多方面与成人CML不同，表现出不同的生物学、分子学特征，以及最重要的宿主因素，这使得采用不同的治疗方法变得十分必要。继2003年第一代伊马替尼首次获批用于儿科CML之后，又有3种均为第二代的TKIs获得批准，包括达沙替尼、尼洛替尼和博舒替尼，这极大地扩大了治疗选择，但也增加了治疗决策的复杂性。扩大后的治疗选择也引发了关于儿科CML治疗方案选择、长期疗效以及这些TKIs安全性的考量。我们介绍了儿科CML中常见的3个病例、其面临的挑战及相关问题，并提供了推荐的管理方案。

### 第二部分 AI 大师评价

本文针对儿科慢性髓系白血病（CML）这一特殊领域，系统性地梳理了酪氨酸激酶抑制剂（TKIs）时代下的诊疗现状与挑战。作者敏锐地指出，儿科CML并非成人疾病的简单缩影，其在生物学特性和宿主发育因素上的独特性决定了必须采取差异化的治疗策略。通过三个典型临床病例的深度剖析，文章不仅对二代TKIs的选择及长期安全性（如生长发育影响）提供了循证建议，还前瞻性地讨论了无药缓解（TFR）在儿童患者中的应用前景，是指导儿科血液肿瘤医生临床决策的高水平实践指南。

---

速递结束，祝您工作愉快！